| Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial 2015 · Enalapril-folic acid group · Adults with hypertension in China, without a history of stroke or myocardial infarction | 800 mcg | 1644 days | 10,348 |
| Effect of folic acid supplementation on cancer risk among adults with hypertension in China: A randomized clinical trial 2017 · enalapril-folic acid group · Adults with hypertension in China without a history of stroke or myocardial infarction; age and sex not specified | 800 mcg | 1643 days | 10,348 |
| Folic acid therapy reduces the risk of mortality associated with heavy proteinuria among hypertensive patients 2017 · Enalapril-folic acid group · Hypertensive patients without a history of major cardiovascular diseases | 800 mcg | 1644 days | 10,348 |
| Efficacy of Folic Acid Therapy on the Progression of Chronic Kidney Disease: The Renal Substudy of the China Stroke Primary Prevention Trial 2016 · Enalapril-folic acid group · Chinese adults aged 45–75 with hypertension, with baseline kidney function ranging from normal to moderate chronic kidney disease | 800 mcg | 1606 days | 7,545 |
| Effects of Folic Acid Therapy on the New-Onset Proteinuria in Chinese Hypertensive Patients: A Post Hoc Analysis of the Renal Substudy of CSPPT (China Stroke Primary Prevention Trial) 2017 · enalapril-folic acid group · Chinese adults with hypertension and no proteinuria at baseline; some had diabetes mellitus | 800 mcg | 1606 days | 6,511 |
| Platelet Count Affects Efficacy of Folic Acid in Preventing First Stroke 2018 · 10 mg enalapril and 0.8 mg folic acid · Chinese hypertensive adults, mean age 59.5 years, 38% male, with no history of stroke or myocardial infarction | 800 mcg | 219 weeks | 5,408 |
| Folic acid for the prevention of colorectal adenomas: a randomized clinical trial 2007 · folic acid · Men and women with a recent history of colorectal adenomas and no previous invasive large intestine carcinoma | 1 mg | 2922 days | 516 |
| Folic acid supplementation and risk of colorectal neoplasia during long-term follow-up of a randomized clinical trial 2019 · Folic acid · Adults recently diagnosed with colorectal adenomas | 1 mg | — | 516 |
| Risk of basal cell carcinoma in a randomized clinical trial of aspirin and folic acid for the prevention of colorectal adenomas 2018 · 1 mg/d folic acid · Adults aged 21–80 recently diagnosed with colorectal adenomas | 1 mg | 6 years | 443 |
| Methyltetrahydrofolate vs Folic Acid Supplementation in Idiopathic Recurrent Miscarriage with Respect to Methylenetetrahydrofolate Reductase C677T and A1298C Polymorphisms: A Randomized Controlled Trial 2015 · folic acid group · Women with three or more idiopathic recurrent abortions and no identified antiphospholipid, anatomic, cytogenetic, hormonal, or infectious cause | 1 mg | — | 110 |
| The influence of folic acid supplement on the outcome of pregnancies in the county of Funen in Denmark. Part I 1999 · 1.0 mg folic acid group · Women of childbearing age who became pregnant; age range and health status not specified | 1 mg | 1187 days | — |
| Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study 2001 · folic acid group · Adults with active rheumatoid arthritis | 1 mg | 48 weeks | — |
| Vitamins B2, B6, and B12 and risk of new colorectal adenomas in a randomized trial of aspirin use and folic acid supplementation 2008 · folic acid group · Adults with a previous history of at least one colorectal adenoma; age and sex not restricted | 1 mg | 995 days | — |
| Colorectal adenomas in a randomized folate trial: the role of baseline dietary and circulating folate levels 2008 · folic acid treatment group · Adults with a history of colorectal adenomas; age and sex ranges are not specified. | 1 mg | 6 years | — |
| Folic acid prevents the initial occurrence of sporadic colorectal adenoma in Chinese older than 50 years of age: a randomized clinical trial 2013 · folic acid group · Adults older than 50 years with no adenomas | 1 mg | 3 years | — |
| Folic Acid Therapy Reduces the First Stroke Risk Associated With Hypercholesterolemia Among Hypertensive Patients 2016 · Enalapril-folic acid group · Hypertensive adults without a history of major cardiovascular disease | 800 mcg | 1644 days | — |
| Homocysteine and Stroke Risk: Modifying Effect of Methylenetetrahydrofolate Reductase C677T Polymorphism and Folic Acid Intervention 2017 · 10-mg enalapril and 0.8-mg folic acid group · Chinese hypertensive adults | 800 mcg | 1643 days | — |
| Effect of Smoking and Folate Levels on the Efficacy of Folic Acid Therapy in Prevention of Stroke in Hypertensive Men 2018 · enalapril 10-mg and folic acid 0.8-mg tablet group · men with hypertension; age range not reported | 800 mcg | 1643 days | — |
| Effect of Vitamin B(12) Levels on the Association Between Folic Acid Treatment and CKD Progression: A Post Hoc Analysis of a Folic Acid Interventional Trial 2020 · Enalapril and folic acid · Hypertensive adults with mild to moderate chronic kidney disease | 800 mcg | 1607 days | — |
| Estimated Stroke-Free Survival of Folic Acid Therapy for Hypertensive Adults: Projection Based on the CSPPT 2020 · enalapril-folic acid group · Adults aged 45–75 with hypertension and no history of stroke or myocardial infarction | 800 mcg | 1643 days | — |
| Interaction of serum vitamin B(12) and folate with MTHFR genotypes on risk of ischemic stroke 2020 · enalapril and folic acid group · hypertensive adults; age and sex not specified | 800 mcg | 1644 days | — |
| Effects of prenatal micronutrients supplementation timing on pregnancy-induced hypertension: Secondary analysis of a double-blind randomized controlled trial 2021 · FA group · Pregnant nulliparous Chinese women aged 20 or older, enrolled before 20 gestational weeks, with haemoglobin above 10.0 g/dl | 400 mcg | — | 6,261 |
| Micronutrient supplementation during pregnancy and the risk of pregnancy-induced hypertension: A randomized clinical trial 2019 · FA group · Nulliparous pregnant women aged 20 years or older, enrolled before 20 weeks of gestation, with hemoglobin at least 10.0 g/dL | 400 mcg | — | 5,923 |
| Effects of Prenatal Micronutrient Supplementation on Spontaneous Preterm Birth: A Double-Blind Randomized Controlled Trial in China 2017 · FA group · Pregnant women aged 20 years or older, nulliparous, enrolled before 20 gestational weeks, with hemoglobin above 10.0 g/dL | 400 mcg | — | 5,888 |
| Impact of micronutrient supplementation during pregnancy on birth weight, duration of gestation, and perinatal mortality in rural western China: double blind cluster randomised controlled trial 2008 · Folic acid · Pregnant women resident in disadvantaged rural counties in Shaanxi Province, China; eligible women enrolled before 28 weeks’ gestation | 400 mcg | — | 2,017 |
| High dosage folic acid supplementation, oral cleft recurrence and fetal growth 2013 · 4 mg folic acid · Women aged 16–45 with an oral cleft themselves or who had a previous child with an oral cleft; not pregnant at enrollment | 4 mg | 3 years | 1,257 |
| High dosage folic acid supplementation, oral cleft recurrence and fetal growth 2013 · 0.4 mg folic acid · Women aged 16–45 with an oral cleft themselves or who had a previous child with an oral cleft; not pregnant at enrollment | 400 mcg | 3 years | 1,251 |
| Effect of high dose folic acid supplementation in pregnancy on pre-eclampsia (FACT): double blind, phase III, randomised controlled, international, multicentre trial 2018 · folic acid group · Pregnant women at 8–16 completed weeks of gestation with at least one risk factor for pre-eclampsia | 4 mg | — | 1,228 |
| Excess risk of preterm birth with periconceptional iron supplementation in a malaria endemic area: analysis of secondary data on birth outcomes in a double blind randomized controlled safety trial in Burkina Faso 2019 · folic acid alone · Nulliparous, non-pregnant women aged 15–24 years in a malaria-endemic area of Burkina Faso who became pregnant during or shortly after supplementation | 400 mcg | 548 days | 979 |
| Risk of malaria in young children after periconceptional iron supplementation 2021 · Control · Nulliparous young women in Burkina Faso; age range and sex beyond female are not specified; no diagnosed condition stated | 400 mcg | 548 days | 979 |
| The effect of folic acid throughout pregnancy among pregnant women at high risk of pre-eclampsia: A randomized clinical trial 2020 · low dose (LD) group · Pregnant women with a history of pre-eclampsia or eclampsia in their last pregnancy | 400 mcg | — | 788 |
| The effect of folic acid throughout pregnancy among pregnant women at high risk of pre-eclampsia: A randomized clinical trial 2020 · high dose (HD) group · Pregnant women with a history of pre-eclampsia or eclampsia in their last pregnancy | 4 mg | — | 788 |
| A randomised trial to evaluate the effects of low-dose aspirin in gestation and reproduction: design and baseline characteristics 2013 · Placebo group · Healthy women aged 18–40 trying to conceive, with one or two prior pregnancy losses and no known infertility diagnosis | 400 mcg | — | 606 |
| Efficacy of 4.0 mg versus 0.4 mg Folic Acid Supplementation on the Reproductive Outcomes: A Randomized Controlled Trial 2021 · 0.4 mg FA group · Women aged 18–44 planning a pregnancy within 12 months; women with specified conditions including epilepsy, diabetes, obesity and megaloblastic anemia were excluded | 400 mcg | 1 year | 531 |
| Efficacy of 4.0 mg versus 0.4 mg Folic Acid Supplementation on the Reproductive Outcomes: A Randomized Controlled Trial 2021 · 4.0 mg FA group · Women aged 18–44 planning a pregnancy within 12 months; women with specified conditions including epilepsy, diabetes, obesity and megaloblastic anemia were excluded | 4 mg | 1 year | 529 |
| Low-Molecular-Weight Heparin for the Treatment of Unexplained Recurrent Miscarriage With Negative Antiphospholipid Antibodies: A Randomized Controlled Trial 2017 · Study group · Women with three or more unexplained recurrent miscarriages and negative antiphospholipid antibodies, who became pregnant | 500 mcg | 20 weeks | 150 |
| Low-Molecular-Weight Heparin for the Treatment of Unexplained Recurrent Miscarriage With Negative Antiphospholipid Antibodies: A Randomized Controlled Trial 2017 · Control group · Women with three or more unexplained recurrent miscarriages and negative antiphospholipid antibodies, who became pregnant | 500 mcg | 20 weeks | 150 |
| Periconceptional use of folic acid and risk of miscarriage - findings of the Oral Cleft Prevention Program in Brazil 2013 · 4.0 mg group · Women aged 16–45 with nonsyndromic orofacial cleft themselves or a previous child with nonsyndromic orofacial cleft | 4 mg | — | 141 |
| Periconceptional iron supplementation does not reduce anemia or improve iron status among pregnant women in rural Bangladesh 2009 · folic acid (FA) · Married, nulliparous women in rural Bangladesh, followed until pregnancy or the end of 9 months | 400 mcg | 274 days | 138 |
| Periconceptional use of folic acid and risk of miscarriage - findings of the Oral Cleft Prevention Program in Brazil 2013 · 0.4 mg group · Women aged 16–45 with nonsyndromic orofacial cleft themselves or a previous child with nonsyndromic orofacial cleft | 400 mcg | — | 127 |
| Folic acid supplementation prevents phenytoin-induced gingival overgrowth in children 2011 · folic acid arm · Children aged 6–15 years with epilepsy starting phenytoin monotherapy | 500 mcg | 26 weeks | 62 |
| Sex and menopausal status influence human dietary requirements for the nutrient choline 2007 · Folic acid supplement group · Healthy men and women aged 18–70 years; participants were not selected for a diagnosed condition or nutrient deficiency | 400 mcg | — | 26 |
| The influence of folic acid supplement on the outcome of pregnancies in the county of Funen in Denmark. Part I 1999 · 2.5 mg folic acid group · Women of childbearing age who became pregnant; age range and health status not specified | 2.5 mg | 1187 days | — |
| Folate supplements prevent recurrence of neural tube defects 1992 · Folate supplementation · Women with a previous neural tube defect pregnancy; age not reported | 4 mg | — | — |
| Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors 2007 · Homocysteine-lowering group · Myocardial infarction survivors | 2 mg | 6 years | — |
| Modifying effects of maternal Hb concentration on infant birth weight in women receiving prenatal iron-containing supplements: a randomised controlled trial 2016 · FA group · Pregnant women aged at least 20 years, nulliparous, with Hb concentration ≥100 g/L and enrolled before 20 weeks of gestation | 400 mcg | — | — |
| Prenatal iron containing supplements provided to Chinese women with no or mild anemia had no effect on hemoglobin concentration in post-partum women or their infants at 6 and 12 months of age 2019 · FA · Nulliparous pregnant women with hemoglobin concentration >100 g/L and no or mild anemia | 400 mcg | — | — |
| Interaction of serum calcium and folic acid treatment on first stroke in hypertensive males 2021 · enalapril and folic acid · Chinese hypertensive adults; male and female participants | 800 mcg | 1643 days | — |
| The effect of myo-inositol supplementation on the prevention of gestational diabetes in overweight pregnant women: a randomized, double-blind, controlled trial 2023 · control group · Overweight pregnant women at 12–14 weeks of gestation | 400 mcg | 10 weeks | — |
| Folic acid supplementation improves cognitive function in participants with cerebral small vascular disease-related cognitive impairment: a randomized controlled trial 2026 · FA group · Adults aged 40–80 years with cerebral small vessel disease and cognitive impairment; men and women | 800 mcg | 26 weeks | 110 |
| Folic Acid Supplementation Mitigates Alzheimer's Disease by Reducing Inflammation: A Randomized Controlled Trial 2016 · folic acid supplementation group · Adults aged 40–90 with newly diagnosed mild-to-moderate possible or probable Alzheimer's disease and normocytic anemia | 1.25 mg | 26 weeks | 81 |
| Cognitive Benefits of Folic Acid, Docosahexaenoic Acid, and a Combination of Both Nutrients in Mild Cognitive Impairment: Possible Alterations through Mitochondrial Function and DNA Damage 2024 · FA · Adults aged 60 years and older with mild cognitive impairment | 800 mcg | 1 year | 70 |
| Comparison of two different folic acid doses with methotrexate--a randomized controlled trial (FOLVARI Study) 2015 · FA10 group · Adults aged 18–75 with active rheumatoid arthritis | 1.43 mg | 24 weeks | 51 |
| Effect of folic acid supplementation on nerve conduction velocity in diabetic polyneuropathy patients 2019 · folic acid group · Patients with diabetic polyneuropathy; age and sex not specified | 1 mg | 16 weeks | 40 |
| A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease 2008 · folic acid · Adults with probable Alzheimer's disease treated concurrently with a cholinesterase inhibitor | 1 mg | 26 weeks | 23 |
| A randomized double-blind comparison of fluoxetine augmentation by high and low dosage folic acid in patients with depressive episodes 2013 · Group I · Female out-patients with moderate or severe depressive episodes, without psychotic symptoms | 1.5 mg | 6 weeks | 23 |
| Carotid artery stiffness in patients with end-stage renal disease: no effect of long-term homocysteine-lowering therapy 2000 · Folic acid 1 mg (40-week phase) · Adults on maintenance dialysis with end-stage renal disease and hyperhomocysteinemia | 1 mg | 40 weeks | — |
| Effects of folic acid supplementation on hearing in older adults: a randomized, controlled trial 2007 · folic acid group · Older men and women with plasma total homocysteine concentrations of at least 13 micromol/L and serum vitamin B12 concentrations of at least 200 pmol/L at screening | 800 mcg | 3 years | — |
| Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial 2007 · folic acid group · Men and women aged 50–70 years with raised plasma total homocysteine and normal serum vitamin B12 at screening | 800 mcg | 3 years | — |
| Effects of folic acid on preschool children's appetite: randomized triple-blind clinical trial 2007 · folic acid · Children aged 3–5 years with low weight-for-age and weight-for-height ratios and parent-reported poor appetite | 1 mg | 20 days | — |
| Folate supplementation in schizophrenia: a possible role for MTHFR genotype 2011 · folate · stable adult outpatients with schizophrenia | 2 mg | 12 weeks | — |
| Effect of folic acid combined with docosahexaenoic acid intervention on mild cognitive impairment in elderly: a randomized double-blind, placebo-controlled trial 2021 · FA · Elderly people with mild cognitive impairment (MCI); age range and sex not specified | 800 mcg | 26 weeks | — |
| Positive effects of folic acid supplementation on cognitive aging are dependent on ω-3 fatty acid status: a post hoc analysis of the FACIT trial 2021 · folic acid · Adults aged 50–70 years with plasma total homocysteine 13–26 µmol/L and serum vitamin B12 ≥200 pmol/L | 800 mcg | 3 years | — |
| Effects of Folic Acid Combined with DHA Supplementation on Cognitive Function and Amyloid-β-Related Biomarkers in Older Adults with Mild Cognitive Impairment by a Randomized, Double Blind, Placebo-Controlled Trial 2021 · folic acid · Adults aged over 60 years with mild cognitive impairment | 800 mcg | 26 weeks | — |
| Effects of prenatal micronutrients supplementation timing on pregnancy-induced hypertension: Secondary analysis of a double-blind randomized controlled trial 2021 · IFA group · Pregnant nulliparous Chinese women aged 20 or older, enrolled before 20 gestational weeks, with haemoglobin above 10.0 g/dl | 400 mcg | — | 6,252 |
| Micronutrient supplementation during pregnancy and the risk of pregnancy-induced hypertension: A randomized clinical trial 2019 · IFA group · Nulliparous pregnant women aged 20 years or older, enrolled before 20 weeks of gestation, with hemoglobin at least 10.0 g/dL | 400 mcg | — | 5,933 |
| Effects of Prenatal Micronutrient Supplementation on Spontaneous Preterm Birth: A Double-Blind Randomized Controlled Trial in China 2017 · IFA group · Pregnant women aged 20 years or older, nulliparous, enrolled before 20 gestational weeks, with hemoglobin above 10.0 g/dL | 400 mcg | — | 5,920 |
| Micronutrient supplementation during pregnancy and the risk of pregnancy-induced hypertension: A randomized clinical trial 2019 · MMN group · Nulliparous pregnant women aged 20 years or older, enrolled before 20 weeks of gestation, with hemoglobin at least 10.0 g/dL | 400 mcg | — | 5,914 |
| Effects of Prenatal Micronutrient Supplementation on Spontaneous Preterm Birth: A Double-Blind Randomized Controlled Trial in China 2017 · MMN group · Pregnant women aged 20 years or older, nulliparous, enrolled before 20 gestational weeks, with hemoglobin above 10.0 g/dL | 400 mcg | — | 5,910 |
| B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial 2010 · B vitamins · Patients with recent stroke or transient ischaemic attack within the past 7 months | 2 mg | 1241 days | 4,089 |
| Treatment with B vitamins and incidence of cancer in patients with previous stroke or transient ischemic attack: results of a randomized placebo-controlled trial 2012 · B vitamins · Patients with recent stroke or transient ischemic attack | 2 mg | 1241 days | 4,082 |
| Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial 2012 · B-vitamins group · Adults with a stroke or transient ischaemic attack within the previous 7 months; men and women, age not restricted | 2 mg | 1241 days | 4,040 |
| Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial 2008 · Active treatment · Women aged 40 years or older with a history of cardiovascular disease or at least three cardiovascular risk factors | 2.5 mg | 2665 days | 2,721 |
| Folic acid, pyridoxine, and cyanocobalamin combination treatment and age-related macular degeneration in women: the Women's Antioxidant and Folic Acid Cardiovascular Study 2009 · folic acid/B6/B12 group · Women at high risk of cardiovascular disease, with preexisting cardiovascular disease or at least three coronary risk factors; women included in these AMD analyses had no AMD diagnosis at baseline. | 2.5 mg | 2665 days | 2,607 |
| Effect of homocysteine-lowering treatment with folic Acid and B vitamins on risk of type 2 diabetes in women: a randomized, controlled trial 2009 · Active treatment · Women aged 45 years or older at high risk for cardiovascular disease, without diabetes at baseline | 2.5 mg | 2665 days | 2,132 |
| Folic Acid, Vitamin B6, and Vitamin B12 in Combination and Age-Related Cataract in a Randomized Trial of Women 2016 · combination treatment group · Women with preexisting cardiovascular disease or at least three coronary risk factors; ages 40 and older | 2.5 mg | 2665 days | 1,969 |
| Effect of prenatal multiple micronutrient supplements and medium-quantity lipid-based nutritional supplements on maternal weight gain and infant birth weight in rural Niger: a cluster-randomised trial 2025 · MQ-LNS · Pregnant women in rural Niger enrolled at up to 30 weeks' gestation | 400 mcg | — | 1,144 |
| Effect of prenatal multiple micronutrient supplements and medium-quantity lipid-based nutritional supplements on maternal weight gain and infant birth weight in rural Niger: a cluster-randomised trial 2025 · MMN · Pregnant women in rural Niger enrolled at up to 30 weeks' gestation | 400 mcg | — | 1,083 |
| Excess risk of preterm birth with periconceptional iron supplementation in a malaria endemic area: analysis of secondary data on birth outcomes in a double blind randomized controlled safety trial in Burkina Faso 2019 · weekly iron and folic acid · Nulliparous, non-pregnant women aged 15–24 years in a malaria-endemic area of Burkina Faso who became pregnant during or shortly after supplementation | 400 mcg | 548 days | 980 |
| Risk of malaria in young children after periconceptional iron supplementation 2021 · Iron · Nulliparous young women in Burkina Faso; age range and sex beyond female are not specified; no diagnosed condition stated | 400 mcg | 548 days | 980 |
| Cost-effectiveness of invitation to food supplementation early in pregnancy combined with multiple micronutrients on infant survival: analysis of data from MINIMat randomized trial, Bangladesh 2015 · EMMS · Pregnant women in rural Bangladesh, irrespective of nutritional status | 400 mcg | — | 740 |
| A randomised trial to evaluate the effects of low-dose aspirin in gestation and reproduction: design and baseline characteristics 2013 · LDA group · Healthy women aged 18–40 trying to conceive, with one or two prior pregnancy losses and no known infertility diagnosis | 400 mcg | — | 606 |
| Nutrient supplementation during the first 1000 days and growth of infants born to pregnant adolescents 2020 · IFA-MNP · Pregnant adolescents under 20 years of age and their children | 400 mcg | — | 388 |
| Nutrient supplementation during the first 1000 days and growth of infants born to pregnant adolescents 2020 · IFA-Control · Pregnant adolescents under 20 years of age | 400 mcg | — | 378 |
| Nutrient supplementation during the first 1000 days and growth of infants born to pregnant adolescents 2020 · IFA-LNS · Pregnant adolescents under 20 years of age and their children | 400 mcg | — | 361 |
| Multivitamin and iron supplementation to prevent periconceptional anemia in rural tanzanian women: a randomized, controlled trial 2015 · Folic acid + iron · Non-pregnant women and adolescent girls aged 15–29 years in rural Tanzania | 400 mcg | 26 weeks | 267 |
| B vitamins to enhance treatment response to antidepressants in middle-aged and older adults: results from the B-VITAGE randomised, double-blind, placebo-controlled trial 2014 · vitamins · Community-dwelling adults aged 50 years or over with DSM-IV-TR major depression | 2 mg | 52 weeks | 77 |
| Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study 2007 · TEGAFOX · Adults aged 18–75 with previously untreated metastatic colorectal cancer | 90 mg | — | 73 |
| Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study 2007 · TEGAFIRI · Adults aged 18–75 with previously untreated metastatic colorectal cancer | 90 mg | — | 68 |
| Folic acid supplementation inhibits recurrence of colorectal adenomas: a randomized chemoprevention trial 2008 · folic acid group · Patients with colorectal adenomas | 5 mg | 3 years | 49 |
| The Effects of Folic Acid Supplementation on Recurrence and Metabolic Status in Endometrial Hyperplasia: A Randomized, Double-Blind, Placebo-Controlled Trial 2018 · folic acid group · Women diagnosed with endometrial hyperplasia | 5 mg | 12 weeks | 30 |
| The effect of Myo-inositol on fertility rates in poor ovarian responder in women undergoing assisted reproductive technique: a randomized clinical trial 2021 · Control group · Infertile women aged 20–43 with poor ovarian response, defined by antral follicle count below 7 or AMH below 1.2 ng/ml | 400 mg | 12 weeks | 30 |
| Effects of folate supplementation on recurrence and metabolic status of cervical intraepithelial neoplasia grade 2/3 in overweight and obese women: a randomized double-blind placebo-controlled trial 2022 · intervention group · Overweight or obese women with CIN2/3 | 5 mg | 12 weeks | 30 |
| Effects of long-term folate supplementation on metabolic status and regression of cervical intraepithelial neoplasia: A randomized, double-blind, placebo-controlled trial 2016 · folate group · Women aged 18–55 with cervical intraepithelial neoplasia grade 1 (CIN1) | 5 mg | 26 weeks | 29 |
| Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study 2001 · folinic acid group · Adults with active rheumatoid arthritis | 357 mcg | 48 weeks | — |
| Homocysteine lowering with folic acid and B vitamins in vascular disease 2006 · active-treatment group · Patients aged 55 years or older with vascular disease or diabetes | 2.5 mg | 5 years | — |
| Long-term effect of folic acid therapy in heart transplant recipients: follow-up analysis of a randomized study 2008 · Folic acid therapy · Heart transplant recipients; age and sex not specified | 15 mg | 1 year | — |
| Effect of combined folic acid, vitamin B6, and vitamin B12 on cancer risk in women: a randomized trial 2008 · combined folic acid/vitamin B6/vitamin B12 treatment · Women aged 40 years or older with a history of cardiovascular disease or at least three coronary risk factors | 2.5 mg | 2666 days | — |
| Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial 2009 · vitamin therapy group · Adults with known cardiovascular disease | 2.5 mg | 5 years | — |
| B-vitamins reduce the long-term risk of depression after stroke: The VITATOPS-DEP trial 2010 · B-vitamins · Stroke survivors; age and sex not specified | 2 mg | 383 days | — |
| Equity in adherence to and effect of prenatal food and micronutrient supplementation on child mortality: results from the MINIMat randomized trial, Bangladesh 2014 · EFe30F (early food invitation; 30 mg iron + 400 μg folic acid) · Pregnant women in rural Bangladesh, enrolled before 14 weeks’ gestation | 400 mcg | — | — |
| Equity in adherence to and effect of prenatal food and micronutrient supplementation on child mortality: results from the MINIMat randomized trial, Bangladesh 2014 · UFe30F (usual food invitation; 30 mg iron + 400 μg folic acid) · Pregnant women in rural Bangladesh, enrolled before 14 weeks’ gestation | 400 mcg | — | — |
| Effect of daily vitamin B-12 and folic acid supplementation on fracture incidence in elderly individuals with an elevated plasma homocysteine concentration: B-PROOF, a randomized controlled trial 2014 · vitamin B-12 plus folic acid group · Adults aged 65 years or older with elevated plasma homocysteine concentrations (12–50 μmol/L) | 400 mcg | 2 years | — |
| Modifying effects of maternal Hb concentration on infant birth weight in women receiving prenatal iron-containing supplements: a randomised controlled trial 2016 · IFA group · Pregnant women aged at least 20 years, nulliparous, with Hb concentration ≥100 g/L and enrolled before 20 weeks of gestation | 400 mcg | — | — |
| Effects of long-term weekly iron and folic acid supplementation on lower genital tract infection - a double blind, randomised controlled trial in Burkina Faso 2017 · control · Healthy nulliparous, non-pregnant women aged 15–24 years at enrolment; some became pregnant during follow-up | 400 mcg | 548 days | — |
| Folic Acid and Vitamin B12 Supplementation and the Risk of Cancer: Long-term Follow-up of the B Vitamins for the Prevention of Osteoporotic Fractures (B-PROOF) Trial 2019 · B vitamins · B-PROOF trial participants; age and specific condition not stated in the abstract | 400 mcg | 3 years | — |
| The effect of myo-inositol supplementation on the prevention of gestational diabetes in overweight pregnant women: a randomized, double-blind, controlled trial 2023 · myo-inositol group · Overweight pregnant women at 12–14 weeks of gestation | 400 mcg | 10 weeks | — |
| Predictors of adherence to micronutrient supplementation before and during pregnancy in Vietnam 2017 · FA (folic acid) preconception group · Women of reproductive age in Vietnam intending to become pregnant | 400 mcg | 400 days | 1,459 |
| Impact of preconceptional micronutrient supplementation on maternal mental health during pregnancy and postpartum: results from a randomized controlled trial in Vietnam 2017 · Folic acid (FA) · Women aged 18–40 planning pregnancy; reproductive-age women without a stated diagnosed condition | 400 mcg | 56 weeks | 572 |
| Preconception micronutrient supplementation positively affects child intellectual functioning at 6 y of age: A randomized controlled trial in Vietnam 2021 · FA (folic acid) group · Women of reproductive age receiving preconception supplementation; offspring were assessed at ages 6–7 years | 400 mcg | 201 days | 472 |
| A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study 2013 · Innovator infliximab 3 mg/kg group · Adults with active rheumatoid arthritis and an inadequate response to methotrexate | 714 mcg | 30 weeks | 304 |
| A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study 2013 · CT-P13 3 mg/kg group · Adults with active rheumatoid arthritis and an inadequate response to methotrexate | 714 mcg | 30 weeks | 302 |
| Computerized counseling for folate knowledge and use: a randomized controlled trial 2008 · Intervention group · English-speaking women aged 18–45 years eligible to become pregnant | 400 mcg | — | 223 |
| The dihydrofolate reductase 19-bp deletion modifies the beneficial effect of B-vitamin therapy in mild cognitive impairment: pooled study of two randomized placebo-controlled trials 2022 · Active treatment, VITACOG (UK) · Older adults with mild cognitive impairment; mean age about 77 years; sex not restricted | 800 mcg | 2 years | 133 |
| Comparative economic evaluation of quetiapine plus lamotrigine combination vs quetiapine monotherapy (and folic acid vs placebo) in patients with bipolar depression (CEQUEL) 2018 · Folic acid · People aged 16 years or older with bipolar disorder type I or II and a current depressive episode requiring new pharmacological treatment | 500 mcg | 52 weeks | 91 |
| Effects of folic acid supplementation on cognitive function and Aβ-related biomarkers in mild cognitive impairment: a randomized controlled trial 2019 · intervention group · Adults with mild cognitive impairment; age and sex not stated | 400 mcg | 2 years | 90 |
| Effects of 6-Month Folic Acid Supplementation on Cognitive Function and Blood Biomarkers in Mild Cognitive Impairment: A Randomized Controlled Trial in China 2016 · oral folic acid group · Adults aged 65 years and older with mild cognitive impairment | 400 mcg | 26 weeks | 80 |
| Biochemical and genetic predictors and correlates of response to lamotrigine and folic acid in bipolar depression: Analysis of the CEQUEL clinical trial 2017 · Folic acid (FA) · Adults with bipolar disorder type I or II | 500 mcg | 12 weeks | 67 |
| Effect of continued folic acid supplementation beyond the first trimester of pregnancy on cognitive performance in the child: a follow-up study from a randomized controlled trial (FASSTT Offspring Trial) 2019 · Folic acid · Healthy pregnant women aged 18–35 with a singleton pregnancy who had taken 400 μg/day folic acid during the first trimester | 400 mcg | 26 weeks | 59 |
| Effects of maternal folic acid supplementation during the second and third trimesters of pregnancy on neurocognitive development in the child: an 11-year follow-up from a randomised controlled trial 2021 · Folic acid · Healthy pregnant women aged 18–35 years with singleton pregnancies who had taken 400 μg/day folic acid in the first trimester | 400 mcg | 26 weeks | 37 |
| Probiotic effects on sexual function in women with polycystic ovary syndrome: a double blinded randomized controlled trial 2022 · Letrozole group (Group B) · Women aged 18–38 with PCOS and infertility | 400 mcg | 8 weeks | 20 |
| The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis 2008 · treatment arm A: MTX plus FA phase · Adults aged 35–70 with moderate-to-severe plaque psoriasis | 2.86 mg | 16 weeks | 10 |
| The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis 2008 · treatment arm B: MTX plus FA phase · Adults aged 35–70 with moderate-to-severe plaque psoriasis | 2.86 mg | 16 weeks | 10 |
| Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial 2000 · fluoxetine plus folic acid group · Patients meeting DSM-III-R criteria for major depression with baseline 17-item Hamilton Rating Scale score of 20 or more; age and sex distribution not fully specified | 500 mcg | 10 weeks | — |
| Short-term folate, vitamin B-12 or vitamin B-6 supplementation slightly affects memory performance but not mood in women of various ages 2002 · folate · healthy younger, middle-aged and older women | 750 mcg | 5 weeks | — |
| Global improvement of vascular function and redox state with low-dose folic acid: implications for folate therapy in patients with coronary artery disease 2007 · low-dose folic acid · Patients with coronary artery disease; age and sex not reported | 400 mcg | 7 weeks | — |
| The administration of folic acid to institutionalized epileptic adults with phenytoin-induced gingival hyperplasia. A double-blind, randomized, placebo-controlled, parallel study 1991 · folic acid group · Institutionalized adults with severe intellectual disability, epilepsy, and phenytoin-induced gingival hyperplasia; age and sex not specified | 3 mg | 16 weeks | — |
| Effects of myo-inositol supplementation on oocyte's quality in PCOS patients: a double blind trial 2011 · Group B · Women with polycystic ovary syndrome undergoing IVF | 400 mcg | 90 days | — |
| A Pilot Randomized Controlled Double-Blind Trial of High- Versus Low-Dose Weekly Folic Acid in People With Rheumatoid Arthritis Receiving Methotrexate 2019 · high-dose group · People with active rheumatoid arthritis receiving stable-dose methotrexate | 714 mcg | 24 weeks | — |
| Effects of antenatal micronutrient supplementation regimens on adolescent emotional and behavioral problems: A 14-year follow-up of a double-blind, cluster-randomized controlled trial 2023 · Folic acid (FA) · Pregnant females in rural western China; age and health condition not reported | 400 mcg | — | — |
| Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial 1994 · 5 mg folic acid each week · People aged 19–78 with rheumatoid arthritis receiving methotrexate | 714 mcg | — | — |
| Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial 1994 · 27.5 mg folic acid each week · People aged 19–78 with rheumatoid arthritis receiving methotrexate | 3.93 mg | — | — |
| Effects of individualized administration of folic acid on prothrombotic state and vascular endothelial function with H-type hypertension: A double-blinded, randomized clinical cohort study 2022 · Intervention group, second treatment phase, CC genotype · Adults with H-type hypertension, hyperhomocysteinemia and a prothrombotic state; MTHFR C677T CC genotype | 800 mcg | 12 weeks | 9 |
| [Efficacy and safety of Enalapril-Folate acid tablets in lowering blood pressure and plasma homocysteine] 2007 · Group 3 · People with mild-to-moderate hypertension; age and sex not specified | 800 mcg | 8 weeks | — |
| Efficacy of folic acid and enalapril combined therapy on reduction of blood pressure and plasma glucose: a multicenter, randomized, double-blind, parallel-controlled, clinical trial 2008 · high-FA group · Chinese adults aged 27–75 with mild to moderate hypertension; some participants had baseline hyperglycemia | 800 mcg | 8 weeks | — |
| [Efficacy of enalapril combined with folic acid in lowering blood pressure and plasma homocysteine level] 2009 · high-dose group · People with essential hypertension; age and sex not specified | 800 mcg | 8 weeks | — |
| Elevated Homocysteine Concentrations Decrease the Antihypertensive Effect of Angiotensin-Converting Enzyme Inhibitors in Hypertensive Patients 2017 · Enalapril (10 mg) and folic acid (0.8 mg) · Previously untreated hypertensive patients; age and sex not specified | 800 mcg | 1643 days | — |
| Impact of micronutrient supplementation during pregnancy on birth weight, duration of gestation, and perinatal mortality in rural western China: double blind cluster randomised controlled trial 2008 · Multiple micronutrients · Pregnant women resident in disadvantaged rural counties in Shaanxi Province, China; eligible women enrolled before 28 weeks’ gestation | 400 mcg | — | 1,899 |
| Equity in adherence to and effect of prenatal food and micronutrient supplementation on child mortality: results from the MINIMat randomized trial, Bangladesh 2014 · EMMS (early food invitation; multiple micronutrients) · Pregnant women in rural Bangladesh, enrolled before 14 weeks’ gestation | 400 mcg | — | — |
| Equity in adherence to and effect of prenatal food and micronutrient supplementation on child mortality: results from the MINIMat randomized trial, Bangladesh 2014 · UMMS (usual food invitation; multiple micronutrients) · Pregnant women in rural Bangladesh, enrolled before 14 weeks’ gestation | 400 mcg | — | — |
| Modifying effects of maternal Hb concentration on infant birth weight in women receiving prenatal iron-containing supplements: a randomised controlled trial 2016 · MMN group · Pregnant women aged at least 20 years, nulliparous, with Hb concentration ≥100 g/L and enrolled before 20 weeks of gestation | 400 mcg | — | — |
| [Prevention of the first occurrence of anencephaly and spina bifida with periconceptional multivitamin supplementation (conclusion)] 1994 · multivitamin supplement · Women planning a pregnancy | 800 mcg | — | 2,471 |
| Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation 1992 · vitamin supplement · Women planning a pregnancy, in most cases their first | 800 mcg | — | 2,104 |
| Impact of micronutrient supplementation during pregnancy on birth weight, duration of gestation, and perinatal mortality in rural western China: double blind cluster randomised controlled trial 2008 · Iron-folic acid · Pregnant women resident in disadvantaged rural counties in Shaanxi Province, China; eligible women enrolled before 28 weeks’ gestation | 400 mcg | — | 1,912 |
| Effect of prenatal multiple micronutrient supplements and medium-quantity lipid-based nutritional supplements on maternal weight gain and infant birth weight in rural Niger: a cluster-randomised trial 2025 · IFA · Pregnant women in rural Niger enrolled at up to 30 weeks' gestation | 400 mcg | — | 1,105 |
| Prenatal fortified balanced energy-protein supplementation and birth outcomes in rural Burkina Faso: A randomized controlled efficacy trial 2022 · Control (IFA only) · Pregnant women aged 15–40 years in rural Burkina Faso | 400 mcg | — | 909 |
| Prenatal fortified balanced energy-protein supplementation and birth outcomes in rural Burkina Faso: A randomized controlled efficacy trial 2022 · Intervention (IFA plus fortified BEP) · Pregnant women aged 15–40 years in rural Burkina Faso | 400 mcg | — | 879 |
| Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial 2008 · folic acid plus vitamin B12 plus vitamin B6 · Adults undergoing coronary angiography with coronary artery disease or aortic valve stenosis | 800 mcg | 165 weeks | 772 |
| Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial 2008 · folic acid plus vitamin B12 · Adults undergoing coronary angiography with coronary artery disease or aortic valve stenosis | 800 mcg | 165 weeks | 772 |
| Cost-effectiveness of invitation to food supplementation early in pregnancy combined with multiple micronutrients on infant survival: analysis of data from MINIMat randomized trial, Bangladesh 2015 · UFe60F · Pregnant women in rural Bangladesh, irrespective of nutritional status | 400 mcg | — | 738 |
| Association between prenatal provision of lipid-based nutrient supplements and caesarean delivery: Findings from a randomised controlled trial in Malawi 2022 · IFA group · Pregnant women aged 15 years or older, enrolled before 20 completed gestational weeks, without chronic health conditions, in Malawi | 400 mcg | — | 420 |
| Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial 2002 · homocysteine-lowering therapy · Patients with coronary artery disease after successful percutaneous coronary intervention; age and sex not specified | 1 mg | 26 weeks | 272 |
| Impact of weekly iron folic acid supplementation with and without vitamin B12 on anaemic adolescent girls: a randomised clinical trial 2016 · Group B · Anaemic adolescent girls aged 11–18 years | 71.4 mcg | 26 weeks | 224 |
| Impact of weekly iron folic acid supplementation with and without vitamin B12 on anaemic adolescent girls: a randomised clinical trial 2016 · Group A · Anaemic adolescent girls aged 11–18 years | 71.4 mcg | 26 weeks | 222 |
| Randomized control trial comparing effectiveness of weekly versus daily antenatal oral iron supplementation in preventing anemia during pregnancy 2018 · weekly supplementation group · Non-anemic pregnant women at 14–22 weeks’ gestation | 429 mcg | — | 149 |
| Randomized control trial comparing effectiveness of weekly versus daily antenatal oral iron supplementation in preventing anemia during pregnancy 2018 · daily supplementation group · Non-anemic pregnant women at 14–22 weeks’ gestation | 1 mg | — | 143 |
| Periconceptional iron supplementation does not reduce anemia or improve iron status among pregnant women in rural Bangladesh 2009 · iron and folic acid (IFA) · Married, nulliparous women in rural Bangladesh, followed until pregnancy or the end of 9 months | 400 mcg | 274 days | 134 |
| Myo-inositol Supplementation for Prevention of Gestational Diabetes in Obese Pregnant Women: A Randomized Controlled Trial 2015 · myo-inositol · Pregnant obese women (prepregnancy BMI 30 or greater) | 400 mcg | — | 110 |
| Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial 2016 · myo-inositol group · Pregnant overweight, non-obese women with pre-pregnancy BMI ≥25 and <30 kg/m² | 400 mcg | — | 110 |
| Effect of dietary myo-inositol supplementation on the insulin resistance and the prevention of gestational diabetes mellitus: an open-label, randomized controlled trial 2024 · MI group · Pregnant women at 11–13+6 weeks of gestation | 400 mcg | — | 100 |
| Multimicronutrient supplementation for undernourished pregnant women and the birth size of their offspring: a double-blind, randomized, placebo-controlled trial 2007 · micronutrient supplementation group · Undernourished pregnant women enrolled at 24–32 weeks of gestation, with BMI <18.5 and/or hemoglobin 7–9 g/dL | 500 mcg | 58 days | 99 |
| Weekly vs daily iron and folic acid supplementation in adolescent Nepalese girls 2002 · Group A · Healthy adolescent girls in Nepal; median age 15 years | 1.5 mg | 100 days | 70 |
| Weekly vs daily iron and folic acid supplementation in adolescent Nepalese girls 2002 · Group B · Healthy adolescent girls in Nepal; median age 15 years | 214 mcg | 14 weeks | 67 |
| Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women 2010 · MYO plus folic acid, with r-FSH added if no pregnancy occurred · Women with polycystic ovary syndrome, menstrual irregularities, chronic anovulation, and female infertility; ages not reported | 400 mcg | — | 60 |
| Effect of early versus late administration of human recombinant erythropoietin on transfusion requirements in premature infants: results of a randomized, placebo-controlled, multicenter trial 2000 · early group · Premature infants with birth weight <1250 g | 2 mg | 8 weeks | 57 |
| Effect of early versus late administration of human recombinant erythropoietin on transfusion requirements in premature infants: results of a randomized, placebo-controlled, multicenter trial 2000 · late group · Premature infants with birth weight <1250 g | 2 mg | 8 weeks | 57 |
| Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer 2018 · Supplemented patients · Adults aged at least 18 years with advanced metastatic or locally advanced unresectable esophagogastric carcinoma | 450 mcg | 22 weeks | 41 |
| Effect of Lipid-Based Multiple Micronutrients Supplementation in Underweight Primigravida Pre-Eclamptic Women on Maternal and Pregnancy Outcomes: Randomized Clinical Trial 2022 · Group 1 · Pregnant primigravida women aged 15–35 with pre-eclampsia and underweight for gestational age | 400 mcg | 48 days | 30 |
| Effect of Lipid-Based Multiple Micronutrients Supplementation in Underweight Primigravida Pre-Eclamptic Women on Maternal and Pregnancy Outcomes: Randomized Clinical Trial 2022 · Group 2 · Pregnant primigravida women aged 15–35 with pre-eclampsia and underweight for gestational age | 400 mcg | 62 days | 30 |
| Albendazole therapy and reduced decline in haemoglobin concentration during pregnancy (Sierra Leone) 2001 · albendazole plus iron-folate supplements · Pregnant women in Sierra Leone | 5 mg | — | — |
| Effects of maternal micronutrient supplementation on fetal loss and infant mortality: a cluster-randomized trial in Nepal 2003 · Folic acid · Pregnant women in rural Nepal | 400 mcg | — | — |
| Effects of maternal micronutrient supplementation on fetal loss and infant mortality: a cluster-randomized trial in Nepal 2003 · Folic acid + iron · Pregnant women in rural Nepal | 400 mcg | — | — |
| Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial 2005 · daily oral treatment with folate and mecobalamin · Adults aged 65 years or older with residual hemiplegia at least 1 year after a first ischemic stroke | 5 mg | 2 years | — |
| Effect of routine prophylactic supplementation with iron and folic acid on preschool child mortality in southern Nepal: community-based, cluster-randomised, placebo-controlled trial 2006 · iron and folic acid · Children aged 1–36 months in southern Nepal | 50 mcg | — | — |
| Effect of routine prophylactic supplementation with iron and folic acid on preschool child mortality in southern Nepal: community-based, cluster-randomised, placebo-controlled trial 2006 · iron and folic acid with zinc · Children aged 1–36 months in southern Nepal | 50 mcg | — | — |
| Daily intake of 100 mg ascorbic acid as urinary tract infection prophylactic agent during pregnancy 2007 · Group A · Pregnant women | 5 mg | 90 days | — |
| Daily intake of 100 mg ascorbic acid as urinary tract infection prophylactic agent during pregnancy 2007 · Group B · Pregnant women | 5 mg | 90 days | — |
| 5-methyltetrahydrofolate administration is associated with prolonged survival and reduced inflammation in ESRD patients 2008 · group B · Hemodialysis patients with end-stage renal disease; age and sex not reported | 5 mg | — | — |
| Treatment and prevention of anemia with ferrous sulfate plus folic acid in children attending daycare centers in Goiânia, Goiás State, Brazil: a randomized controlled trial 2008 · Treatment group receiving ferrous sulfate plus folic acid · Children aged 6–24 months with anemia attending municipal daycare centers in Goiânia, Brazil | 50 mcg | 90 days | — |
| Treatment and prevention of anemia with ferrous sulfate plus folic acid in children attending daycare centers in Goiânia, Goiás State, Brazil: a randomized controlled trial 2008 · Prevention group receiving ferrous sulfate plus folic acid · Non-anemic children aged 6–24 months attending municipal daycare centers in Goiânia, Brazil | 50 mcg | 90 days | — |
| Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial 2012 · standard multivitamin with high doses of folic acid, vitamin B6 and vitamin B12 · Men and women aged 35–75 years, at least 6 months after kidney transplant, with stable kidney function and elevated serum homocysteine | 5 mg | — | — |
| myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study 2013 · myo-inositol group · Pregnant women recruited at 12–13 weeks’ gestation with a first-degree relative with type 2 diabetes, prepregnancy BMI <30 kg/m², and no pregestational diabetes or PCOS | 400 mcg | — | — |
| Equity in adherence to and effect of prenatal food and micronutrient supplementation on child mortality: results from the MINIMat randomized trial, Bangladesh 2014 · EFe60F (early food invitation; 60 mg iron + 400 μg folic acid) · Pregnant women in rural Bangladesh, enrolled before 14 weeks’ gestation | 400 mcg | — | — |
| Equity in adherence to and effect of prenatal food and micronutrient supplementation on child mortality: results from the MINIMat randomized trial, Bangladesh 2014 · UFe60F (usual food invitation; 60 mg iron + 400 μg folic acid) · Pregnant women in rural Bangladesh, enrolled before 14 weeks’ gestation | 400 mcg | — | — |
| Effectiveness of homocysteine lowering vitamins in prevention of thrombotic tendency at high altitude area: A randomized field trial 2015 · intervention · Indian soldiers freshly inducted to a high-altitude area | 5 mg | 2 years | — |
| Effects of long-term weekly iron and folic acid supplementation on lower genital tract infection - a double blind, randomised controlled trial in Burkina Faso 2017 · iron · Healthy nulliparous, non-pregnant women aged 15–24 years at enrolment; some became pregnant during follow-up | 400 mcg | 548 days | — |
| Prevention of congenital abnormalities by periconceptional multivitamin supplementation 1993 · multivitamin group · Women in the Hungarian family planning programme around conception; age and health condition not stated | 800 mcg | — | — |
| The higher rate of multiple births after periconceptional multivitamin supplementation: an analysis of causes 1994 · multivitamin group · Women receiving periconceptional supplementation; pregnancy | 800 mcg | — | — |
| Reduction of urinary tract and cardiovascular defects by periconceptional multivitamin supplementation 1996 · multivitamin group · Women receiving periconceptional supplementation; age and health condition not specified | 800 mcg | — | — |
| Predictors of adherence to micronutrient supplementation before and during pregnancy in Vietnam 2017 · IFA (iron and folic acid) preconception group · Women of reproductive age in Vietnam intending to become pregnant | 400 mcg | 400 days | 1,489 |
| Effect of B vitamins and lowering homocysteine on cognitive impairment in patients with previous stroke or transient ischemic attack: a prespecified secondary analysis of a randomized, placebo-controlled trial and meta-analysis 2013 · B-vitamins · Patients with previous stroke or transient ischemic attack who were cognitively unimpaired at the cognitive assessment | 2 mg | 1241 days | 1,110 |
| Evaluation of multiple micronutrient supplementation and medium-quantity lipid-based nutrient supplementation in pregnancy on child development in rural Niger: A secondary analysis of a cluster randomized controlled trial 2022 · MMS · Pregnant women under 30 weeks’ gestation at enrollment, without the specified chronic health conditions or pregnancy complications | 400 mcg | — | 1,083 |
| Effect of a randomised exclusive breastfeeding counselling intervention nested into the MINIMat prenatal nutrition trial in Bangladesh 2017 · Fe30 · Pregnant women in rural Bangladesh, enrolled before 14 weeks of gestation | 400 mcg | — | 917 |
| Effect of a randomised exclusive breastfeeding counselling intervention nested into the MINIMat prenatal nutrition trial in Bangladesh 2017 · MMS · Pregnant women in rural Bangladesh, enrolled before 14 weeks of gestation | 400 mcg | — | 914 |
| Impact of preconceptional micronutrient supplementation on maternal mental health during pregnancy and postpartum: results from a randomized controlled trial in Vietnam 2017 · Iron and folic acid (IFA) · Women aged 18–40 planning pregnancy; reproductive-age women without a stated diagnosed condition | 400 mcg | 56 weeks | 526 |
| Impact of preconceptional micronutrient supplementation on maternal mental health during pregnancy and postpartum: results from a randomized controlled trial in Vietnam 2017 · Multiple micronutrients (MM) · Women aged 18–40 planning pregnancy; reproductive-age women without a stated diagnosed condition | 400 mcg | 56 weeks | 518 |
| Prenatal and postnatal lipid-based nutrient supplementation and cognitive, social-emotional, and motor function in preschool-aged children in Ghana: a follow-up of a randomized controlled trial 2019 · multiple micronutrients (MMN) group · Pregnant women aged 18 years or older, enrolled at up to 20 weeks of gestation; supplementation continued postpartum | 400 mcg | — | 439 |
| Preconception micronutrient supplementation positively affects child intellectual functioning at 6 y of age: A randomized controlled trial in Vietnam 2021 · IFA (iron and folic acid) group · Women of reproductive age receiving preconception supplementation; offspring were assessed at ages 6–7 years | 400 mcg | 194 days | 427 |
| Preconception micronutrient supplementation positively affects child intellectual functioning at 6 y of age: A randomized controlled trial in Vietnam 2021 · MM (multiple micronutrient) group · Women of reproductive age receiving preconception supplementation; offspring were assessed at ages 6–7 years | 400 mcg | 200 days | 422 |
| Lipid-based nutrient supplement increases the birth size of infants of primiparous women in Ghana 2015 · IFA · Pregnant women in Ghana, aged 20 years or younger in pregnancy (≤20 weeks); primiparous subgroup reported | 400 mcg | — | 349 |
| Effects of prenatal food and micronutrient supplementation on child growth from birth to 54 months of age: a randomized trial in Bangladesh 2011 · Early invitation food supplementation + Fe60F · Pregnant women in rural Bangladesh; fetal viability and gestational age under 14 weeks; all eligible maternal nutritional statuses | 400 mcg | — | 291 |
| Effects of prenatal food and micronutrient supplementation on child growth from birth to 54 months of age: a randomized trial in Bangladesh 2011 · Early invitation food supplementation + MMS · Pregnant women in rural Bangladesh; fetal viability and gestational age under 14 weeks; all eligible maternal nutritional statuses | 400 mcg | — | 290 |
| Effects of prenatal food and micronutrient supplementation on child growth from birth to 54 months of age: a randomized trial in Bangladesh 2011 · Usual invitation food supplementation + Fe60F · Pregnant women in rural Bangladesh; fetal viability and gestational age under 14 weeks; all eligible maternal nutritional statuses | 400 mcg | — | 275 |
| Effects of prenatal food and micronutrient supplementation on child growth from birth to 54 months of age: a randomized trial in Bangladesh 2011 · Usual invitation food supplementation + Fe30F · Pregnant women in rural Bangladesh; fetal viability and gestational age under 14 weeks; all eligible maternal nutritional statuses | 400 mcg | — | 260 |
| Effects of prenatal food and micronutrient supplementation on child growth from birth to 54 months of age: a randomized trial in Bangladesh 2011 · Usual invitation food supplementation + MMS · Pregnant women in rural Bangladesh; fetal viability and gestational age under 14 weeks; all eligible maternal nutritional statuses | 400 mcg | — | 260 |
| Effects of prenatal food and micronutrient supplementation on child growth from birth to 54 months of age: a randomized trial in Bangladesh 2011 · Early invitation food supplementation + Fe30F · Pregnant women in rural Bangladesh; fetal viability and gestational age under 14 weeks; all eligible maternal nutritional statuses | 400 mcg | — | 258 |
| The dihydrofolate reductase 19-bp deletion modifies the beneficial effect of B-vitamin therapy in mild cognitive impairment: pooled study of two randomized placebo-controlled trials 2022 · Active treatment, Hong Kong trial · Older adults with mild cognitive impairment; mean age about 77 years; sex not restricted | 400 mcg | 2 years | 131 |
| Vitamin B12 and Folic Acid Improve Gross Motor and Problem-Solving Skills in Young North Indian Children: A Randomized Placebo-Controlled Trial 2015 · Folic acid · Children aged 6–30 months from low- to middle-socioeconomic-class families in New Delhi, India | 150 mcg | 26 weeks | 107 |
| Folate and Vitamin B(12)-Related Biomarkers in Relation to Brain Volumes 2016 · B-vitamin group · Adults aged 65 years or older with mildly elevated plasma homocysteine (12–50 µmol/L) | 400 mcg | 2 years | 106 |
| DHA status influences effects of B-vitamin supplementation on cognitive ageing: a post-hoc analysis of the B-proof trial 2022 · B-vitamin group · Men and women aged 65 years and older with elevated plasma homocysteine levels (12–50 µmol/L), cognitively healthy | 400 mcg | 2 years | 94 |
| Folate improves endothelial function in coronary artery disease: an effect mediated by reduction of intracellular superoxide? 2001 · folic acid · Patients with coronary artery disease; age and sex not reported | 5 mg | 6 weeks | 52 |
| Comparison of two different folic acid doses with methotrexate--a randomized controlled trial (FOLVARI Study) 2015 · FA30 group · Adults aged 18–75 with active rheumatoid arthritis | 4.29 mg | 24 weeks | 49 |
| Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term? 2000 · FA 5 mg daily · Adults with rheumatoid arthritis established on methotrexate and folic acid | 5 mg | 1 year | 38 |
| Folic acid improves endothelial function in children and adolescents with type 1 diabetes 2004 · Folic acid · Children and adolescents with type 1 diabetes; mean age 13.6 years (SD 2.6) | 5 mg | 8 weeks | 36 |
| Folic acid does not improve endothelial function in healthy hyperhomocysteinaemic subjects 2004 · folic acid · Healthy adults with hyperhomocysteinaemia and no additional coronary artery disease risk factors; age range not stated | 5 mg | 8 weeks | 26 |
| Effects of oral folic acid supplementation on endothelial function in familial hypercholesterolemia. A randomized placebo-controlled trial 1999 · folic acid treatment · Adults with familial hypercholesterolemia; age and sex not specified | 5 mg | 4 weeks | 20 |
| Folic acid improves endothelial dysfunction in type 2 diabetes--an effect independent of homocysteine-lowering 2006 · folic acid · patients with type 2 diabetes without vascular disease | 10 mg | 2 weeks | 19 |
| A randomized double-blind comparison of fluoxetine augmentation by high and low dosage folic acid in patients with depressive episodes 2013 · Group II · Female out-patients with moderate or severe depressive episodes, without psychotic symptoms | 5 mg | 6 weeks | 19 |
| Oral folate enhances endothelial function in hyperhomocysteinaemic subjects 1999 · oral folic acid · healthy adults with mild hyperhomocysteinaemia (entry homocysteine >13 micromol L-1) | 5 mg | 6 weeks | 18 |
| Folic acid improves arterial endothelial function in adults with hyperhomocystinemia 1999 · folic acid · Adults aged 44–64 with fasting total homocystine levels above the 75th percentile (hyperhomocystinemia), without the listed cardiovascular risk conditions | 10 mg | 8 weeks | 17 |
| Short-Term Effects of Folate Supplementation in Combination With Vitamin B6 for Treating Acute Manic Episodes in Bipolar I Disorder: A Randomized Controlled Trial 2025 · Folate group · Adults aged 18–45 with bipolar I disorder in an acute manic episode | 5 mg | 6 weeks | 15 |
| High-dose folic acid acutely improves coronary vasodilator function in patients with coronary artery disease 2005 · folate · adult men and women with coronary artery disease and normal serum homocysteine | 30 mg | 1 day | 14 |
| Folic acid supplementation increases cutaneous vasodilator sensitivity to sympathetic nerve activity in older adults 2017 · folic acid · Older adults, mean age 66 ± 1 years; 8 male and 6 female; no specific condition stated | 5 mg | 6 weeks | 14 |
| Pyridoxine improves endothelial function in cardiac transplant recipients 2001 · folate · Cardiac transplant recipients; age and sex not specified | 5 mg | 10 weeks | 12 |
| [Decrease of folic acid and cognitive alterations in patients with epilepsy treated with phenytoin or carbamazepine, pilot study] 2005 · study group · Patients with epilepsy treated with phenytoin, carbamazepine, or both | 5 mg | 26 weeks | 9 |
| Effect of folic acid on recurrence of phenytoin-induced gingival overgrowth following gingivectomy 1991 · treatment group · Residents of an institution for people with developmental disabilities with phenytoin-induced gingival overgrowth following gingivectomy | 5 mg | 26 weeks | 4 |
| Influence of folic acid on postprandial endothelial dysfunction 2000 · folic acid · Healthy volunteers aged 18–33 years | 10 mg | 2 weeks | — |
| Carotid artery stiffness in patients with end-stage renal disease: no effect of long-term homocysteine-lowering therapy 2000 · Folic acid 5 mg daily, without betaine (12-week phase) · Adults on maintenance dialysis with end-stage renal disease and hyperhomocysteinemia | 5 mg | 12 weeks | — |
| Carotid artery stiffness in patients with end-stage renal disease: no effect of long-term homocysteine-lowering therapy 2000 · Folic acid 5 mg (40-week phase) · Adults on maintenance dialysis with end-stage renal disease and hyperhomocysteinemia | 5 mg | 40 weeks | — |
| Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure? 2000 · folic acid group · Adults with predialysis chronic renal failure; mean age 62 years; 67 men across the study | 5 mg | 12 weeks | — |
| A randomized double-blind placebo-controlled trial of the effect of homocysteine-lowering therapy with folic acid on endothelial function in patients with coronary artery disease 2001 · folic acid group · Adults aged 46–79 years with coronary artery disease; 79 of the 90 participants were men | 5 mg | 12 weeks | — |
| Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study 2001 · folic acid · healthy men aged 19 to 32 years | 10 mg | 7 days | — |
| Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering 2002 · folic acid · Patients with coronary artery disease; age and sex not reported | 5 mg | 6 weeks | — |
| Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial 2002 · folic acid and placebo · Fertile and subfertile men | 5 mg | 26 weeks | — |
| Folic acid enhances endothelial function and reduces blood pressure in smokers: a randomized controlled trial 2002 · folic acid · Healthy adult cigarette smokers; mean age 37.8 years | 5 mg | 4 weeks | — |
| C677T methylenetetrahydrofolate reductase polymorphism interferes with the effects of folic acid and zinc sulfate on sperm concentration 2003 · folic acid group · fertile and subfertile males | 5 mg | 26 weeks | — |
| Folic Acid improves baroreceptor sensitivity in hypertension 2005 · folic acid group · male patients with hypertension | 5 mg | 1 day | — |
| Short-term oral folic acid supplementation enhances endothelial function in patients with type 2 diabetes 2005 · oral folic acid · Adults with type 2 diabetes, mean age 56.5 years, with no history of cardiovascular disease | 5 mg | 4 weeks | — |
| Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial 2006 · FA group · Patients with psoriasis stable on long-term methotrexate doses and not receiving folic acid | 5 mg | 12 weeks | — |
| Folate and vitamin B6 rapidly normalize endothelial dysfunction in children with type 1 diabetes mellitus 2006 · Folate · Children with type 1 diabetes mellitus; age and sex not specified | 5 mg | 8 weeks | — |
| Effect of folic acid on endothelial function following acute myocardial infarction 2007 · group A · Patients after acute myocardial infarction referred for coronary intervention; 16 had normal homocysteine and 24 had elevated homocysteine across the study | 10 mg | 6 weeks | — |
| Global improvement of vascular function and redox state with low-dose folic acid: implications for folate therapy in patients with coronary artery disease 2007 · high-dose folic acid · Patients with coronary artery disease; age and sex not reported | 5 mg | 7 weeks | — |
| The association of betaine, homocysteine and related metabolites with cognitive function in Dutch elderly people 2007 · cobalamin plus folic acid group · Dutch elderly people; no diagnosed condition stated | 400 mcg | 24 weeks | — |
| Effect of folic acid combined with fluoxetine in patients with major depression on plasma homocysteine and vitamin B12, and serotonin levels in lymphocytes 2008 · fluoxetine and folic acid · Patients with major depression; age and sex not reported | 10 mg | 6 weeks | — |
| A trial of B vitamins and cognitive function among women at high risk of cardiovascular disease 2008 · B vitamin group · Women aged 65 years or older with cardiovascular disease or at least three coronary risk factors; female health professionals | 2.5 mg | 2411 days | — |
| Assessment of the efficacy of combination therapy with folic acid and tadalafil for the management of erectile dysfunction in men with type 2 diabetes mellitus 2013 · Group A · Men with type 2 diabetes mellitus and erectile dysfunction | 5 mg | 90 days | — |
| Effects of pre- and postnatal nutrition interventions on child growth and body composition: the MINIMat trial in rural Bangladesh 2013 · Fe30F · Pregnant women enrolled before 14 weeks’ gestation; age 14–50 years | 400 mcg | — | — |
| Effects of pre- and postnatal nutrition interventions on child growth and body composition: the MINIMat trial in rural Bangladesh 2013 · MMS · Pregnant women enrolled before 14 weeks’ gestation; age 14–50 years | 400 mcg | — | — |
| Results of 2-year vitamin B treatment on cognitive performance: secondary data from an RCT 2014 · B-vitamin group · Adults aged 65 years and older with homocysteine levels of 12–50 µmol/L | 400 mcg | 2 years | — |
| Folic acid supplementation improves microvascular function in older adults through nitric oxide-dependent mechanisms 2015 · Folic acid treatment · Healthy young and older adults; age ranges and arm size not stated | 5 mg | 6 weeks | — |
| Effects of 2-year vitamin B12 and folic acid supplementation in hyperhomocysteinemic elderly on arterial stiffness and cardiovascular outcomes within the B-PROOF trial 2015 · B-vitamin supplementation · Adults aged at least 65 years with hyperhomocysteinemia (12–50 μmol/l) | 400 mcg | 2 years | — |
| Comparative Study of the Effects of Tamoxifen Citrate and Folate on Semen Quality of the Infertile Male with Semen Abnormality 2015 · Tamoxifen citrate plus Folate · Infertile men with semen abnormalities | 5 mg | 90 days | — |
| Effects of Two-Year Vitamin B(12) and Folic Acid Supplementation on Depressive Symptoms and Quality of Life in Older Adults with Elevated Homocysteine Concentrations: Additional Results from the B-PROOF Study, an RCT 2016 · intervention group · Adults aged 65 years or older from the general population with elevated homocysteine concentrations (12–50 µmol/L) | 400 mcg | 2 years | — |
| The effects of folic acid and pyridoxine supplementation on characteristics of migraine attacks in migraine patients with aura: A double-blind, randomized placebo-controlled, clinical trial 2017 · folic acid alone · Adults aged 18–65 with migraine with aura | 5 mg | 90 days | — |
| Preconception Micronutrient Supplementation with Iron and Folic Acid Compared with Folic Acid Alone Affects Linear Growth and Fine Motor Development at 2 Years of Age: A Randomized Controlled Trial in Vietnam 2017 · IFA group · Women in Vietnam receiving preconception supplementation; age and health status not stated | 400 mcg | — | — |
| A Pilot Randomized Controlled Double-Blind Trial of High- Versus Low-Dose Weekly Folic Acid in People With Rheumatoid Arthritis Receiving Methotrexate 2019 · low-dose group · People with active rheumatoid arthritis receiving stable-dose methotrexate | 114 mcg | 24 weeks | — |
| B-vitamins and body composition: integrating observational and experimental evidence from the B-PROOF study 2020 · intervention group · Adults aged 65 years and older with elevated homocysteine levels (12–50 µmol/L) | 400 mcg | 2 years | — |
| A randomized placebo-controlled trial of using B vitamins to prevent cognitive decline in older mild cognitive impairment patients 2020 · B vitamins supplementation · Adults aged 65 years or older with mild cognitive impairment and serum homocysteine ≥10.0 μmol/L | 400 mcg | 2 years | — |
| Folic acid supplementation in postmenopausal women with hot flushes: phase III randomised double-blind placebo-controlled trial 2021 · folic acid group · Postmenopausal women experiencing at least 50 hot flushes weekly | 5 mg | 12 weeks | — |
| B Vitamin Supplementation Slows Cognitive Decline in Mild Cognitive Impairment Patients with Frontal Lobe Atrophy 2022 · B vitamin supplementation · Mild cognitive impairment outpatients; age and sex not specified | 400 mcg | 2 years | — |
| Effects of antenatal micronutrient supplementation regimens on adolescent emotional and behavioral problems: A 14-year follow-up of a double-blind, cluster-randomized controlled trial 2023 · Multiple micronutrient (MMN) · Pregnant females in rural western China; age and health condition not reported | 400 mcg | — | — |
| Prenatal and postnatal small-quantity lipid-based nutrient supplements and children's social-emotional difficulties at ages 9-11 y in Ghana: follow-up of a randomized controlled trial 2023 · multiple micronutrient (MMN) group · Pregnant women in Ghana; children were followed through infancy and assessed at ages 9–11 years | 400 mcg | — | — |
| Effect of folic acid on the sexual function of postmenopausal women: a triple-blind randomized controlled trial 2023 · folic acid group · Postmenopausal women; mean age 53.2 years | 5 mg | 8 weeks | — |
| Thiamine and folate treatment of chronic epileptic patients: a controlled study with the Wechsler IQ scale 1993 · second group · Patients with epilepsy receiving phenytoin alone or with phenobarbital for more than 4 years; age and sex not reported | 5 mg | 26 weeks | — |
| Effects of individualized administration of folic acid on prothrombotic state and vascular endothelial function with H-type hypertension: A double-blinded, randomized clinical cohort study 2022 · Intervention group, second treatment phase, CT genotype · Adults with H-type hypertension, hyperhomocysteinemia and a prothrombotic state; MTHFR C677T CT genotype | 2.5 mg | 12 weeks | 14 |
| [Efficacy and safety of Enalapril-Folate acid tablets in lowering blood pressure and plasma homocysteine] 2007 · Group 2 · People with mild-to-moderate hypertension; age and sex not specified | 400 mcg | 8 weeks | — |
| Efficacy of folic acid and enalapril combined therapy on reduction of blood pressure and plasma glucose: a multicenter, randomized, double-blind, parallel-controlled, clinical trial 2008 · low-FA group · Chinese adults aged 27–75 with mild to moderate hypertension; some participants had baseline hyperglycemia | 400 mcg | 8 weeks | — |
| [Efficacy of enalapril combined with folic acid in lowering blood pressure and plasma homocysteine level] 2009 · low-dose group · People with essential hypertension; age and sex not specified | 400 mcg | 8 weeks | — |
| A pilot study of D-chiro-inositol plus folic acid in overweight patients with type 1 diabetes 2017 · control group · Overweight or obese patients with type 1 diabetes receiving intensive insulin therapy | 400 mcg | 24 weeks | — |
| Multivitamin and iron supplementation to prevent periconceptional anemia in rural tanzanian women: a randomized, controlled trial 2015 · Folic acid, iron, multivitamins · Non-pregnant women and adolescent girls aged 15–29 years in rural Tanzania | 400 mcg | 26 weeks | 267 |
| The effect of myo-inositol, vitamin D3 and melatonin on the oocyte quality and pregnancy in in vitro fertilization: a randomized prospective controlled trial 2020 · Study group · Women undergoing ICSI | 600 mcg | 26 weeks | 50 |
| Effects of a nutritional supplement on the immune response and cytokine production in free-living Chilean elderly 2004 · special nutritional formula · Healthy adults aged 70 years or older with Mini Mental score ≥22 | 400 mcg | 1 year | 30 |
| Effects of maternal micronutrient supplementation on fetal loss and infant mortality: a cluster-randomized trial in Nepal 2003 · Folic acid + iron + zinc · Pregnant women in rural Nepal | 400 mcg | — | — |
| Effects of maternal micronutrient supplementation on fetal loss and infant mortality: a cluster-randomized trial in Nepal 2003 · Multiple micronutrients · Pregnant women in rural Nepal | 400 mcg | — | — |
| Multivitamin supplementation of HIV-positive women during pregnancy reduces hypertension 2005 · Multivitamin plus vitamin A · HIV-positive pregnant Tanzanian women | 800 mcg | — | — |
| Multivitamin supplementation of HIV-positive women during pregnancy reduces hypertension 2005 · Multivitamin without vitamin A · HIV-positive pregnant Tanzanian women | 800 mcg | — | — |
| Randomized, double-blind, placebo-controlled trial of selenium supplements among HIV-infected pregnant women in Tanzania: effects on maternal and child outcomes 2008 · selenium group · Infants born to women with HIV in the selenium group; follow-up after birth | 1.05 mg | — | — |
| Aged garlic extract with supplement is associated with increase in brown adipose, decrease in white adipose tissue and predict lack of progression in coronary atherosclerosis 2013 · AGE-S · Subjects evaluated for coronary artery calcium; age, sex, and specific condition are not stated | 300 mcg | 1 year | — |
| Predictors of adherence to micronutrient supplementation before and during pregnancy in Vietnam 2017 · MM (multiple micronutrients) preconception group · Women of reproductive age in Vietnam intending to become pregnant | 400 mcg | 54 weeks | 1,469 |
| Effects of antenatal multiple micronutrient supplementation on children's weight and size at 2 years of age in Nepal: follow-up of a double-blind randomised controlled trial 2008 · intervention group · Pregnant women enrolled at no earlier than 12 weeks’ gestation, with singleton pregnancies and gestation up to 20 completed weeks | 400 mcg | — | 600 |
| Effect of antenatal multiple micronutrient supplementation on anthropometry and blood pressure in mid-childhood in Nepal: follow-up of a double-blind randomised controlled trial 2014 · intervention group (multiple micronutrient supplement) · Pregnant women attending antenatal care in Nepal; no specific age range or deficiency criterion stated | 400 mcg | — | 600 |
| Assessing the adherence and acceptability to iron and folic acid compared with multiple micronutrient supplements during pregnancy: a cluster-randomized noninferiority trial in Cambodia 2025 · MMS-180 · Healthy pregnant individuals aged 18–45 years, in the first 14 weeks of a low-risk singleton pregnancy | 400 mcg | 180 days | 516 |
| Assessing the adherence and acceptability to iron and folic acid compared with multiple micronutrient supplements during pregnancy: a cluster-randomized noninferiority trial in Cambodia 2025 · MMS-90 · Healthy pregnant individuals aged 18–45 years, in the first 14 weeks of a low-risk singleton pregnancy | 400 mcg | 180 days | 515 |
| Adherence in a pragmatic randomized controlled trial on prophylactic iron supplementation during pregnancy in Maputo, Mozambique 2015 · routine Fe · Pregnant women aged 18 years or older with non-high-risk pregnancies, at least 12 weeks’ gestation, attending prenatal care in Maputo, Mozambique | 400 mcg | — | 2,184 |
| Adherence in a pragmatic randomized controlled trial on prophylactic iron supplementation during pregnancy in Maputo, Mozambique 2015 · selective Fe · Pregnant women aged 18 years or older with non-high-risk pregnancies, at least 12 weeks’ gestation, attending prenatal care in Maputo, Mozambique | 1 mg | — | 2,142 |
| Evaluation of multiple micronutrient supplementation and medium-quantity lipid-based nutrient supplementation in pregnancy on child development in rural Niger: A secondary analysis of a cluster randomized controlled trial 2022 · IFA (routine care) · Pregnant women under 30 weeks’ gestation at enrollment, without the specified chronic health conditions or pregnancy complications | 400 mcg | — | 1,105 |
| Effect of a randomised exclusive breastfeeding counselling intervention nested into the MINIMat prenatal nutrition trial in Bangladesh 2017 · Fe60 · Pregnant women in rural Bangladesh, enrolled before 14 weeks of gestation | 400 mcg | — | 958 |
| Prevalence of morbidity symptoms among pregnant and postpartum women receiving different nutrient supplements in Ghana and Malawi: A secondary outcome analysis of two randomised controlled trials 2023 · IFA supplement group · Pregnant women aged 18 years or older in Ghana and pregnant women aged 15 years or older in Malawi; supplementation began by 20 weeks of pregnancy, with follow-up through lactation | 400 mcg | — | 904 |
| Effects of antenatal multiple micronutrient supplementation on children's weight and size at 2 years of age in Nepal: follow-up of a double-blind randomised controlled trial 2008 · control group · Pregnant women enrolled at no earlier than 12 weeks’ gestation, with singleton pregnancies and gestation up to 20 completed weeks | 400 mcg | — | 600 |
| Assessing the adherence and acceptability to iron and folic acid compared with multiple micronutrient supplements during pregnancy: a cluster-randomized noninferiority trial in Cambodia 2025 · IFA-90 · Healthy pregnant individuals aged 18–45 years, in the first 14 weeks of a low-risk singleton pregnancy | 400 mcg | 90 days | 515 |
| The effect of blister packaging Iron and Folate on adherence to medication and hemoglobin levels among pregnant women at National Referral Hospital antenatal clinics in a low to middle income country: a Randomised Controlled Trial (The IFAd Trial) 2022 · IFA in blister packaging · Pregnant women in their second trimester up to 28 weeks, aged 15–43 years, eligible for iron and folic acid supplementation | 400 mcg | 8 weeks | 478 |
| The effect of blister packaging Iron and Folate on adherence to medication and hemoglobin levels among pregnant women at National Referral Hospital antenatal clinics in a low to middle income country: a Randomised Controlled Trial (The IFAd Trial) 2022 · IFA in loose packaging · Pregnant women in their second trimester up to 28 weeks, aged 15–43 years, eligible for iron and folic acid supplementation | 400 mcg | 8 weeks | 474 |
| Oral folic acid and vitamin B-12 supplementation to prevent cognitive decline in community-dwelling older adults with depressive symptoms--the Beyond Ageing Project: a randomized controlled trial 2012 · daily oral folic acid + vitamin B-12 supplementation · Adults aged 60–74 with elevated psychological distress | 400 mcg | 2 years | 450 |
| Small-quantity, lipid-based nutrient supplements provided to women during pregnancy and 6 mo postpartum and to their infants from 6 mo of age increase the mean attained length of 18-mo-old children in semi-urban Ghana: a randomized controlled trial 2016 · IFA · Pregnant women aged 18 years or older enrolled at up to 20 weeks of gestation; their infants received no supplement | 400 mcg | — | 441 |
| Maternal Supplementation with Small-Quantity Lipid-Based Nutrient Supplements Compared with Multiple Micronutrients, but Not with Iron and Folic Acid, Reduces the Prevalence of Low Gestational Weight Gain in Semi-Urban Ghana: A Randomized Controlled Trial 2017 · IFA group · Pregnant women aged 18 years or older, enrolled at 20 weeks’ gestation or earlier; semi-urban Ghana | 400 mcg | — | 441 |
| Prenatal and postnatal lipid-based nutrient supplementation and cognitive, social-emotional, and motor function in preschool-aged children in Ghana: a follow-up of a randomized controlled trial 2019 · iron and folic acid (IFA) group · Pregnant women aged 18 years or older, enrolled at up to 20 weeks of gestation | 400 mcg | — | 441 |
| Effect of prenatal micronutrient-fortified balanced energy-protein supplementation on maternal and newborn body composition: A sub-study from the MISAME-III randomized controlled efficacy trial in rural Burkina Faso 2023 · Intervention · Pregnant women aged 15–40 years, enrolled before 21 completed weeks of gestation; maternal and newborn body composition were assessed postpartum | 400 mcg | — | 440 |
| Sustained effects of small-quantity lipid-based nutrient supplements provided during the first 1000 days on child growth at 9-11 y in a randomized controlled trial in Ghana 2024 · daily IFA tablets · Pregnant females aged 18 years or older enrolled at up to 20 weeks of gestation; their children received no infant supplementation | 400 mcg | — | 440 |
| Homocysteine lowering and cognition in CKD: the Veterans Affairs homocysteine study 2009 · vitamin group · Adults aged 21 years or older with advanced chronic kidney disease or end-stage renal disease and high plasma homocysteine | 40 mg | 1128 days | 339 |
| Maternal zinc supplementation and growth in Peruvian infants 2008 · zinc group · Pregnant women enrolled at 10–24 weeks of gestation; low-risk pregnancy | 250 mcg | — | 273 |
| Maternal zinc supplementation and growth in Peruvian infants 2008 · control group · Pregnant women enrolled at 10–24 weeks of gestation; low-risk pregnancy | 250 mcg | — | 273 |
| High-dose B vitamin supplementation and progression of subclinical atherosclerosis: a randomized controlled trial 2009 · B-vitamin group · Men and postmenopausal women aged 40 years or older with fasting total homocysteine ≥8.5 μmol/L and no clinical signs or symptoms of cardiovascular disease | 5 mg | 1132 days | 254 |
| High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial 2008 · high-dose supplement group · Adults over 50 with mild to moderate probable Alzheimer disease and normal vitamin B12 and folate levels | 5 mg | 548 days | 240 |
| Associations of maternal nutrition during pregnancy and post-partum with maternal cognition and caregiving 2018 · IFA · Pregnant women enrolled at ≤20 weeks’ gestation in Malawi, followed through 6 months postpartum | 400 mcg | 1 year | 238 |
| Association of prenatal lipid-based nutritional supplementation with fetal growth in rural Gambia 2017 · MMN · Pregnant women aged 18–45 years in rural Gambia, enrolled at 10–20 weeks’ gestation | 400 mcg | — | 164 |
| Association of prenatal lipid-based nutritional supplementation with fetal growth in rural Gambia 2017 · PE · Pregnant women aged 18–45 years in rural Gambia, enrolled at 10–20 weeks’ gestation | 400 mcg | — | 151 |
| Vitamins B12, B6, and folic acid for onset of depressive symptoms in older men: results from a 2-year placebo-controlled randomized trial 2008 · treatment with vitamins · Men aged 75 years and older, free of clinically significant depression at baseline | 2 mg | 2 years | 150 |
| Association of prenatal lipid-based nutritional supplementation with fetal growth in rural Gambia 2017 · FeFol · Pregnant women aged 18–45 years in rural Gambia, enrolled at 10–20 weeks’ gestation | 400 mcg | — | 146 |
| Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial 2012 · B-vitamin group · Adults aged 70 years or older with mild cognitive impairment | 800 mcg | 2 years | 133 |
| Effect of Picture-based health education and counselling on knowledge and adherence to preconception Iron-folic acid supplementation among women planning to be pregnant in Eastern Ethiopia: a randomized controlled trial 2022 · Intervention group · Women aged 18–45 planning pregnancy after stopping contraception or following spontaneous abortion | 400 mcg | 90 days | 122 |
| Effect of Picture-based health education and counselling on knowledge and adherence to preconception Iron-folic acid supplementation among women planning to be pregnant in Eastern Ethiopia: a randomized controlled trial 2022 · Control group · Women aged 18–45 planning pregnancy after stopping contraception or following spontaneous abortion | 400 mcg | 90 days | 122 |
| Vitamin B12 and Folic Acid Improve Gross Motor and Problem-Solving Skills in Young North Indian Children: A Randomized Placebo-Controlled Trial 2015 · Vitamin B12 & Folic Acid · Children aged 6–30 months from low- to middle-socioeconomic-class families in New Delhi, India | 150 mcg | 26 weeks | 101 |
| Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia 2013 · folate plus B12 · Adults aged 18–68 with schizophrenia, stable on antipsychotic treatment and with persistent symptoms | 2 mg | 16 weeks | 94 |
| Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial 2010 · Active treatment group · Adults aged 70 years or older with mild cognitive impairment | 800 mcg | 2 years | 85 |
| Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial 2000 · treatment group · Healthy siblings of patients with premature atherothrombotic disease | 5 mg | 2 years | 78 |
| Cognitive Benefits of Folic Acid, Docosahexaenoic Acid, and a Combination of Both Nutrients in Mild Cognitive Impairment: Possible Alterations through Mitochondrial Function and DNA Damage 2024 · FA + DHA · Adults aged 60 years and older with mild cognitive impairment | 800 mcg | 1 year | 70 |
| Effects of Folic Acid and Vitamin B12 Supplementation on Cognitive Impairment and Inflammation in Patients with Alzheimer's Disease: A Randomized, Single-Blinded, Placebo-Controlled Trial 2021 · Folate and vitB12 group · Adults older than 45 years with probable Alzheimer's disease, MoCA score below 22, receiving dementia medication | 1.2 mg | 26 weeks | 60 |
| Improved vascular endothelial function after oral B vitamins: An effect mediated through reduced concentrations of free plasma homocysteine 2000 · Folic acid and vitamin B(12) · Men aged 39–67 years with coronary heart disease | 5 mg | 8 weeks | 59 |
| Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS 2007 · myo-inositol plus folic acid · Women with oligomenorrhea and polycystic ovaries | 400 mcg | 14 weeks | 45 |
| Additive effect of homocysteine- and cholesterol-lowering therapy on endothelium-dependent vasodilation in patients with cardiovascular disease 2012 · combined therapy · Patients with cardiovascular disease at high cardiovascular risk; age and sex not reported | 1 mg | 6 weeks | 36 |
| Folate and vitamin B12 supplementation in patients with schizophrenia and low serum folate level: A 24-week randomized, double-blind, placebo-controlled study 2026 · folate group · Patients with schizophrenia and serum folate levels lower than 6 mg/L | 5 mg | 24 weeks | 36 |
| Acute autonomic effects of vitamins and fats in male smokers 2009 · moderate vitamins · Male smokers, mean age 34.2 years (SD 6.9) | 1 mg | 1 day | 30 |
| Acute autonomic effects of vitamins and fats in male smokers 2009 · high doses of vitamins · Male smokers, mean age 34.2 years (SD 6.9) | 5 mg | 1 day | 30 |
| A pilot study of thiamin and folic acid in hemodialysis patients with cognitive impairment 2021 · Treatment group · Adults aged 18–80 with end-stage kidney disease receiving maintenance hemodialysis for at least 3 months and cognitive impairment | 30 mg | 96 weeks | 25 |
| Effect of folic acid supplementation on mood and serotonin response in healthy males 2005 · Folic acid intervention · Healthy, folate-replete males; age not reported | 300 mcg | 12 weeks | 23 |
| Probiotic effects on sexual function in women with polycystic ovary syndrome: a double blinded randomized controlled trial 2022 · Probiotic plus letrozole group (Group A) · Women aged 18–38 with PCOS and infertility | 400 mcg | 8 weeks | 20 |
| Additive effect of homocysteine- and cholesterol-lowering therapy on endothelium-dependent vasodilation in patients with cardiovascular disease 2012 · group V · Patients with cardiovascular disease at high cardiovascular risk; age and sex not reported | 1 mg | 6 weeks | 18 |
| Integrating Calcium Into Antenatal Iron-Folic Acid Supplementation in Ethiopia: Women's Experiences, Perceptions of Acceptability, and Strategies to Support Calcium Supplement Adherence 2020 · 3-event regimen · Healthy pregnant women aged 16 years or older, 12–28 weeks’ gestation, in rural Ethiopia | 400 mcg | 6 weeks | 17 |
| Integrating Calcium Into Antenatal Iron-Folic Acid Supplementation in Ethiopia: Women's Experiences, Perceptions of Acceptability, and Strategies to Support Calcium Supplement Adherence 2020 · 2-event regimen · Healthy pregnant women aged 16 years or older, 12–28 weeks’ gestation, in rural Ethiopia | 400 mcg | 6 weeks | 16 |
| Integrating Calcium Into Antenatal Iron-Folic Acid Supplementation in Ethiopia: Women's Experiences, Perceptions of Acceptability, and Strategies to Support Calcium Supplement Adherence 2020 · 4-event regimen · Healthy pregnant women aged 16 years or older, 12–28 weeks’ gestation, in rural Ethiopia | 400 mcg | 6 weeks | 15 |
| Short-Term Effects of Folate Supplementation in Combination With Vitamin B6 for Treating Acute Manic Episodes in Bipolar I Disorder: A Randomized Controlled Trial 2025 · Folate/vitamin B6 group · Adults aged 18–45 with bipolar I disorder in an acute manic episode | 5 mg | 6 weeks | 14 |
| [Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition] 2012 · diet, metformin and MYO (D+M+I) · Overweight or obese women with polycystic ovary syndrome; age not reported | 400 mcg | 90 days | 9 |
| Carotid artery stiffness in patients with end-stage renal disease: no effect of long-term homocysteine-lowering therapy 2000 · Folic acid 5 mg daily with betaine 4 g per day (12-week phase) · Adults on maintenance dialysis with end-stage renal disease and hyperhomocysteinemia | 5 mg | 12 weeks | — |
| Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial 2002 · zinc sulfate and folic acid · Fertile and subfertile men | 5 mg | 26 weeks | — |
| C677T methylenetetrahydrofolate reductase polymorphism interferes with the effects of folic acid and zinc sulfate on sperm concentration 2003 · folic acid and zinc sulfate group · fertile and subfertile males | 5 mg | 26 weeks | — |
| Significant correlations of plasma homocysteine and serum methylmalonic acid with movement and cognitive performance in elderly subjects but no improvement from short-term vitamin therapy: a placebo-controlled randomized study 2005 · Vitamin therapy · Community-dwelling elderly adults, median age 76 years; both sexes; vitamin deficiencies were present in a subset | 800 mcg | 120 days | — |
| Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men? 2006 · Folic acid and zinc sulphate intervention · Fertile and subfertile males | 5 mg | 26 weeks | — |
| Folate and vitamin B6 rapidly normalize endothelial dysfunction in children with type 1 diabetes mellitus 2006 · Folate/vitamin B6 · Children with type 1 diabetes mellitus; age and sex not specified | 5 mg | 8 weeks | — |
| Combined iron and folic acid supplementation with or without zinc reduces time to walking unassisted among Zanzibari infants 5- to 11-mo old 2006 · iron+folic acid (FeFA) · Children aged 5–11 months at the start of supplementation, nutritionally at risk, in Pemba, Zanzibar | 50 mcg | 1 year | — |
| Combined iron and folic acid supplementation with or without zinc reduces time to walking unassisted among Zanzibari infants 5- to 11-mo old 2006 · iron+folic acid+zinc (FeFA+Zn) · Children aged 5–11 months at the start of supplementation, nutritionally at risk, in Pemba, Zanzibar | 50 mcg | 1 year | — |
| Myoinositol/folic acid combination for the treatment of erectile dysfunction in type 2 diabetes men: a double-blind, randomized, placebo-controlled study 2006 · myoinositol/folic acid combination · men with type 2 diabetes and erectile dysfunction | 400 mcg | — | — |
| Clinical trial: B vitamins improve health in patients with coeliac disease living on a gluten-free diet 2009 · B vitamin supplementation · Adults aged 45–64 years with longstanding coeliac disease, on a strict gluten-free diet for several years | 800 mcg | 26 weeks | — |
| A study of the treatment of Rett syndrome with folate and betaine 2009 · Folate–betaine combination, participants weighing less than 30 kg · Females aged 1.2–28.9 years with Rett syndrome and a MECP2 gene mutation; participants in this dose subgroup weighed less than 30 kg | 15 mg | 1 year | — |
| A study of the treatment of Rett syndrome with folate and betaine 2009 · Folate–betaine combination, participants weighing more than 30 kg · Females aged 1.2–28.9 years with Rett syndrome and a MECP2 gene mutation; participants in this dose subgroup weighed more than 30 kg | 15 mg | 1 year | — |
| The effects of iron and/or zinc supplementation on maternal reports of sleep in infants from Nepal and Zanzibar 2009 · iron–folic acid · Infants aged 4–18 months in Pemba Island, Zanzibar, or Sarlahi District, Nepal | 50 mcg | 1 year | — |
| The effects of iron and/or zinc supplementation on maternal reports of sleep in infants from Nepal and Zanzibar 2009 · iron–folic acid and zinc · Infants aged 4–18 months in Pemba Island, Zanzibar, or Sarlahi District, Nepal | 50 mcg | 1 year | — |
| Physical work capacity of young underprivileged school girls impact of daily vs intermittent iron folic acid supplementation: a randomized controlled trial 2009 · daily IFA group · Schoolgirls aged 9–13 years from underprivileged communities | 500 mcg | 1 year | — |
| Maternal zinc supplementation reduces diarrheal morbidity in peruvian infants 2010 · zinc · Pregnant women in a periurban slum of Lima, Peru | 250 mcg | — | — |
| Daily supplementation with iron plus folic acid, zinc, and their combination is not associated with younger age at first walking unassisted in malnourished preschool children from a deficient population in rural Nepal 2010 · iron+folic acid · Malnourished children aged 1–36 months in a deficient population in rural Nepal | 50 mcg | — | — |
| Daily supplementation with iron plus folic acid, zinc, and their combination is not associated with younger age at first walking unassisted in malnourished preschool children from a deficient population in rural Nepal 2010 · zinc+iron+folic acid · Malnourished children aged 1–36 months in a deficient population in rural Nepal | 50 mcg | — | — |
| A randomized placebo controlled trial of homocysteine lowering to reduce cognitive decline in older demented people 2011 · supplement group · Older people with mild to moderate Alzheimer disease or vascular dementia | 5 mg | 2 years | — |
| Coronary blood flow in patients with stable coronary artery disease treated long term with folic acid and vitamin B12 2011 · Folic acid and vitamin B12, without vitamin B6 · Adults with stable coronary artery disease; mean age 57.8 years; sex not specified | 800 mcg | 2 years | — |
| Coronary blood flow in patients with stable coronary artery disease treated long term with folic acid and vitamin B12 2011 · Folic acid and vitamin B12 plus vitamin B6 · Adults with stable coronary artery disease; mean age 57.8 years; sex not specified | 800 mcg | 2 years | — |
| Effects of myo-inositol supplementation on oocyte's quality in PCOS patients: a double blind trial 2011 · Group A · Women with polycystic ovary syndrome undergoing IVF | 400 mcg | 90 days | — |
| Developmental effects of micronutrient supplementation and malaria in Zanzibari children 2013 · FeFA alone · Zanzibari children aged 5–14 months at baseline | 50 mcg | — | — |
| Developmental effects of micronutrient supplementation and malaria in Zanzibari children 2013 · FeFA with zinc · Zanzibari children aged 5–14 months at baseline | 50 mcg | — | — |
| Effects of pre- and postnatal nutrition interventions on child growth and body composition: the MINIMat trial in rural Bangladesh 2013 · Fe60F · Pregnant women enrolled before 14 weeks’ gestation; age 14–50 years | 400 mcg | — | — |
| The effects of folic acid and pyridoxine supplementation on characteristics of migraine attacks in migraine patients with aura: A double-blind, randomized placebo-controlled, clinical trial 2017 · folic acid plus pyridoxine · Adults aged 18–65 with migraine with aura | 5 mg | 90 days | — |
| B-Vitamin Therapy for Kidney Transplant Recipients Lowers Homocysteine and Improves Selective Cognitive Outcomes in the Randomized FAVORIT Ancillary Cognitive Trial 2017 · treatment group (high-dose vitamin group) · Men and women aged 35–75 with stable kidney function for at least 6 months after kidney transplantation and elevated plasma homocysteine | 5 mg | 2008 days | — |
| The Vitamins in Psychosis Study: A Randomized, Double-Blind, Placebo-Controlled Trial of the Effects of Vitamins B(12), B(6), and Folic Acid on Symptoms and Neurocognition in First-Episode Psychosis 2019 · B-vitamin supplement group · Patients with first-episode psychosis; age and sex not specified | 5 mg | 12 weeks | — |
| The myo-inositol effect on the oocyte quality and fertilization rate among women with polycystic ovary syndrome undergoing assisted reproductive technology cycles: a randomized clinical trial 2019 · study group · infertile women with PCOS undergoing assisted reproductive technology cycles; age not reported | 400 mg | 30 days | — |
| Effect of folic acid combined with docosahexaenoic acid intervention on mild cognitive impairment in elderly: a randomized double-blind, placebo-controlled trial 2021 · FA + DHA · Elderly people with mild cognitive impairment (MCI); age range and sex not specified | 800 mcg | 26 weeks | — |
| The impact of myo-inositol supplementation on sleep quality in pregnant women: a randomized, double-blind, placebo-controlled study 2022 · myo-inositol supplementation · Pregnant women with low-risk singleton pregnancies, at least 14 weeks’ gestation | 200 mcg | 10 weeks | — |
| Effects of Folic Acid Combined with DHA Supplementation on Cognitive Function and Amyloid-β-Related Biomarkers in Older Adults with Mild Cognitive Impairment by a Randomized, Double Blind, Placebo-Controlled Trial 2021 · folic acid + DHA · Adults aged over 60 years with mild cognitive impairment | 800 mcg | 26 weeks | — |
| Effects of antenatal micronutrient supplementation regimens on adolescent emotional and behavioral problems: A 14-year follow-up of a double-blind, cluster-randomized controlled trial 2023 · Iron-folic acid (IFA) · Pregnant females in rural western China; age and health condition not reported | 400 mcg | — | — |
| Fortified balanced energy-protein supplementation during pregnancy and lactation and infant growth in rural Burkina Faso: A 2 × 2 factorial individually randomized controlled trial 2023 · Prenatal BEP and IFA supplementation · Pregnant women aged 15–40 years in rural Burkina Faso | 400 mcg | — | — |
| Fortified balanced energy-protein supplementation during pregnancy and lactation and infant growth in rural Burkina Faso: A 2 × 2 factorial individually randomized controlled trial 2023 · Postnatal BEP and IFA supplementation · Women in rural Burkina Faso who had given birth; maternal ages 15–40 years at enrollment | 400 mcg | 26 weeks | — |
| Fortified balanced energy-protein supplementation during pregnancy and lactation and infant growth in rural Burkina Faso: A 2 × 2 factorial individually randomized controlled trial 2023 · Prenatal and postnatal BEP and IFA supplementation · Pregnant women aged 15–40 years in rural Burkina Faso who continued into lactation | 400 mcg | — | — |
| Prenatal and postnatal small-quantity lipid-based nutrient supplements and children's social-emotional difficulties at ages 9-11 y in Ghana: follow-up of a randomized controlled trial 2023 · iron and folic acid (IFA) group · Pregnant women in Ghana; children were followed through infancy and assessed at ages 9–11 years | 400 mcg | — | — |
| Preconception Micronutrient Supplementation Affects Maternal BMI and Body Composition Postpartum: A Randomized Controlled Trial in Vietnam 2024 · Folic acid only (FA) · Females in Vietnam receiving preconception supplementation who later delivered live offspring; age and health condition not specified | 400 mcg | — | — |
| Effect of Early-Life Lipid-Based Nutrient Supplement and Home Environment on Autonomic Nervous System Regulation at 9-11 Years: A Follow-Up of a Randomized Controlled Trial 2025 · Iron and folic acid (IFA) group · Pregnant women; their offspring received no supplementation | 400 mcg | — | — |
| Improvement in biochemical manifestations of the serum and follicular fluid and ICSI outcomes in PCOS patients with myo-inositol administration: prospective randomized research 2025 · MI group · Infertile women with PCOS undergoing ovulation induction for ICSI; age not reported | 2 mg | 6 weeks | — |
| Thiamine and folate treatment of chronic epileptic patients: a controlled study with the Wechsler IQ scale 1993 · fourth group · Patients with epilepsy receiving phenytoin alone or with phenobarbital for more than 4 years; age and sex not reported | 5 mg | 26 weeks | — |
| Adding zinc to prenatal iron and folate tablets improves fetal neurobehavioral development 1999 · iron and folate without zinc · Pregnant women in a Peruvian population; gestational age not otherwise specified | 250 mcg | — | — |
| Adding zinc to prenatal iron and folate tablets improves fetal neurobehavioral development 1999 · iron, folate, and zinc · Pregnant women in a Peruvian population; gestational age not otherwise specified | 250 mcg | — | — |
| Maternal Blood Pressure in Relation to Prenatal Lipid-Based Nutrient Supplementation and Adverse Birth Outcomes in a Ghanaian Cohort: A Randomized Controlled Trial and Cohort Analysis 2021 · MMN group · Pregnant Ghanaian women aged 18 years or older, enrolled by 20 weeks of gestation | 400 mcg | — | 354 |
| Maternal Blood Pressure in Relation to Prenatal Lipid-Based Nutrient Supplementation and Adverse Birth Outcomes in a Ghanaian Cohort: A Randomized Controlled Trial and Cohort Analysis 2021 · LNS group · Pregnant Ghanaian women aged 18 years or older, enrolled by 20 weeks of gestation | 400 mcg | — | 354 |
| Folic acid supplementation for 3 wk reduces pulse pressure and large artery stiffness independent of MTHFR genotype 2005 · folic acid · asymptomatic men with normal or high-normal ambulatory blood pressure | 5 mg | 3 weeks | 41 |
| Effects of individualized administration of folic acid on prothrombotic state and vascular endothelial function with H-type hypertension: A double-blinded, randomized clinical cohort study 2022 · Intervention group, second treatment phase, TT genotype · Adults with H-type hypertension, hyperhomocysteinemia and a prothrombotic state; MTHFR C677T TT genotype | 5 mg | 12 weeks | 32 |
| Folic acid and vitamin B12 supplementation in subjects with type 2 diabetes mellitus: A multi-arm randomized controlled clinical trial 2020 · Group A · Patients with type 2 diabetes mellitus on stable oral antidiabetic drugs | 5 mg | 8 weeks | 20 |
| A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) 2000 · combination group · Patients with primary hypercholesterolaemia; age and sex not reported | 2 mg | 6 weeks | — |
| Effect of folic acid supplementation on biochemical indices in overweight and obese men with type 2 diabetes 2011 · folic acid group · Overweight and obese men aged about 58 years with type 2 diabetes, receiving metformin | 5 mg | 8 weeks | — |
| Combined food and micronutrient supplements during pregnancy have limited impact on child blood pressure and kidney function in rural Bangladesh 2013 · Fe30F · Pregnant women in rural Bangladesh; age range not specified | 400 mcg | — | — |
| Combined food and micronutrient supplements during pregnancy have limited impact on child blood pressure and kidney function in rural Bangladesh 2013 · MMS · Pregnant women in rural Bangladesh; age range not specified | 400 mcg | — | — |
| A pilot study of D-chiro-inositol plus folic acid in overweight patients with type 1 diabetes 2017 · treated group · Overweight or obese patients with type 1 diabetes receiving intensive insulin therapy | 400 mcg | 24 weeks | — |
| Folic acid supplementation in children with sickle cell disease: a randomized double-blind noninferiority cross-over trial 2025 · Folic acid · Children aged 2–19 years with sickle cell disease who had routinely received daily folic acid for at least 12 weeks before enrolment | 1 mg | 85 days | 25 |
| Ethnicity and race influence the folate status response to controlled folate intakes in young women 2004 · 800 μg DFE/d repletion group · Women aged 18–45 with the MTHFR 677 CC genotype; Mexican American, African American, and Caucasian (7 of each) | 800 mcg | 7 weeks | 21 |
| Folic acid improves phenytoin pharmacokinetics 1995 · treatment 2 · Six fertile women receiving phenytoin therapy for epilepsy | 1 mg | — | 6 |
| A prospective study of serum folate levels in patients with solid tumors treated with olaparib 2025 · Folic acid supplementation · Adult women with stage III–IV solid tumors, including breast or ovarian cancer, who developed folate deficiency with concomitant anemia while receiving olaparib | 1 mg | — | 2 |
| Kinetics of folate turnover in pregnant women (second trimester) and nonpregnant controls during folic acid supplementation: stable-isotopic labeling of plasma folate, urinary folate and folate catabolites shows subtle effects of pregnancy on turnover of folate pools 2001 · 1.93 micromol/d total folate intake · Second-trimester pregnant women and nonpregnant controls; exact allocation to this intake level is not stated | 850 mcg | 12 weeks | — |
| Effect of folic Acid supplementation on the folate status of buccal mucosa and lymphocytes 2004 · folic acid group · Adults aged 20–60 years with red-cell folate concentrations between 200 and 650 nmol/L | 1.2 mg | 12 weeks | — |
| Effect of different dosage and administration schedules of folic acid on blood folate levels in a population of Honduran women of reproductive age 2008 · 1 mg/d group · Women factory workers aged 18 to 49 years in Honduras | 1 mg | 12 weeks | — |
| Gender and body size affect the response of erythrocyte folate to folic acid treatment 2008 · 800 microg/d folic acid, 3-y trial · men and women; age and health condition not reported | 800 mcg | 3 years | — |
| Gender and body size affect the response of erythrocyte folate to folic acid treatment 2008 · 800 microg/d folic acid, 12-wk trial · men and women; age and health condition not reported | 800 mcg | 12 weeks | — |
| Steady state folate concentrations achieved with 5 compared with 1.1 mg folic acid supplementation among women of childbearing age 2009 · 1.1 mg folic acid group · Nonpregnant women aged 18–45 years who did not take folic acid supplements | 1.1 mg | 30 weeks | — |
| Effects of folic acid supplementation on serum folate and plasma homocysteine concentrations in older adults: a dose-response trial 2010 · 1,000 μg/day folic acid · Adults aged 60–90 years; healthy older adults | 1 mg | 6 weeks | — |
| Effects of folic acid supplementation on serum folate and plasma homocysteine concentrations in older adults: a dose-response trial 2010 · 2,000 μg/day folic acid · Adults aged 60–90 years; healthy older adults | 2 mg | 6 weeks | — |
| Effect of folic acid intervention on the change of serum folate level in hypertensive Chinese adults: do methylenetetrahydrofolate reductase and methionine synthase gene polymorphisms affect therapeutic responses? 2012 · high-FA group · Chinese adults with mild or moderate essential hypertension | 800 mcg | 8 weeks | — |
| Differences in erythrocyte folate concentrations in older adults reached steady-state within one year in a two-year, controlled, 1 mg/d folate supplementation trial 2012 · folate-supplemented group · Adults aged 65 years or older | 1 mg | 2 years | — |
| Pregnancy-induced changes in the long-term pharmacokinetics of 1.1 mg vs. 5 mg folic acid: a randomized clinical trial 2015 · 1.1 mg (regular dose) · Pregnant women who were not previously taking folic acid | 1.1 mg | — | — |
| l-5-Methyltetrahydrofolate Supplementation Increases Blood Folate Concentrations to a Greater Extent than Folic Acid Supplementation in Malaysian Women 2018 · folic acid group · Healthy Malaysian women aged 20–45 years | 1 mg | 12 weeks | — |
| Maternal folate status during extended lactation and the effect of supplemental folic acid 1999 · 1 mg folic acid/d · Lactating women; age and health condition not specified | 1 mg | 26 weeks | — |
| Small-quantity, lipid-based nutrient supplements provided to women during pregnancy and 6 mo postpartum and to their infants from 6 mo of age increase the mean attained length of 18-mo-old children in semi-urban Ghana: a randomized controlled trial 2016 · LNS (women and infants) · Pregnant women aged 18 years or older enrolled at up to 20 weeks of gestation, and their infants from 6 to 18 months of age | 80 mcg | 1 year | 440 |
| Prenatal and postnatal lipid-based nutrient supplementation and cognitive, social-emotional, and motor function in preschool-aged children in Ghana: a follow-up of a randomized controlled trial 2019 · LNS group · Pregnant women aged 18 years or older and their children, from pregnancy through the child's age of 18 months | 480 mcg | — | 440 |
| Associations of maternal nutrition during pregnancy and post-partum with maternal cognition and caregiving 2018 · MMN · Pregnant women enrolled at ≤20 weeks’ gestation in Malawi, followed through 6 months postpartum | 400 mcg | 1 year | 239 |
| Associations of maternal nutrition during pregnancy and post-partum with maternal cognition and caregiving 2018 · LNS · Pregnant women enrolled at ≤20 weeks’ gestation in Malawi, followed through 6 months postpartum | 400 mcg | 1 year | 234 |
| Association of prenatal lipid-based nutritional supplementation with fetal growth in rural Gambia 2017 · PE + MMN · Pregnant women aged 18–45 years in rural Gambia, enrolled at 10–20 weeks’ gestation | 400 mcg | — | 159 |
| Acceptability of multiple micronutrient powders and iron syrup in Bihar, India 2018 · multiple micronutrient powder (MNP) · Children aged 6–23 months in rural Bihar, not currently taking iron supplements | 160 mcg | 30 days | 100 |
| Effects of a food supplement containing phosphatidylserine on cognitive function in Chinese older adults with mild cognitive impairment: A randomized double-blind, placebo-controlled trial 2025 · intervention group · Chinese adults with mild cognitive impairment; mean age 67.95 years; 70 male and 120 female | 180 mcg | 1 year | 95 |
| Enhanced physical and cognitive performance in active duty Airmen: evidence from a randomized multimodal physical fitness and nutritional intervention 2020 · exercise plus nutritional supplement group · Active-duty Air Force Airmen aged 18–45; no qualifying disease or deficiency was stated | 200 mcg | 12 weeks | 70 |
| A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia 2010 · NF group, 3-month blinded trial · Community-dwelling adults aged 18–86 years, both sexes, without dementia or clinical memory difficulties | 400 mcg | 90 days | 59 |
| Efficacy of multivitamin supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer's disease: a 26-week, randomized, double-blind, placebo-controlled study in Taiwanese patients 2007 · mecobalamin (B12) + multivitamin supplement · Taiwanese men and women aged over 50 with mild to moderate Alzheimer's disease and normal folic acid and vitamin B12 concentrations | 1 mg | 26 weeks | 45 |
| L-Arginine and B vitamins improve endothelial function in subjects with mild to moderate blood pressure elevation 2018 · Nutritional intervention group · Men and postmenopausal women aged 40–65 with slightly to moderately elevated blood pressure | 400 mcg | 26 weeks | 40 |
| L-Arginine and B vitamins improve endothelial function in subjects with mild to moderate blood pressure elevation 2018 · Placebo group receiving open-label TAP in follow-up · Men and postmenopausal women aged 40–65 with slightly to moderately elevated blood pressure | 400 mcg | 13 weeks | 40 |
| Effects of Low-Dose Dairy Protein Plus Micronutrient Supplementation during Resistance Exercise on Muscle Mass and Physical Performance in Older Adults: A Randomized, Controlled Trial 2018 · ExPM (resistance exercise plus low-dose dairy protein and micronutrient supplementation) · Adults aged 65–80 years, non-disabled and not exercising regularly | 200 mcg | 12 weeks | 40 |
| A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia 2010 · Open-label NF group, separate 6-month trial · Community-dwelling adults, both sexes, without dementia or clinical memory difficulties | 400 mcg | 26 weeks | 38 |
| Effects of ingesting a pre-workout dietary supplement with and without synephrine for 8 weeks on training adaptations in resistance-trained males 2017 · PWS · Apparently healthy, resistance-trained males; mean age about 21 years | 50 mg | 8 weeks | 27 |
| Effects of ingesting a pre-workout dietary supplement with and without synephrine for 8 weeks on training adaptations in resistance-trained males 2017 · PWS + S · Apparently healthy, resistance-trained males; mean age about 22 years | 50 mg | 8 weeks | 26 |
| Effects of acute ingestion of a pre-workout dietary supplement with and without p-synephrine on resting energy expenditure, cognitive function and exercise performance 2017 · PWS · Resistance-trained healthy adults; 20 men and 5 women, mean age 21.7 years | 50 mg | 1 day | 25 |
| Effects of acute ingestion of a pre-workout dietary supplement with and without p-synephrine on resting energy expenditure, cognitive function and exercise performance 2017 · PWS + S · Resistance-trained healthy adults; 20 men and 5 women, mean age 21.7 years | 50 mg | 1 day | 25 |
| Effects of an L-arginine-based multi ingredient product on endothelial function in subjects with mild to moderate hypertension and hyperhomocysteinemia - a randomized, double-blind, placebo-controlled, cross-over trial 2017 · AbMIP (vasoLoges® protect) · Men and postmenopausal women aged 40–65 with elevated systolic blood pressure and homocysteine ≥10 μmol/L | 600 mcg | 4 weeks | 25 |
| Short-Term Effects of a Ready-to-Drink Pre-Workout Beverage on Exercise Performance and Recovery 2017 · RTD · Recreationally active men and women aged 18–40 years with at least six months of resistance-training experience | 325 mcg | 7 days | 25 |
| Opicapone in Parkinson's Disease on Levodopa-Carbidopa Intestinal Gel Treatment: A Pilot, Randomized Study 2025 · addOPC group · Adults with Parkinson's disease receiving levodopa-carbidopa intestinal gel and experiencing nocturnal, morning, or afternoon akinesia | 400 mcg | 1 year | 11 |
| Opicapone in Parkinson's Disease on Levodopa-Carbidopa Intestinal Gel Treatment: A Pilot, Randomized Study 2025 · nOPC group · Adults with Parkinson's disease receiving levodopa-carbidopa intestinal gel and experiencing nocturnal, morning, or afternoon akinesia | 400 mcg | 1 year | 11 |
| Micronutrient supplementation may reduce symptoms of depression in Guatemalan women 2009 · weekly 5,000 microg folic acid group · Women in Guatemala; age range and health condition not specified | 714 mcg | 12 weeks | — |
| Micronutrient supplementation may reduce symptoms of depression in Guatemalan women 2009 · weekly 2,800 microg folic acid group · Women in Guatemala; age range and health condition not specified | 400 mcg | 12 weeks | — |
| Micronutrient supplementation may reduce symptoms of depression in Guatemalan women 2009 · daily 400 microg folic acid group · Women in Guatemala; age range and health condition not specified | 400 mcg | 12 weeks | — |
| Micronutrient supplementation may reduce symptoms of depression in Guatemalan women 2009 · daily 200 microg folic acid group · Women in Guatemala; age range and health condition not specified | 200 mcg | 12 weeks | — |
| A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia 2010 · NF group, 2-week blinded trial · Community-dwelling adults, both sexes, without dementia or clinical memory difficulties | 400 mcg | 2 weeks | — |
| Improving neuropathy scores in type 2 diabetic patients using micronutrients supplementation 2011 · Group MVB · Patients with type 2 diabetes | 1 mg | 120 days | — |
| Three-month B vitamin supplementation in pre-school children affects folate status and homocysteine, but not cognitive performance 2014 · B vitamin supplementation group · Healthy preschool children selected for low urinary folate-status ranking | 220 mcg | 90 days | — |
| Low-dose B vitamins supplementation ameliorates cardiovascular risk: a double-blind randomized controlled trial in healthy Chinese elderly 2015 · treatment group · Healthy adults aged 60–74 years | 400 mcg | 1 year | — |
| Preconception Micronutrient Supplementation Affects Maternal BMI and Body Composition Postpartum: A Randomized Controlled Trial in Vietnam 2024 · Iron and folic acid (IFA) · Females in Vietnam receiving preconception supplementation who later delivered live offspring; age and health condition not specified | 400 mcg | — | — |
| Folic acid therapy reduces serum uric acid in hypertensive patients: a substudy of the China Stroke Primary Prevention Trial (CSPPT) 2017 · enalapril-folic acid group · hypertensive adults; age and sex not specified | 800 mcg | 1606 days | 7,685 |
| Interaction of neutrophil counts and folic acid treatment on new-onset proteinuria in hypertensive patients 2021 · enalapril and folic acid · Adults with hypertension; mean age 59.5 years | 800 mcg | 1606 days | 4,101 |
| Optimal folic acid dosage in lowering homocysteine: Precision Folic Acid Trial to lower homocysteine (PFAT-Hcy) 2024 · 2.0 mg folic acid group · Chinese men and women aged 45–75 with hypertension and elevated total homocysteine | 2 mg | 8 weeks | 337 |
| Higher baseline global leukocyte DNA methylation is associated with MTX non-response in early RA patients 2019 · All MTX treatment groups · Adults with treatment-naive early rheumatoid arthritis | 1.43 mg | 90 days | 336 |
| Optimal folic acid dosage in lowering homocysteine: Precision Folic Acid Trial to lower homocysteine (PFAT-Hcy) 2024 · 0.8 mg folic acid group · Chinese men and women aged 45–75 with hypertension and elevated total homocysteine | 800 mcg | 8 weeks | 336 |
| Optimal folic acid dosage in lowering homocysteine: Precision Folic Acid Trial to lower homocysteine (PFAT-Hcy) 2024 · 1.2 mg folic acid group · Chinese men and women aged 45–75 with hypertension and elevated total homocysteine | 1.2 mg | 8 weeks | 336 |
| Optimal folic acid dosage in lowering homocysteine: Precision Folic Acid Trial to lower homocysteine (PFAT-Hcy) 2024 · 1.6 mg folic acid group · Chinese men and women aged 45–75 with hypertension and elevated total homocysteine | 1.6 mg | 8 weeks | 336 |
| Betaine and choline status modify the effects of folic acid and creatine supplementation on arsenic methylation in a randomized controlled trial of Bangladeshi adults 2021 · 800FA · Adults aged 24–55 in Bangladesh exposed to arsenic through household drinking water | 800 mcg | 12 weeks | 154 |
| Folic Acid and Creatine as Therapeutic Approaches to Lower Blood Arsenic: A Randomized Controlled Trial 2015 · FA800, first phase · Adults aged 20–65 in Bangladesh selected for drinking from a well with arsenic above 50 μg/L; both folate-deficient and folate-sufficient participants | 800 mcg | 12 weeks | 151 |
| Protective Effect of Folic Acid on Oxidative DNA Damage: A Randomized, Double-Blind, and Placebo Controlled Clinical Trial 2015 · high-FA group · Adults aged 18–79 chronically exposed to arsenic in drinking water | 800 mcg | 8 weeks | 150 |
| The Folic Acid and Creatine Trial: Treatment Effects of Supplementation on Arsenic Methylation Indices and Metabolite Concentrations in Blood in a Bangladeshi Population 2023 · 800FA · Adults aged 20–65 years in Bangladesh exposed to arsenic in drinking water; men and women, recruited independent of folate status | 800 mcg | 12 weeks | 150 |
| MTHFR C677T and MTR A2756G polymorphisms and the homocysteine lowering efficacy of different doses of folic acid in hypertensive Chinese adults 2012 · High FA group · Chinese adults with mild or moderate hypertension; mean age approximately 57 years; men and women | 800 mcg | 8 weeks | 146 |
| Combined use of amlodipine and folic acid are significantly more efficacious than amlodipine alone in lowering plasma homocysteine and blood pressure among hypertensive patients with hyperhomocysteinemia and intolerance to ACEI: A multicenter, randomized, double-blind, parallel-controlled clinical trial 2023 · B group (amlodipine 5 mg/FA 0.8 mg) · Chinese adults with hypertension, hyperhomocysteinemia, and intolerance to ACE inhibitors; mean age 62.9 years in this arm; men and women | 800 mcg | 8 weeks | 118 |
| Increasing the number of SNP loci does not necessarily improve prediction power at least in the comparison of MTHFR SNP and haplotypes 2008 · folic acid group · Healthy Japanese men; age range not stated | 1 mg | 90 days | 101 |
| Folic Acid and Creatine as Therapeutic Approaches to Lower Blood Arsenic: A Randomized Controlled Trial 2015 · FA800 continued, second phase · Adults aged 20–65 in Bangladesh selected for drinking from a well with arsenic above 50 μg/L; both folate-deficient and folate-sufficient participants | 800 mcg | 24 weeks | 77 |
| Effects of individualized administration of folic acid on prothrombotic state and vascular endothelial function with H-type hypertension: A double-blinded, randomized clinical cohort study 2022 · Intervention group, first treatment phase · Adults over 18 with H-type hypertension, hyperhomocysteinemia and a prothrombotic state | 800 mcg | 12 weeks | 55 |
| Effects of polymorphisms in endothelial nitric oxide synthase and folate metabolizing genes on the concentration of serum nitrate, folate, and plasma total homocysteine after folic acid supplementation: a double-blind crossover study 2015 · Folic acid · Healthy individuals; age and sex not specified | 800 mcg | 2 weeks | 52 |
| Effect of homocysteine-lowering nutrients on blood lipids: results from four randomised, placebo-controlled studies in healthy humans 2005 · Study 3 folic acid group · Healthy adults aged 50–70 years with plasma total homocysteine below 26 μmol/L | 800 mcg | 6 weeks | 40 |
| Effect of different doses of folic acid on serum homocysteine level in patients on hemodialysis 2011 · 2 mg/d folic acid · Adults on maintenance hemodialysis; mean age 57.6 years; 17 women and 14 men completed all phases | 2 mg | 4 weeks | 31 |
| The impact of folate status and folic acid supplementation on the micronucleus frequency in human erythrocytes 2006 · folic acid supplementation group · Both-sex participants without folate deficiency; age not reported | 1 mg | 7 days | 30 |
| Sensitivity of markers of DNA stability and DNA repair activity to folate supplementation in healthy volunteers 2006 · folic acid group · Healthy men and women aged 20–60 years, with red cell folate 250–650 nmol/L and no folate deficiency | 1.2 mg | 12 weeks | 30 |
| Metabolic response to folate supplementation in overweight women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial 2014 · Folate-1 · Women aged 18–40 years with obesity and polycystic ovary syndrome | 1 mg | 8 weeks | 27 |
| Comparison of efficacy of folic acid and silymarin in the management of antiepileptic drug induced liver injury: a randomized clinical trial 2017 · folic acid · children with epilepsy and antiepileptic drug-induced liver injury | 1 mg | 30 days | 26 |
| The effects of folate supplementation on inflammatory factors and biomarkers of oxidative stress in overweight and obese women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled clinical trial 2014 · folate-1 · Women aged 18–40 with polycystic ovary syndrome who were overweight or obese | 1 mg | 8 weeks | 23 |
| Effect of folic acid on bone metabolism: a randomized double blind clinical trial in postmenopausal osteoporotic women 2014 · folic acid · Postmenopausal women with osteoporosis; age range not stated | 1 mg | 26 weeks | 17 |
| Effect of homocysteine-lowering nutrients on blood lipids: results from four randomised, placebo-controlled studies in healthy humans 2005 · Study 1 folic acid group · Healthy adults aged 30–50 years with plasma total homocysteine below 25 μmol/L | 800 mcg | 6 weeks | 12 |
| Hyperhomocysteinemia in children treated with antiepileptic drugs is normalized by folic acid supplementation 2005 · folic acid supplementation · Children with hyperhomocysteinemia receiving antiepileptic drugs | 1 mg | 90 days | 10 |
| Impact of folic acid supplementation on the epigenetic profile in healthy unfortified individuals - a randomized intervention trial 2024 · 800 μg folic acid · Healthy men aged 23–61 years with normal baseline folate levels | 800 mcg | 8 weeks | 7 |
| Effect of folate supplementation on mucosal cell proliferation in high risk patients for colon cancer 2002 · treatment group · 11 patients with recurrent adenomatous polyps of the colon; age and sex not reported | 2 mg | 90 days | 6 |
| Effect of folic acid and betaine on fasting and postmethionine-loading plasma homocysteine and methionine levels in chronic haemodialysis patients 1999 · Folic acid 1 mg daily · Adults with end-stage renal disease receiving maintenance haemodialysis | 1 mg | 40 weeks | — |
| Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients 2000 · control group · Critically ill anemic adults admitted to a multidisciplinary intensive care unit | 1 mg | — | — |
| Randomized trial of folic acid supplementation and serum homocysteine levels 2001 · 0.8 mg/d folic acid · Patients with ischemic heart disease; age and sex not specified | 800 mcg | 90 days | — |
| Randomized trial of folic acid supplementation and serum homocysteine levels 2001 · 1.0 mg/d folic acid · Patients with ischemic heart disease; age and sex not specified | 1 mg | 90 days | — |
| Dose-dependent effects of folic acid on plasma homocysteine in a randomized trial conducted among 723 individuals with coronary heart disease 2002 · 2.0 mg folic acid · People with a history of myocardial infarction or unstable angina | 2 mg | — | — |
| Folic acid and reduction of plasma homocysteine concentrations in older adults: a dose-response study 2003 · 800 micro g folic acid · Healthy men and women aged 50–75 years | 800 mcg | 12 weeks | — |
| Assessment of tailor-made prevention of atherosclerosis with folic acid supplementation: randomized, double-blind, placebo-controlled trials in each MTHFR C677T genotype 2005 · folic acid group · healthy Japanese men | 1 mg | 90 days | — |
| Effect of lowering of homocysteine levels on inflammatory markers: a randomized controlled trial 2005 · folic acid group · men and postmenopausal women with homocysteine concentrations of at least 13 micromol/L at screening | 800 mcg | 1 year | — |
| No effect of folic acid supplementation in the course of 1 year on haemostasis markers and C-reactive protein in older adults 2005 · folic acid group · Older adults with plasma total homocysteine concentrations above 13 mM at screening | 800 mcg | 1 year | — |
| Effects of short-term folic acid and/or riboflavin supplementation on serum folate and plasma total homocysteine concentrations in young Japanese male subjects 2006 · FA group · Healthy Japanese men aged 20–29 years | 800 mcg | 2 weeks | — |
| Effect of folate supplementation on N-terminal pro-brain natriuretic peptide 2007 · 1.0 mg FA daily · Healthy adults, median age 57 years | 1 mg | 8 weeks | — |
| Blood folate status and expression of proteins involved in immune function, inflammation, and coagulation: biochemical and proteomic changes in the plasma of humans in response to long-term synthetic folic acid supplementation 2010 · 1.2 mg folic acid daily · Human subjects; age, sex, and health status not specified | 1.2 mg | 12 weeks | — |
| A dose-finding trial of the effect of long-term folic acid intervention: implications for food fortification policy 2011 · 0.8 mg/d folic acid · Patients with ischemic heart disease and healthy volunteers; ages and sex not specified | 800 mcg | 26 weeks | — |
| Association between folate levels and CpG Island hypermethylation in normal colorectal mucosa 2010 · folic acid group · Adults with a history of at least one colorectal adenoma, mean age 57.8 years; both sexes | 1 mg | 3 years | — |
| Effect of folic acid intervention on ALT concentration in hypertensives without known hepatic disease: a randomized, double-blind, controlled trial 2012 · high FA group · Chinese adults with mild or moderate essential hypertension and no known hepatic disease | 800 mcg | 8 weeks | — |
| Effects of combined enalapril and folic acid therapy on the serum uric acid levels in hypertensive patients: a multicenter, randomized, double-blind, parallel-controlled clinical trial 2015 · high-FA group · Adults aged 27–75 with mild to moderate hypertension in China | 800 mcg | 8 weeks | — |
| Supplementation with Folic Acid, but Not Creatine, Increases Plasma Betaine, Decreases Plasma Dimethylglycine, and Prevents a Decrease in Plasma Choline in Arsenic-Exposed Bangladeshi Adults 2016 · FA800 · Arsenic-exposed adults aged 24–55 in Bangladesh | 800 mcg | 12 weeks | — |
| MTHFR Gene and Serum Folate Interaction on Serum Homocysteine Lowering: Prospect for Precision Folic Acid Treatment 2018 · 10-mg enalapril+0.8-mg folic acid · Chinese adults with hypertension | 800 mcg | 1643 days | — |
| Folic acid supplementation enhances arsenic methylation: results from a folic acid and creatine supplementation randomized controlled trial in Bangladesh 2019 · 800 μg folic acid group · Bangladeshi participants exposed to arsenic through drinking water; the majority were folate sufficient | 800 mcg | 24 weeks | — |
| Relationship of visceral adiposity index with new-onset proteinuria in hypertensive patients 2021 · 10 mg enalapril and 0.8 mg folic acid · Hypertensive patients without proteinuria at baseline and without major cardiovascular diseases | 800 mcg | 1606 days | — |
| No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients 1998 · 1 mg folic acid (phase 2) · Haemodialysis patients with hyperhomocysteinaemia; age and sex not reported | 1 mg | 40 weeks | — |
| Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: no change in endothelial function after long-term therapy 1998 · 1 mg folic acid daily · Peritoneal dialysis patients with hyperhomocysteinemia | 1 mg | 40 weeks | — |
| Maternal Blood Pressure in Relation to Prenatal Lipid-Based Nutrient Supplementation and Adverse Birth Outcomes in a Ghanaian Cohort: A Randomized Controlled Trial and Cohort Analysis 2021 · IFA group · Pregnant Ghanaian women aged 18 years or older, enrolled by 20 weeks of gestation | 400 mcg | — | 349 |
| Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids 2001 · Alendronate+calcium group · 25 female patients with rheumatoid arthritis | 2.5 mg | 26 weeks | 25 |
| Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids 2001 · Calcium-only group · 25 female patients with rheumatoid arthritis | 2.5 mg | 26 weeks | 25 |
| Folic acid and vitamin B12 supplementation in subjects with type 2 diabetes mellitus: A multi-arm randomized controlled clinical trial 2020 · Group C · Patients with type 2 diabetes mellitus on stable oral antidiabetic drugs | 5 mg | 8 weeks | 20 |
| Nitrate-Rich Beetroot Juice Reduces Blood Pressure in Tanzanian Adults with Elevated Blood Pressure: A Double-Blind Randomized Controlled Feasibility Trial 2020 · N + F (combined intervention) · Adults aged 50–70 years in Tanzania with elevated blood pressure; nonsmokers with systolic blood pressure 130–170 mm Hg | 5 mg | 60 days | 16 |
| Cardiovascular effects of oral Supplementation of vitamin C, E and folic acid in young healthy males 2004 · vitamin intervention · 31 young healthy male adults; 14 received the vitamin intervention | 10 mg | 12 weeks | 14 |
| Lowering homocysteine with B vitamins has no effect on blood pressure in older adults 2007 · Vitamins group · Healthy adults aged 65 years or older with homocysteine concentrations of at least 13 micromol/L | 1 mg | 2 years | — |
| Combined food and micronutrient supplements during pregnancy have limited impact on child blood pressure and kidney function in rural Bangladesh 2013 · Fe60F · Pregnant women in rural Bangladesh; age range not specified | 400 mcg | — | — |
| Low daily dose of 3 mg monacolin K from RYR reduces the concentration of LDL-C in a randomized, placebo-controlled intervention 2016 · supplement group with RYR · Adults with hypercholesterolemia who were not treated with statins | 200 mcg | 12 weeks | — |
| Impact of Preconception Micronutrient Supplementation on Anemia and Iron Status during Pregnancy and Postpartum: A Randomized Controlled Trial in Rural Vietnam 2016 · Folic acid (FA control) · Women aged 18–40 planning pregnancy in rural Vietnam; no specific diagnosed condition required | 400 mcg | 56 weeks | 555 |
| Methylenetetrahydrofolate reductase 677C-->T genotype modulates homocysteine responses to a folate-rich diet or a low-dose folic acid supplement: a randomized controlled trial 2002 · supplement · Healthy adults with MTHFR 677 TT, CT, or CC genotypes | 400 mcg | 120 days | 126 |
| School-administered weekly iron-folate supplements improve hemoglobin and ferritin concentrations in Malaysian adolescent girls 1999 · Folic acid only · Otherwise healthy adolescent girls with hemoglobin 120–130 g/L (group B, borderline anemia) | 714 mcg | 22 weeks | 90 |
| Evidence from a Randomized Trial That Exposure to Supplemental Folic Acid at Recommended Levels during Pregnancy Does Not Lead to Increased Unmetabolized Folic Acid Concentrations in Maternal or Cord Blood 2016 · placebo group · Pregnant women aged 18–35 years who had taken 400 μg folic acid daily during the first trimester | 400 mcg | — | 67 |
| Impact of continuing folic acid after the first trimester of pregnancy: findings of a randomized trial of Folic Acid Supplementation in the Second and Third Trimesters 2013 · 400 μg FA/d treatment group · Pregnant women aged 18–35 with singleton uncomplicated pregnancies who had taken folic acid supplements in the first trimester | 400 mcg | 22 weeks | 59 |
| Evidence from a Randomized Trial That Exposure to Supplemental Folic Acid at Recommended Levels during Pregnancy Does Not Lead to Increased Unmetabolized Folic Acid Concentrations in Maternal or Cord Blood 2016 · folic acid group · Pregnant women aged 18–35 years who had taken 400 μg folic acid daily during the first trimester | 400 mcg | — | 59 |
| Long-term effect of low-dose folic acid intake: potential effect of mandatory fortification on the prevention of neural tube defects 2011 · 400 μg folic acid group · Women aged 18–40 years; reproductive-aged women | 400 mcg | 40 weeks | 48 |
| Folate status of reproductive age women and neural tube defect risk: the effect of long-term folic acid supplementation at doses of 140 µg and 400 µg per day 2011 · 400 μg folic acid/day · Healthy reproductive-age women aged 18–40 years; not pregnant or lactating and not planning pregnancy in the next 12 months | 400 mcg | 40 weeks | 48 |
| Folic acid fortified milk increases blood folate to concentrations associated with a very low risk of neural tube defects in Singaporean women of childbearing age 2016 · fortified milk (FM) group · Non-pregnant women aged 21–35 years | 400 mcg | 12 weeks | 35 |
| Folic acid causes higher prevalence of detectable unmetabolized folic acid in serum than B-complex: a randomized trial 2016 · FA · Elderly people | 400 mcg | 23 days | 31 |
| Optimum dose of oral folic acid supplementation in transfusion-dependent thalassemia: a randomized controlled trial 2022 · Group 2 · Children aged 5–18 years with transfusion-dependent thalassemia | 2.5 mg | 39 weeks | 30 |
| Optimum dose of oral folic acid supplementation in transfusion-dependent thalassemia: a randomized controlled trial 2022 · Group 3 · Children aged 5–18 years with transfusion-dependent thalassemia | 714 mcg | 39 weeks | 30 |
| Folate-status response to a controlled folate intake in nonpregnant, pregnant, and lactating women 2012 · Lactating women · Lactating women 5–15 weeks postpartum | 750 mcg | 11 weeks | 28 |
| Homocysteine metabolism and effects of folic acid supplementation in patients affected with spina bifida 2000 · Folic acid intervention · Patients with spina bifida (n=12) and disabled control patients (n=15) | 500 mcg | 4 weeks | 27 |
| Choline deficiency increases lymphocyte apoptosis and DNA damage in humans 2006 · dietary folate supplemented with 400 μg folic acid/d · Healthy men and women aged 18–70 years | 400 mcg | 6 weeks | 26 |
| Folate-status response to a controlled folate intake in nonpregnant, pregnant, and lactating women 2012 · Pregnant women · Third-trimester pregnant women | 750 mcg | 11 weeks | 26 |
| [6S]-5-methyltetrahydrofolate increases plasma folate more effectively than folic acid in women with the homozygous or wild-type 677C-->T polymorphism of methylenetetrahydrofolate reductase 2009 · folic acid · healthy females with either the homozygous (TT) or wild-type (CC) MTHFR 677C→T genotype | 400 mcg | 1 day | 24 |
| Pharmacokinetics of Sodium and Calcium Salts of (6S)-5-Methyltetrahydrofolic Acid Compared to Folic Acid and Indirect Comparison of the Two Salts 2020 · Folic acid · Healthy men and women aged 18–50 years | 400 mcg | 1 day | 24 |
| Ethnicity and race influence the folate status response to controlled folate intakes in young women 2004 · 400 μg DFE/d repletion group · Women aged 18–45 with the MTHFR 677 CC genotype; Mexican American, African American, and Caucasian (7 of each) | 400 mcg | 7 weeks | 21 |
| Folate-status response to a controlled folate intake in nonpregnant, pregnant, and lactating women 2012 · Nonpregnant women · Nonpregnant women of childbearing age | 750 mcg | 11 weeks | 21 |
| Impact of high-dose folic acid supplementation in pregnancy on biomarkers of folate status and 1-carbon metabolism: An ancillary study of the Folic Acid Clinical Trial (FACT) 2021 · high-dose FA · Pregnant women randomized at 8–16 gestational weeks; maternal folate and 1-carbon metabolism biomarkers were assessed at 24–26 gestational weeks. | 4 mg | — | 19 |
| Aleurone flour increases red-cell folate and lowers plasma homocyst(e)ine substantially in man 2005 · FA · Free-living healthy individuals, mean age 46–52 years; sex not specified | 640 mcg | 16 weeks | 18 |
| Relative bioavailability of iron and folic acid from a new powdered supplement compared to a traditional tablet in pregnant women 2009 · Tablet Supplement (Materna®) · Healthy pregnant women aged 18–45 years, at 24–32 weeks’ gestation | 1 mg | 1 day | 18 |
| Folic Acid Supplementation in Postpolypectomy Patients in a Randomized Controlled Trial Increases Tissue Folate Concentrations and Reduces Aberrant DNA Biomarkers in Colonic Tissues Adjacent to the Former Polyp Site 2016 · folic acid · Adults with adenomatous polyps after initial colonoscopy and polypectomy; mean age 64.3 years | 600 mcg | 26 weeks | 12 |
| Availability of food folate in humans 1999 · meal C · healthy volunteers; age and sex not reported | 400 mcg | 1 day | — |
| Kinetics of folate turnover in pregnant women (second trimester) and nonpregnant controls during folic acid supplementation: stable-isotopic labeling of plasma folate, urinary folate and folate catabolites shows subtle effects of pregnancy on turnover of folate pools 2001 · 1.02 micromol/d total folate intake · Second-trimester pregnant women and nonpregnant controls; exact allocation to this intake level is not stated | 450 mcg | 12 weeks | — |
| Effects of once-a-week or daily folic acid supplementation on red blood cell folate concentrations in women 2004 · once-a-week folic acid group · Nonpregnant women aged 18–40 years with screening red blood cell folate concentrations of 295–905 nmol/L | 400 mcg | 12 weeks | — |
| Effects of once-a-week or daily folic acid supplementation on red blood cell folate concentrations in women 2004 · daily folic acid group · Nonpregnant women aged 18–40 years with screening red blood cell folate concentrations of 295–905 nmol/L | 400 mcg | 12 weeks | — |
| The short-term bioavailabilities of [6S]-5-methyltetrahydrofolate and folic acid are equivalent in men 2004 · 500 micro g FA capsule · Men presaturated with folic acid | 500 mcg | 1 day | — |
| [6S]-5-Methyltetrahydrofolate is at least as effective as folic acid in preventing a decline in blood folate concentrations during lactation 2006 · Folic acid reference group · Pregnant women enrolled at 36 weeks gestation who were healthy Canadian women during lactation | 400 mcg | 16 weeks | — |
| Red blood cell folate concentrations increase more after supplementation with [6S]-5-methyltetrahydrofolate than with folic acid in women of childbearing age 2006 · 400 microg folic acid group · Healthy women aged 19–33 years | 400 mcg | 24 weeks | — |
| Milk folate secretion is not impaired during iron deficiency in humans 2006 · multivitamin without iron · Breast-feeding mothers; age not reported | 400 mcg | — | — |
| Effects of fish-oil and folate supplementation of pregnant women on maternal and fetal plasma concentrations of docosahexaenoic acid and eicosapentaenoic acid: a European randomized multicenter trial 2007 · MTHF · Pregnant women from gestation week 22 until delivery | 400 mcg | — | — |
| Effect of different dosage and administration schedules of folic acid on blood folate levels in a population of Honduran women of reproductive age 2008 · 5 mg/week group · Women factory workers aged 18 to 49 years in Honduras | 714 mcg | 12 weeks | — |
| Influence of green and black tea on folic acid pharmacokinetics in healthy volunteers: potential risk of diminished folic acid bioavailability 2008 · 0.4 mg folic acid with water · Healthy volunteers; age and sex not specified | 400 mcg | 1 day | — |
| Gender and body size affect the response of erythrocyte folate to folic acid treatment 2008 · 400 microg/d folic acid, 12-wk trial · men and women; age and health condition not reported | 400 mcg | 12 weeks | — |
| Gender and body size affect the response of erythrocyte folate to folic acid treatment 2008 · 600 microg/d folic acid, 12-wk trial · men and women; age and health condition not reported | 600 mcg | 12 weeks | — |
| Folate status and homocysteine response to folic acid doses and withdrawal among young Chinese women in a large-scale randomized double-blind trial 2008 · 400 microg 1 time/d · Young Chinese women not exposed to other sources of folic acid | 400 mcg | 26 weeks | — |
| Folate status and homocysteine response to folic acid doses and withdrawal among young Chinese women in a large-scale randomized double-blind trial 2008 · 100 microg 4 times/d · Young Chinese women not exposed to other sources of folic acid | 400 mcg | 26 weeks | — |
| Folate status and homocysteine response to folic acid doses and withdrawal among young Chinese women in a large-scale randomized double-blind trial 2008 · 4000 microg 1 time/d · Young Chinese women not exposed to other sources of folic acid | 4 mg | 26 weeks | — |
| Folate status and homocysteine response to folic acid doses and withdrawal among young Chinese women in a large-scale randomized double-blind trial 2008 · 4000 microg 1 time/wk · Young Chinese women not exposed to other sources of folic acid | 571 mcg | 26 weeks | — |
| Unmetabolized folic acid and total folate concentrations in breast milk are unaffected by low-dose folate supplements 2009 · folic acid · Lactating women enrolled within 1 week postpartum | 400 mcg | 16 weeks | — |
| Effects of folic acid supplementation on serum folate and plasma homocysteine concentrations in older adults: a dose-response trial 2010 · 400 μg/day folic acid · Adults aged 60–90 years; healthy older adults | 400 mcg | 6 weeks | — |
| MTHFR 677C->T genotype is associated with folate and homocysteine concentrations in a large, population-based, double-blind trial of folic acid supplementation 2011 · 400 μg/d folic acid · Northern Chinese women of childbearing age | 400 mcg | 26 weeks | — |
| MTHFR 677C->T genotype is associated with folate and homocysteine concentrations in a large, population-based, double-blind trial of folic acid supplementation 2011 · 4000 μg/d folic acid · Northern Chinese women of childbearing age | 4 mg | 26 weeks | — |
| MTHFR 677C->T genotype is associated with folate and homocysteine concentrations in a large, population-based, double-blind trial of folic acid supplementation 2011 · 4000 μg/wk folic acid · Northern Chinese women of childbearing age | 571 mcg | 26 weeks | — |
| Effect of folic acid intervention on the change of serum folate level in hypertensive Chinese adults: do methylenetetrahydrofolate reductase and methionine synthase gene polymorphisms affect therapeutic responses? 2012 · low-FA group · Chinese adults with mild or moderate essential hypertension | 400 mcg | 8 weeks | — |
| Response of serum and red blood cell folate concentrations to folic acid supplementation depends on methylenetetrahydrofolate reductase C677T genotype: results from a crossover trial 2013 · 400 μg folic acid · Adults aged 18–69 years without chronic disease or diseases known to interfere with folate metabolism | 400 mcg | 12 weeks | — |
| Wheat rolls fortified with microencapsulated L-5-methyltetrahydrofolic acid or equimolar folic acid increase blood folate concentrations to a similar extent in healthy men and women 2013 · folic acid wheat roll group · Healthy men and women aged 18–45 years | 400 mcg | 16 weeks | — |
| Relative bioavailability of 13C5-folic acid in pectin-coated folate fortified rice in humans using stable isotope techniques 2017 · Trial 1: aqueous 13C5-PteGlu · Healthy volunteers aged 18–39 | 400 mcg | 1 day | — |
| Relative bioavailability of 13C5-folic acid in pectin-coated folate fortified rice in humans using stable isotope techniques 2017 · Trial 2: cooked white rice with 13C5-PteGlu · Healthy volunteers aged 18–39 | 400 mcg | 1 day | — |
| Relative bioavailability of 13C5-folic acid in pectin-coated folate fortified rice in humans using stable isotope techniques 2017 · Trial 3: pectin-coated fortified cooked rice · Healthy volunteers aged 18–39 | 400 mcg | 1 day | — |
| Supplementation with (6S)-5-methyltetrahydrofolic acid appears as effective as folic acid in maintaining maternal folate status while reducing unmetabolised folic acid in maternal plasma: a randomised trial of pregnant women in Canada 2024 · Folic acid group · Pregnant individuals at 8–21 weeks’ gestation | 600 mcg | 16 weeks | — |
| Effect of increasing dietary folate on red-cell folate: implications for prevention of neural tube defects 1996 · folic acid supplement (group I) · Women recruited from university staff and students; no condition stated | 400 mcg | 90 days | — |
| Minimum effective dose of folic acid for food fortification to prevent neural-tube defects 1997 · 400 micrograms/day group · Women with red-cell folate concentrations between 150 and 400 micrograms/L | 400 mcg | 26 weeks | — |
| Folate status response to controlled folate intake in pregnant women 1997 · 730 microg/d synthetic folic acid group · Pregnant women in their second trimester and nonpregnant women; the abstract does not give the number in this dose group | 730 mcg | 12 weeks | — |
| Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention 1998 · 5 mg folic acid supplementation per week · Patients with rheumatoid arthritis taking low-dose methotrexate; age and sex not reported | 714 mcg | 1 year | — |
| Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention 1998 · 27.5 mg folic acid supplementation per week · Patients with rheumatoid arthritis taking low-dose methotrexate; age and sex not reported | 3.93 mg | 1 year | — |
| A 2-Year Randomized Controlled Trial With Low-Dose B-Vitamin Supplementation Shows Benefits on Bone Mineral Density in Adults With Lower B12 Status 2022 · B-vitamin treatment · Community-dwelling adults aged 50 years or older; men and women; no specific diagnosed condition, and not currently taking B-vitamin supplements at screening | 200 mcg | 2 years | 103 |
| Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endotelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trial 2015 · Combination A · Adults aged 18–70 with hypercholesterolemia not requiring statins or statin-intolerant | 200 mcg | 4 weeks | 23 |
| Aged garlic extract supplemented with B vitamins, folic acid and L-arginine retards the progression of subclinical atherosclerosis: a randomized clinical trial 2009 · AGE+S · Intermediate-risk adults, mean age 60 ± 9 years; 79% male | 300 mcg | 1 year | — |
| Optimal folic acid dosage in lowering homocysteine: Precision Folic Acid Trial to lower homocysteine (PFAT-Hcy) 2024 · 2.4 mg folic acid group · Chinese men and women aged 45–75 with hypertension and elevated total homocysteine | 2.4 mg | 8 weeks | 339 |
| Optimal folic acid dosage in lowering homocysteine: Precision Folic Acid Trial to lower homocysteine (PFAT-Hcy) 2024 · 0.4 mg folic acid group · Chinese men and women aged 45–75 with hypertension and elevated total homocysteine | 400 mcg | 8 weeks | 338 |
| Optimal folic acid dosage in lowering homocysteine: Precision Folic Acid Trial to lower homocysteine (PFAT-Hcy) 2024 · 0.6 mg folic acid group · Chinese men and women aged 45–75 with hypertension and elevated total homocysteine | 600 mcg | 8 weeks | 336 |
| Sex-Specific Associations between One-Carbon Metabolism Indices and Posttranslational Histone Modifications in Arsenic-Exposed Bangladeshi Adults 2017 · 400 µg FA/day · Adults aged 20–65 exposed to household well-water arsenic ≥50 µg/L | 400 mcg | 12 weeks | 156 |
| Betaine and choline status modify the effects of folic acid and creatine supplementation on arsenic methylation in a randomized controlled trial of Bangladeshi adults 2021 · 400FA · Adults aged 24–55 in Bangladesh exposed to arsenic through household drinking water | 400 mcg | 12 weeks | 156 |
| Folic Acid and Creatine as Therapeutic Approaches to Lower Blood Arsenic: A Randomized Controlled Trial 2015 · FA400, first phase · Adults aged 20–65 in Bangladesh selected for drinking from a well with arsenic above 50 μg/L; both folate-deficient and folate-sufficient participants | 400 mcg | 12 weeks | 153 |
| Low-Dose Creatine Supplementation Lowers Plasma Guanidinoacetate, but Not Plasma Homocysteine, in a Double-Blind, Randomized, Placebo-Controlled Trial 2015 · FA group · Bangladeshi adults | 400 mcg | 12 weeks | 153 |
| The Folic Acid and Creatine Trial: Treatment Effects of Supplementation on Arsenic Methylation Indices and Metabolite Concentrations in Blood in a Bangladeshi Population 2023 · 400FA · Adults aged 20–65 years in Bangladesh exposed to arsenic in drinking water; men and women, recruited independent of folate status | 400 mcg | 12 weeks | 153 |
| Protective Effect of Folic Acid on Oxidative DNA Damage: A Randomized, Double-Blind, and Placebo Controlled Clinical Trial 2015 · low-FA group · Adults aged 18–79 chronically exposed to arsenic in drinking water | 400 mcg | 8 weeks | 150 |
| MTHFR C677T and MTR A2756G polymorphisms and the homocysteine lowering efficacy of different doses of folic acid in hypertensive Chinese adults 2012 · Low FA group · Chinese adults with mild or moderate hypertension; mean age approximately 57 years; men and women | 400 mcg | 8 weeks | 147 |
| Combined use of amlodipine and folic acid are significantly more efficacious than amlodipine alone in lowering plasma homocysteine and blood pressure among hypertensive patients with hyperhomocysteinemia and intolerance to ACEI: A multicenter, randomized, double-blind, parallel-controlled clinical trial 2023 · A group (amlodipine 5 mg/FA 0.4 mg) · Chinese adults with hypertension, hyperhomocysteinemia, and intolerance to ACE inhibitors; mean age 63.4 years in this arm; men and women | 400 mcg | 8 weeks | 116 |
| Folate and arsenic metabolism: a double-blind, placebo-controlled folic acid-supplementation trial in Bangladesh 2006 · folic acid group · Bangladeshi men and women aged 18–65 years with low plasma folate, exposed to arsenic in drinking water | 400 mcg | 12 weeks | 97 |
| A randomized controlled trial of folic acid intervention in pregnancy highlights a putative methylation-regulated control element at ZFP57 2019 · folic acid · Pregnant women recruited at approximately 14 weeks of gestation, with singleton pregnancies | 400 mcg | 22 weeks | 96 |
| Folic acid intervention during pregnancy alters DNA methylation, affecting neural target genes through two distinct mechanisms 2022 · FA group · Women with singleton pregnancies who had taken folic acid in the first trimester; age not specified | 400 mcg | — | 96 |
| Folic Acid and Creatine as Therapeutic Approaches to Lower Blood Arsenic: A Randomized Controlled Trial 2015 · FA400 continued, second phase · Adults aged 20–65 in Bangladesh selected for drinking from a well with arsenic above 50 μg/L; both folate-deficient and folate-sufficient participants | 400 mcg | 24 weeks | 77 |
| Myoinositol plus α-lactalbumin supplementation, insulin resistance and birth outcomes in women with gestational diabetes mellitus: a randomized, controlled study 2021 · Control group · Women aged 18–44 with gestational diabetes mellitus and a singleton pregnancy | 400 mcg | 60 days | 60 |
| Effect of myo-inositol supplementation on ICSI outcomes among poor ovarian responder patients: A randomized controlled trial 2020 · Group B · Poor responder patients undergoing ICSI; age and sex details not reported | 400 mcg | — | 56 |
| Low-Dose folic acid supplementation decreases plasma homocysteine concentrations: a randomised trial 2000 · 500 microg folic acid per day · Healthy women aged 18–40 years | 500 mcg | 4 weeks | 45 |
| Randomized clinical trial of folate supplementation in patients with peripheral arterial disease 2009 · folic acid · People with peripheral arterial disease (PAD); age and sex not reported | 400 mcg | 16 weeks | 45 |
| The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes 2011 · control group · Women with gestational diabetes treated with diet | 400 mcg | 8 weeks | 45 |
| Genomic DNA methylation changes in response to folic acid supplementation in a population-based intervention study among women of reproductive age 2011 · 400 µg/day folic acid group · Women of reproductive age; mean age 30.7 years in the analyzed sample; not pregnant or breastfeeding and without chronic disease | 400 mcg | 26 weeks | 45 |
| Genomic DNA methylation changes in response to folic acid supplementation in a population-based intervention study among women of reproductive age 2011 · 4,000 µg/day folic acid group · Women of reproductive age; mean age 29.9 years in the analyzed sample; not pregnant or breastfeeding and without chronic disease | 4 mg | 26 weeks | 45 |
| Low-dose folic acid supplementation decreases plasma homocysteine concentrations: a randomized trial 1999 · 500 microgram/d group · Healthy women aged 18–40 years | 500 mcg | 4 weeks | 45 |
| The impact of a standardized micronutrient supplementation on PCOS-typical parameters: a randomized controlled trial 2019 · Control group · Women aged 19–35 with polycystic ovary syndrome (PCOS) | 400 mcg | 90 days | 30 |
| The effects of high and low doses of folic acid on oxidation of protein levels during pregnancy: a randomized double-blind clinical trial 2017 · Group 2 (0.5 mg/day folic acid) · Pregnant women, from before pregnancy through the 36th week of pregnancy | 500 mcg | — | 23 |
| Human milk oligosaccharide composition following supplementation with folic acid vs (6S)-5-methyltetrahydrofolic acid during pregnancy and mediation by human milk folate forms 2024 · Folic acid group · Pregnant women recruited at 8–21 weeks’ gestation in Vancouver, Canada; no diagnosed condition stated | 600 mcg | 16 weeks | 20 |
| The potential adding therapeutic effect of pentoxifylline and/or folic acid for chronic kidney disease patients: randomized controlled trial 2025 · FA group · Adults aged 18–60 with stable stage 3–5 chronic kidney disease | 500 mcg | 26 weeks | 20 |
| Effect of Myo-Inositol Treatment on Serum Asprosin Levels of Pregnant Women: A Prospective Randomized Controlled Pilot Study 2025 · Group 2 · Pregnant women aged 18–40 without the stated exclusion conditions | 400 mcg | 21 weeks | 20 |
| Low-dose folic acid supplementation reduces plasma levels of the cardiovascular risk factor homocysteine in postmenopausal women 2000 · group receiving folic acid · postmenopausal women | 500 mcg | 4 weeks | 18 |
| Folic acid and vitamin B(12) supplementation lowers plasma homocysteine but has no effect on serum bone turnover markers in elderly women: a randomized, double-blind, placebo-controlled trial 2013 · vitamin group · Women aged 65–93 years with homocysteine levels greater than 10 μmol/L | 800 mcg | 120 days | 17 |
| Effect of folic acid supplementation on genomic DNA methylation in patients with colorectal adenoma 2005 · folic acid supplement · Patients with histologically confirmed colorectal adenoma | 400 mcg | 10 weeks | 15 |
| Short-term folate supplementation in physiological doses has no effect on ESR1 and MLH1 methylation in colonic mucosa of individuals with adenoma 2012 · folic acid group · Individuals with colorectal adenoma; age and sex not specified | 400 mcg | 10 weeks | 15 |
| Stability of the human sperm DNA methylome to folic acid fortification and short-term supplementation 2017 · supplement containing folic acid · Men with no history of infertility; age range not reported | 400 mcg | 90 days | 10 |
| Impact of folic acid supplementation on the epigenetic profile in healthy unfortified individuals - a randomized intervention trial 2024 · 400 μg folic acid · Healthy men aged 23–61 years with normal baseline folate levels | 400 mcg | 8 weeks | 9 |
| Antioxidants, but not B-group vitamins increase the resistance of low-density lipoprotein to oxidation: a randomized, factorial design, placebo-controlled trial 1999 · B group vitamins alone · Men aged 30–49 with plasma homocysteine concentration ≥8.34 μmol/L | 1 mg | 8 weeks | — |
| Low-dose folic acid supplementation does not influence plasma methionine concentrations in young non-pregnant women 1999 · 500 micrograms folic acid each day · Young non-pregnant women | 500 mcg | 4 weeks | — |
| Randomized trial of folic acid supplementation and serum homocysteine levels 2001 · 0.4 mg/d folic acid · Patients with ischemic heart disease; age and sex not specified | 400 mcg | 90 days | — |
| Randomized trial of folic acid supplementation and serum homocysteine levels 2001 · 0.6 mg/d folic acid · Patients with ischemic heart disease; age and sex not specified | 600 mcg | 90 days | — |
| Optimization of dietary folate or low-dose folic acid supplements lower homocysteine but do not enhance endothelial function in healthy adults, irrespective of the methylenetetrahydrofolate reductase (C677T) genotype 2001 · daily 400-microg folic acid supplement plus natural diet · Healthy adults; 42 of each MTHFR genotype | 400 mcg | 120 days | — |
| 5,10-Methylenetetrahydrofolate reductase genotype determines the plasma homocysteine-lowering effect of supplementation with 5-methyltetrahydrofolate or folic acid in healthy young women 2002 · folic acid · healthy young women | 400 mcg | 8 weeks | — |
| The effect of folic acid supplementation on plasma homocysteine in an elderly population 2002 · 400 microg folic acid group · Adults aged 65–75 years | 400 mcg | 6 weeks | — |
| The effect of folic acid supplementation on plasma homocysteine in an elderly population 2002 · 600 microg folic acid group · Adults aged 65–75 years | 600 mcg | 6 weeks | — |
| Effect of riboflavin supplementation on plasma homocysteine in elderly people with low riboflavin status 2002 · Folic acid group (Part 2, first phase) · Healthy elderly people with sub-optimal riboflavin status | 400 mcg | 6 weeks | — |
| Low-dose folic acid lowers plasma homocysteine levels in women of child-bearing age 2002 · 400 microg/day folic acid group · Premenopausal women of child-bearing age | 400 mcg | 10 weeks | — |
| Effect of low doses of 5-methyltetrahydrofolate and folic acid on plasma homocysteine in healthy subjects with or without the 677C-->T polymorphism of methylenetetrahydrofolate reductase 2002 · Folic acid · Healthy subjects, including wild-type and homozygous carriers of the MTHFR 677C-->T polymorphism | 400 mcg | 7 weeks | — |
| Weekly high-dose folic Acid supplementation is effective in lowering serum homocysteine concentrations in women 2003 · weekly folic acid group · Healthy women of childbearing age | 400 mcg | 12 weeks | — |
| Weekly high-dose folic Acid supplementation is effective in lowering serum homocysteine concentrations in women 2003 · daily folic acid group · Healthy women of childbearing age | 400 mcg | 12 weeks | — |
| Folic acid and reduction of plasma homocysteine concentrations in older adults: a dose-response study 2003 · 400 micro g folic acid · Healthy men and women aged 50–75 years | 400 mcg | 12 weeks | — |
| Folic acid and reduction of plasma homocysteine concentrations in older adults: a dose-response study 2003 · 600 micro g folic acid · Healthy men and women aged 50–75 years | 600 mcg | 12 weeks | — |
| Supplementation with micronutrients in addition to iron and folic acid does not further improve the hematologic status of pregnant women in rural Nepal 2003 · folic acid alone · Pregnant women in rural Nepal | 400 mcg | — | — |
| Supplementation with [6S]-5-methyltetrahydrofolate or folic acid equally reduces plasma total homocysteine concentrations in healthy women 2004 · 400 micro g folic acid · healthy women | 400 mcg | 24 weeks | — |
| [6S]5-methyltetrahydrofolate or folic acid supplementation and absorption and initial elimination of folate in young and middle-aged adults 2005 · folic acid supplementation · Healthy young and middle-aged adults | 400 mcg | 5 weeks | — |
| Effect of folic acid treatment on carotid intima-media thickness of patients with coronary disease 2007 · Group A · Patients with coronary disease and homocysteine levels ≥9 micromol/L; normal vitamin B12 values | 2.5 mg | 3 years | — |
| Effect of folate supplementation on N-terminal pro-brain natriuretic peptide 2007 · 0.4 mg FA daily · Healthy adults, median age 57 years | 400 mcg | 8 weeks | — |
| High- but not low-dose folic acid improves endothelial function in coronary artery disease 2006 · 400 microg folic acid group · Patients with coronary artery disease; age and sex not reported | 400 mcg | 6 weeks | — |
| Folic acid supplementation lowers blood arsenic 2007 · folic acid group · Bangladeshi adults selected for low plasma folate; pregnant people and people with cobalamin deficiency were excluded | 400 mcg | 12 weeks | — |
| Comparison study on the effect of prenatal administration of high dose and low dose folic acid 2009 · group 2 (low dose) · nulliparous pregnant women | 500 mcg | — | — |
| A dose-finding trial of the effect of long-term folic acid intervention: implications for food fortification policy 2011 · 0.4 mg/d folic acid · Patients with ischemic heart disease and healthy volunteers; ages and sex not specified | 400 mcg | 26 weeks | — |
| Effect of folic acid intervention on ALT concentration in hypertensives without known hepatic disease: a randomized, double-blind, controlled trial 2012 · low FA group · Chinese adults with mild or moderate essential hypertension and no known hepatic disease | 400 mcg | 8 weeks | — |
| Folic acid supplementation does not reduce intracellular homocysteine, and may disturb intracellular one-carbon metabolism 2013 · folic acid group · Volunteers; age and sex not specified | 500 mcg | 8 weeks | — |
| Effects of combined enalapril and folic acid therapy on the serum uric acid levels in hypertensive patients: a multicenter, randomized, double-blind, parallel-controlled clinical trial 2015 · low-FA group · Adults aged 27–75 with mild to moderate hypertension in China | 400 mcg | 8 weeks | — |
| Supplementation with Folic Acid, but Not Creatine, Increases Plasma Betaine, Decreases Plasma Dimethylglycine, and Prevents a Decrease in Plasma Choline in Arsenic-Exposed Bangladeshi Adults 2016 · FA400 · Arsenic-exposed adults aged 24–55 in Bangladesh | 400 mcg | 12 weeks | — |
| Supplementation with [6S]-5-methyltetrahydrofolate or folic acid equally reduces serum homocysteine concentrations in older adults 2018 · Folic acid group · Healthy adults aged 50–65 with normal serum folate who had not used B-vitamin supplements for 6 months | 400 mcg | 4 weeks | — |
| Gene-specific DNA methylation in newborns in response to folic acid supplementation during the second and third trimesters of pregnancy: epigenetic analysis from a randomized controlled trial 2018 · ongoing folic acid supplementation · Pregnant women receiving supplementation during the second and third trimesters; newborn cord blood was analyzed | 400 mcg | — | — |
| Folic acid supplementation enhances arsenic methylation: results from a folic acid and creatine supplementation randomized controlled trial in Bangladesh 2019 · 400 μg folic acid group · Bangladeshi participants exposed to arsenic through drinking water; the majority were folate sufficient | 400 mcg | 24 weeks | — |
| Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid 1995 · 2.5 mg folic acid group · Patients with acute myocardial infarction; age and sex not reported | 2.5 mg | 6 weeks | — |
| Vitamin requirements for the treatment of hyperhomocysteinemia in humans 1994 · folic acid · men with hyperhomocysteinemia | 650 mcg | 6 weeks | — |
| Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers 1998 · 0.5 mg folic acid · Healthy volunteers without hyperhomocysteinemia | 500 mcg | — | — |
| Plasma homocyst(e)ine concentrations in pregnant and nonpregnant women with controlled folate intake 1998 · 850 microg/day folate intake · Women in the second trimester of pregnancy and young, healthy nonpregnant women | 730 mcg | 12 weeks | — |
| Effects of folic acid and combinations of folic acid and vitamin B-12 on plasma homocysteine concentrations in healthy, young women 1998 · 400 microg folic acid · Female volunteers of childbearing age | 400 mcg | 4 weeks | — |
| Antenatal Multiple Micronutrient Supplementation Compared to Iron-Folic Acid Affects Micronutrient Status but Does Not Eliminate Deficiencies in a Randomized Controlled Trial Among Pregnant Women of Rural Bangladesh 2019 · IFA · Pregnant women aged 12–45 years in rural Bangladesh | 600 mcg | 165 days | 777 |
| Impact of Preconception Micronutrient Supplementation on Anemia and Iron Status during Pregnancy and Postpartum: A Randomized Controlled Trial in Rural Vietnam 2016 · IFA (iron and folic acid) · Women aged 18–40 planning pregnancy in rural Vietnam; no specific diagnosed condition required | 400 mcg | 56 weeks | 518 |
| A Prenatal Multiple Micronutrient Supplement Produces Higher Maternal Vitamin B-12 Concentrations and Similar Folate, Ferritin, and Zinc Concentrations as the Standard 60-mg Iron Plus 400-μg Folic Acid Supplement in Rural Bangladeshi Women 2016 · Fe30F · Pregnant women in rural Bangladesh enrolled before 14 weeks of pregnancy | 400 mcg | 114 days | 213 |
| Newborn micronutrient status biomarkers in a cluster-randomized trial of antenatal multiple micronutrient compared with iron folic acid supplementation in rural Bangladesh 2020 · IFA · Pregnant women in rural Bangladesh; age range not specified; no disease condition specified | 600 mcg | — | 157 |
| Effect of Combined Treatment With Folic Acid, Vitamin B(6), and Vitamin B(12) on Plasma Biomarkers of Inflammation and Endothelial Dysfunction in Women 2018 · Folic Acid/B6/B12 · Adult women at increased cardiovascular risk, with pre-existing cardiovascular disease or at least three coronary risk factors | 2.5 mg | 2665 days | 150 |
| Weekly iron-folic acid supplements containing 2.8 mg folic acid are associated with a lower risk of neural tube defects than the current practice of 0.4 mg: a randomised controlled trial in Malaysia 2020 · 2.8 mg folic acid group · Women aged 18–45 years, predominantly 18–21, non-pregnant and not planning pregnancy | 400 mcg | 16 weeks | 111 |
| Consumption of multiple micronutrients or small-quantity lipid-based nutrient supplements containing iodine at the recommended dose during pregnancy, compared with iron and folic acid, does not affect women's urinary iodine concentration in rural Malawi: a secondary outcome analysis of the iLiNS DYAD trial 2021 · MMN group · Pregnant women enrolled at no more than 20 completed weeks of pregnancy in rural Malawi | 400 mcg | — | 106 |
| Long-term effect of low-dose folic acid intake: potential effect of mandatory fortification on the prevention of neural tube defects 2011 · 140 μg folic acid group · Women aged 18–40 years; reproductive-aged women | 140 mcg | 40 weeks | 49 |
| Folate status of reproductive age women and neural tube defect risk: the effect of long-term folic acid supplementation at doses of 140 µg and 400 µg per day 2011 · 140 μg folic acid/day · Healthy reproductive-age women aged 18–40 years; not pregnant or lactating and not planning pregnancy in the next 12 months | 140 mcg | 40 weeks | 49 |
| Functionality of endogenous folates from rye and orange juice using human in vivo model 2002 · fortified wheat bread and apple juice group · Healthy human volunteers aged 20–66 years | 188 mcg | 4 weeks | 31 |
| Optimum dose of oral folic acid supplementation in transfusion-dependent thalassemia: a randomized controlled trial 2022 · Group 1 · Children aged 5–18 years with transfusion-dependent thalassemia | 5 mg | 39 weeks | 30 |
| Bioavailability of food folates is 80% of that of folic acid 2007 · Group A · Healthy adults; age and sex not reported | 58 mcg | 4 weeks | 29 |
| Folic acid absorption in patients infected with the human immunodeficiency virus 1991 · oral folic acid absorption study · people with HIV infection; age and sex not reported | 5 mg | 1 day | 25 |
| Human milk unmetabolized folic acid is increased following supplementation with synthetic folic acid as compared to (6S)-5-methyltetrahydrofolic acid 2023 · folic acid · Pregnant women aged 19–42 years with singleton pregnancies, continuing supplementation through approximately 1 week postpartum | 600 mcg | 24 weeks | 21 |
| Effects of folic acid on epithelial apoptosis and expression of Bcl-2 and p53 in premalignant gastric lesions 2005 · treatment group · Patients with premalignant gastric lesions, including colonic-type intestinal metaplasia or mild to moderate dysplasia; age and sex not reported | 30 mg | 90 days | 19 |
| Determining bioavailability of food folates in a controlled intervention study 2004 · folic acid group · men; age and health status not specified | 200 mcg | 30 days | 18 |
| Relative bioavailability of iron and folic acid from a new powdered supplement compared to a traditional tablet in pregnant women 2009 · Powdered Supplement · Healthy pregnant women aged 18–45 years, at 24–32 weeks’ gestation | 600 mcg | 1 day | 18 |
| Study of wheat breakfast rolls fortified with folic acid. The effect on folate status in women during a 3-month intervention 2002 · group H · healthy women; age not reported | 355 mcg | 12 weeks | 15 |
| Study of wheat breakfast rolls fortified with folic acid. The effect on folate status in women during a 3-month intervention 2002 · group L · healthy women; age not reported | 166 mcg | 12 weeks | 14 |
| Postpartum folic acid supplementation of adolescents: impact on maternal folate and zinc status and milk composition 1995 · folic acid supplement lactating (SL) · Breastfeeding adolescents aged 14–19 years postpartum | 300 mcg | 12 weeks | 14 |
| Folate bioavailability from breads and a meal assessed with a human stable-isotope area under the curve and ileostomy model 2010 · Whole-meal bread containing labeled folic acid · Healthy ileostomists; age and sex not reported | 200 mcg | 1 day | 8 |
| Folate bioavailability from breads and a meal assessed with a human stable-isotope area under the curve and ileostomy model 2010 · Fortified breakfast meal containing labeled folic acid · Healthy ileostomists; age and sex not reported | 200 mcg | 1 day | 8 |
| Folic acid handling by the human gut: implications for food fortification and supplementation 2014 · 13C5-folic acid · Adults aged 44–61 with stable liver cirrhosis and an in situ TIPSS | 220 mcg | 1 day | 6 |
| School-administered weekly iron-folate supplements improve hemoglobin and ferritin concentrations in Malaysian adolescent girls 1999 · 60 mg Fe plus 3.5 mg folic acid weekly · Adolescent girls with hemoglobin 80–119.9 g/L (group A, mild-to-moderate anemia) and 120–130 g/L (group B, borderline anemia); otherwise healthy | 500 mcg | 22 weeks | — |
| School-administered weekly iron-folate supplements improve hemoglobin and ferritin concentrations in Malaysian adolescent girls 1999 · 120 mg Fe plus 3.5 mg folic acid weekly · Adolescent girls with hemoglobin 80–119.9 g/L (group A, mild-to-moderate anemia) and 120–130 g/L (group B, borderline anemia); otherwise healthy | 500 mcg | 22 weeks | — |
| Effect of folic acid and vitamin C supplementation on folate status and homocysteine level: a randomised controlled trial in Italian smoker-blood donors 2002 · A: folic acid · Italian repeat blood donors who smoked more than 15 cigarettes per day; age and sex not specified | 5 mg | 45 days | — |
| Assessment of three levels of folic acid on serum folate and plasma homocysteine: a randomised placebo-controlled double-blind dietary intervention trial 2002 · 100 microg folic acid group · Men and women aged 29–90 years with plasma total homocysteine ≥10 micromol/L | 100 mcg | 4 weeks | — |
| Assessment of three levels of folic acid on serum folate and plasma homocysteine: a randomised placebo-controlled double-blind dietary intervention trial 2002 · 200 microg folic acid group · Men and women aged 29–90 years with plasma total homocysteine ≥10 micromol/L | 200 mcg | 4 weeks | — |
| Assessment of three levels of folic acid on serum folate and plasma homocysteine: a randomised placebo-controlled double-blind dietary intervention trial 2002 · 300 microg folic acid group · Men and women aged 29–90 years with plasma total homocysteine ≥10 micromol/L | 300 mcg | 4 weeks | — |
| Increases in blood folate indices are similar in women of childbearing age supplemented with [6S]-5-methyltetrahydrofolate and folic acid 2002 · Folic acid group · Women aged 18–49 years of childbearing age | 100 mcg | 24 weeks | — |
| Acute absorption of folic acid from a fortified low-fat spread 2003 · A: fortified spread and placebo tablet · Male volunteers aged 31.8 ± 13.2 years | 200 mcg | 1 day | — |
| Acute absorption of folic acid from a fortified low-fat spread 2003 · B: placebo spread and folic acid tablet · Male volunteers aged 31.8 ± 13.2 years | 200 mcg | 1 day | — |
| Pharmacokinetic study on the utilisation of 5-methyltetrahydrofolate and folic acid in patients with coronary artery disease 2004 · 5 mg folic acid · Patients with coronary artery disease who were homozygous for the 677C→T MTHFR mutation | 5 mg | 1 day | — |
| Zinc plus beta-carotene supplementation of pregnant women is superior to beta-carotene supplementation alone in improving vitamin A status in both mothers and infants 2004 · zinc · Pregnant women; age and specific condition not stated | 400 mcg | — | — |
| Folic acid fortified milk increases blood folate and lowers homocysteine concentration in women of childbearing age 2005 · fortified milk · Non-pregnant women aged 18–47 years | 375 mcg | 12 weeks | — |
| Bioavailability of folic acid from fortified pasteurised and UHT-treated milk in humans 2005 · Pasteurised milk fortified with folic acid · Healthy, free-living adults aged 18–49 years | 200 mcg | 4 weeks | — |
| Bioavailability of folic acid from fortified pasteurised and UHT-treated milk in humans 2005 · UHT-treated milk fortified with folic acid · Healthy, free-living adults aged 18–49 years | 200 mcg | 4 weeks | — |
| Influence of green and black tea on folic acid pharmacokinetics in healthy volunteers: potential risk of diminished folic acid bioavailability 2008 · 0.4 mg folic acid with green tea · Healthy volunteers; age and sex not specified | 400 mcg | 1 day | — |
| Influence of green and black tea on folic acid pharmacokinetics in healthy volunteers: potential risk of diminished folic acid bioavailability 2008 · 0.4 mg folic acid with black tea · Healthy volunteers; age and sex not specified | 400 mcg | 1 day | — |
| Influence of green and black tea on folic acid pharmacokinetics in healthy volunteers: potential risk of diminished folic acid bioavailability 2008 · 5 mg folic acid with water · Healthy volunteers; age and sex not specified | 5 mg | 1 day | — |
| Gender and body size affect the response of erythrocyte folate to folic acid treatment 2008 · 50 microg/d folic acid, 12-wk trial · men and women; age and health condition not reported | 50 mcg | 12 weeks | — |
| Gender and body size affect the response of erythrocyte folate to folic acid treatment 2008 · 100 microg/d folic acid, 12-wk trial · men and women; age and health condition not reported | 100 mcg | 12 weeks | — |
| Gender and body size affect the response of erythrocyte folate to folic acid treatment 2008 · 200 microg/d folic acid, 12-wk trial · men and women; age and health condition not reported | 200 mcg | 12 weeks | — |
| Folate status and homocysteine response to folic acid doses and withdrawal among young Chinese women in a large-scale randomized double-blind trial 2008 · 100 microg 1 time/d · Young Chinese women not exposed to other sources of folic acid | 100 mcg | 26 weeks | — |
| Folate status and homocysteine response to folic acid doses and withdrawal among young Chinese women in a large-scale randomized double-blind trial 2008 · 25 microg 4 times/d · Young Chinese women not exposed to other sources of folic acid | 100 mcg | 26 weeks | — |
| Steady state folate concentrations achieved with 5 compared with 1.1 mg folic acid supplementation among women of childbearing age 2009 · 5 mg folic acid group · Nonpregnant women aged 18–45 years who did not take folic acid supplements | 5 mg | 30 weeks | — |
| Effects of folic acid supplementation on serum folate and plasma homocysteine concentrations in older adults: a dose-response trial 2010 · 100 μg/day folic acid · Adults aged 60–90 years; healthy older adults | 100 mcg | 6 weeks | — |
| MTHFR 677C->T genotype is associated with folate and homocysteine concentrations in a large, population-based, double-blind trial of folic acid supplementation 2011 · 100 μg/d folic acid · Northern Chinese women of childbearing age | 100 mcg | 26 weeks | — |
| The effects of folic acid on markers of endothelial function in patients with type 1 diabetes mellitus 2012 · folic acid · Type 1 diabetic patients aged 5–20 years | 5 mg | 8 weeks | — |
| Response of serum and red blood cell folate concentrations to folic acid supplementation depends on methylenetetrahydrofolate reductase C677T genotype: results from a crossover trial 2013 · 200 μg folic acid · Adults aged 18–69 years without chronic disease or diseases known to interfere with folate metabolism | 200 mcg | 12 weeks | — |
| Iron-containing micronutrient supplementation of Chinese women with no or mild anemia during pregnancy improved iron status but did not affect perinatal anemia 2014 · IFA group · Pregnant nulliparous women aged 20 years or older, enrolled by 20 weeks’ gestation, with hemoglobin at least 100 g/L and no or mild anemia | 400 mcg | — | — |
| Iron-containing micronutrient supplementation of Chinese women with no or mild anemia during pregnancy improved iron status but did not affect perinatal anemia 2014 · MM group · Pregnant nulliparous women aged 20 years or older, enrolled by 20 weeks’ gestation, with hemoglobin at least 100 g/L and no or mild anemia | 400 mcg | — | — |
| Pregnancy-induced changes in the long-term pharmacokinetics of 1.1 mg vs. 5 mg folic acid: a randomized clinical trial 2015 · 5 mg (high dose) · Pregnant women who were not previously taking folic acid | 5 mg | — | — |
| Minimum effective dose of folic acid for food fortification to prevent neural-tube defects 1997 · 100 micrograms/day group · Women with red-cell folate concentrations between 150 and 400 micrograms/L | 100 mcg | 26 weeks | — |
| Minimum effective dose of folic acid for food fortification to prevent neural-tube defects 1997 · 200 micrograms/day group · Women with red-cell folate concentrations between 150 and 400 micrograms/L | 200 mcg | 26 weeks | — |
| Folate status response to controlled folate intake in pregnant women 1997 · 330 microg/d synthetic folic acid group · Pregnant women in their second trimester and nonpregnant women; the abstract does not give the number in this dose group | 330 mcg | 12 weeks | — |
| Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease 1998 · Cereal providing 499 microg of folic acid daily · Men and women with coronary artery disease | 499 mcg | — | — |
| Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease 1998 · Cereal providing 665 microg of folic acid daily · Men and women with coronary artery disease | 665 mcg | — | — |
| Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial 2012 · UFT/LV group · Adults aged 20–80 with resected stage III colon adenocarcinoma | 75 mg | 25 weeks | 748 |
| Impact of Preconception Micronutrient Supplementation on Anemia and Iron Status during Pregnancy and Postpartum: A Randomized Controlled Trial in Rural Vietnam 2016 · Multiple micronutrients (MM) · Women aged 18–40 planning pregnancy in rural Vietnam; no specific diagnosed condition required | 400 mcg | 56 weeks | 508 |
| Provision of Lipid-Based Nutrient Supplements to Mothers During Pregnancy and 6 Months Postpartum and to Their Infants from 6 to 18 Months Promotes Infant Gut Microbiota Diversity at 18 Months of Age but Not Microbiota Maturation in a Rural Malawian Setting: Secondary Outcomes of a Randomized Trial 2020 · MMN group · Pregnant women aged 15 years or older, enrolled at 20 or more weeks of gestation; mothers and infants in the MMN group, with no direct infant supplementation | 400 mcg | 548 days | 291 |
| Daily Folic Acid and/or Vitamin B12 Supplementation Between 6 and 30 Months of Age and Cardiometabolic Risk Markers After 6-7 Years: A Follow-Up of a Randomized Controlled Trial 2023 · Folic acid only · Children aged 6–30 months at enrollment | 150 mcg | 180 days | 204 |
| The Effect of High Dose Folic Acid throughout Pregnancy on Homocysteine (Hcy) Concentration and Pre-Eclampsia: A Randomized Clinical Trial 2016 · Group 1 (Low dose) · Healthy nulliparous pregnant women aged 20–30 years with singleton pregnancies | 500 mcg | — | 200 |
| Prenatal nutrition supplementation and growth biomarkers in preadolescent Bangladeshi children: A birth cohort study 2022 · Fe30F · Pregnant women in rural Bangladesh; age and sex beyond pregnancy not specified | 400 mcg | — | 189 |
| Prenatal nutrition supplementation and growth biomarkers in preadolescent Bangladeshi children: A birth cohort study 2022 · MM · Pregnant women in rural Bangladesh; age and sex beyond pregnancy not specified | 400 mcg | — | 162 |
| Consumption of multiple micronutrients or small-quantity lipid-based nutrient supplements containing iodine at the recommended dose during pregnancy, compared with iron and folic acid, does not affect women's urinary iodine concentration in rural Malawi: a secondary outcome analysis of the iLiNS DYAD trial 2021 · LNS group · Pregnant women enrolled at no more than 20 completed weeks of pregnancy in rural Malawi | 400 mcg | — | 107 |
| Plasma Methylmalonic Acid Concentration in Folic Acid-Supplemented Depressed Patients with Low or Marginal Vitamin B-12: A Randomized Trial 2021 · Folic acid · Adults with moderate to severe depression, aged about 46 years, with low or marginal serum vitamin B-12 (150–280 ng/L) | 5 mg | 12 weeks | 92 |
| Folic acid treatment normalizes NOS-dependence of vascular tone in the metabolic syndrome 2011 · folic acid treatment · Obese subjects with and without metabolic syndrome | 5 mg | 4 weeks | 75 |
| A Randomized Trial of Short-term Treatment with Folic Acid to Reduce the Oxidative Stress of Patients with Chronic Kidney Disease 2021 · folic acid treatment · Adults with chronic kidney disease stages 3a and 3b | 5 mg | 90 days | 66 |
| Hyperhomocysteinemia in Japanese patients with convalescent stage ischemic stroke: effect of combined therapy with folic acid and mecobalamine 2002 · folic acid group · Japanese patients with ischemic stroke in the convalescent stage | 5 mg | 8 weeks | 64 |
| The effect of folic acid supplementation on carotid intima-media thickness in patients with cardiovascular risk: a randomized, placebo-controlled trial 2010 · group I · Patients with at least one cardiovascular risk factor | 5 mg | 78 weeks | 53 |
| Nutraceutical approaches to homocysteine lowering in hypertensive subjects at low cardiovascular risk: a multicenter, randomized clinical trial 2016 · Control group · Adults with stage 1 essential hypertension and hyper-homocysteinemia (HCys ≥15 μmol/L), without a history of cardiovascular or cerebrovascular disease; mean age 62.8 years, 63.5% male | 5 mg | 60 days | 52 |
| Low-Dose folic acid supplementation decreases plasma homocysteine concentrations: a randomised trial 2000 · 500 microg folic acid every second day (250 microg/day) · Healthy women aged 18–40 years | 250 mcg | 4 weeks | 50 |
| Short-term high-dose folic acid does not alter markers of endothelial cell damage in patients with coronary heart disease 2004 · folic acid · Patients with coronary heart disease and normal serum creatinine | 5 mg | 6 weeks | 50 |
| Evaluation of the deoxyuridine suppression test by using whole blood samples from folic acid-supplemented subjects 1990 · F group · Women with cervical dysplasia; age range not reported | 10 mg | 26 weeks | 50 |
| Folic acid effect on homocysteine, sortilin levels and glycemic control in type 2 diabetes mellitus patients 2022 · folic acid group · Adults aged 45–75 with type 2 diabetes mellitus | 5 mg | 12 weeks | 50 |
| Low-dose folic acid supplementation decreases plasma homocysteine concentrations: a randomized trial 1999 · 250 microgram/d group · Healthy women aged 18–40 years | 250 mcg | 4 weeks | 50 |
| Genomic DNA methylation changes in response to folic acid supplementation in a population-based intervention study among women of reproductive age 2011 · 100 µg/day folic acid group · Women of reproductive age; mean age 30.6 years in the analyzed sample; not pregnant or breastfeeding and without chronic disease | 100 mcg | 26 weeks | 45 |
| Different doses of oral folic acid for homocysteine-lowering therapy in patients on hemodialysis: a randomized controlled trial 2009 · group 1 · Adults on hemodialysis | 5 mg | 60 days | 40 |
| Different doses of oral folic acid for homocysteine-lowering therapy in patients on hemodialysis: a randomized controlled trial 2009 · group 2 · Adults on hemodialysis | 15 mg | 60 days | 40 |
| Homocysteine lowering by folate-rich diet or pharmacological supplementations in subjects with moderate hyperhomocysteinemia 2013 · Folic acid · Adults aged 18–60 with moderate hyperhomocysteinemia | 200 mcg | 13 weeks | 37 |
| Prospective evaluation of folic acid supplementation on plasma homocysteine concentrations during weight reduction: a randomized, double-blinded, placebo-controlled study in obese women 2005 · folic acid supplementation · Obese women, mean age 41 years, participating in a weight-reduction program | 5 mg | 12 weeks | 36 |
| Homocysteine--a treatable risk factor for allograft vascular disease after heart transplantation? 2001 · folic acid · Heart transplant recipients, mean age 55.0 years; 61 of the 69 participants were male | 5 mg | 90 days | 34 |
| Effect of different doses of folic acid on serum homocysteine level in patients on hemodialysis 2011 · 5 mg/d folic acid · Adults on maintenance hemodialysis; mean age 57.6 years; 17 women and 14 men completed all phases | 5 mg | 4 weeks | 31 |
| Effect of different doses of folic acid on serum homocysteine level in patients on hemodialysis 2011 · 10 mg/d folic acid · Adults on maintenance hemodialysis; mean age 57.6 years; 17 women and 14 men completed all phases | 10 mg | 4 weeks | 31 |
| Effect of different doses of folic acid on serum homocysteine level in patients on hemodialysis 2011 · 15 mg/d folic acid · Adults on maintenance hemodialysis; mean age 57.6 years; 17 women and 14 men completed all phases | 15 mg | 4 weeks | 31 |
| [Effects of intervention therapy of methylcobalamin and folic acid on plasma homocysteine concentration and homocysteine thiolactonases/paraoxonase activity in patients with type 2 diabetes mellitus] 2007 · Group II · Patients with type 2 diabetes mellitus | 5 mg | 12 weeks | 30 |
| Effects of plasma homocysteine levels on serum HTase/PON activity in patients with type 2 diabetes 2008 · Group II · Patients with type 2 diabetes; age and sex not specified | 5 mg | 2 weeks | 30 |
| The Effects of Folate Supplementation on Carotid Intima-Media Thickness and Metabolic Status in Patients with Metabolic Syndrome 2016 · group A · Overweight adults aged 40–85 with type 2 diabetes, coronary heart disease, and metabolic syndrome | 5 mg | 12 weeks | 30 |
| Folate supplementation in peritoneal dialysis patients with normal erythrocyte folate: effect on plasma homocysteine 2001 · oral folate · Peritoneal dialysis patients with hyperhomocysteinemia (>15 micromol/l) and normal folate status (erythrocyte folate >600 nmol/l) | 5 mg | 60 days | 29 |
| Metabolic response to folate supplementation in overweight women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial 2014 · Folate-5 · Women aged 18–40 years with obesity and polycystic ovary syndrome | 5 mg | 8 weeks | 27 |
| Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients 2003 · 5 mg per day · Chronic hemodialysis patients | 5 mg | 1 year | 26 |
| Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients 2003 · 15 mg per day · Chronic hemodialysis patients | 15 mg | 1 year | 25 |
| Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration 2003 · fenofibrate in combination with folate · Adults with total cholesterol ≥6 mmol/L and triglycerides <5 mmol/L, normal blood pressure and glucose, and no clinical vascular or metabolic disease; mean age 54.9 years | 10 mg | 90 days | 24 |
| Effect of Folic Acid, Betaine, Vitamin B₆, and Vitamin B12 on Homocysteine and Dimethylglycine Levels in Middle-Aged Men Drinking White Wine 2016 · Folate group · Healthy men aged 37–65 years who were moderate alcohol consumers | 5 mg | 4 weeks | 24 |
| No effect of folic acid on markers of endothelial dysfunction or inflammation in patients with type 2 diabetes mellitus and mild hyperhomocysteinaemia 2004 · folic acid · Patients with type 2 diabetes mellitus and mild hyperhomocysteinaemia (homocysteine ≥14 micromol/L) | 5 mg | 26 weeks | 23 |
| The effects of folate supplementation on inflammatory factors and biomarkers of oxidative stress in overweight and obese women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled clinical trial 2014 · folate-5 · Women aged 18–40 with polycystic ovary syndrome who were overweight or obese | 5 mg | 8 weeks | 23 |
| The effects of high and low doses of folic acid on oxidation of protein levels during pregnancy: a randomized double-blind clinical trial 2017 · Group 1 (5 mg/day folic acid) · Pregnant women, from before pregnancy through the 36th week of pregnancy | 5 mg | — | 23 |
| Homocysteine-lowering therapy and early progression of transplant vasculopathy: a prospective, randomized, IVUS-based study 2005 · 15 mg/day of 5-methyl-tetrahydrofolate · De novo heart transplant recipients | 15 mg | 1 year | 22 |
| Effect of folate supplementation on DNA methylation of rectal mucosa in patients with colonic adenomas: correlation with nutrient intake 1998 · folate supplementation · 20 patients with resected colonic adenomas | 5 mg | — | 20 |
| Administration of B-group vitamins reduces circulating homocysteine in polycystic ovarian syndrome patients treated with metformin: a randomized trial 2005 · group 3 · Women with polycystic ovarian syndrome treated with metformin; age not reported | 348 mcg | 90 days | 20 |
| [Hyperhomocysteinemia and treatment with antiepileptic drugs. Effects of different doses of folic acid] 2005 · 5.2 mg folic acid group · Adults with hyperhomocysteinemia receiving antiepileptic drugs | 5.2 mg | 90 days | 20 |
| The effect of postmenopausal hormone therapy with or without folic acid supplementation on serum homocysteine level 2005 · HT + FA · Healthy postmenopausal women, mean age 52 years | 5 mg | 90 days | 20 |
| Effect of folate supplementation on serum homocysteine and plasma total antioxidant capacity in hypercholesterolemic adults under lovastatin treatment: a double-blind randomized controlled clinical trial 2009 · Group A · Adults with newly diagnosed hypercholesterolemia | 5 mg | 8 weeks | 20 |
| Randomized controlled trial of the effect of short-term coadministration of methylcobalamin and folate on serum ADMA concentration in patients receiving long-term hemodialysis 2010 · folate group · Patients undergoing long-term hemodialysis | 15 mg | 3 weeks | 20 |
| Effect of inositol stereoisomers at different dosages in gestational diabetes: an open-label, parallel, randomized controlled trial 2018 · DCI treatment · Pregnant women with gestational diabetes mellitus | 400 mcg | 8 weeks | 20 |
| The potential adding therapeutic effect of pentoxifylline and/or folic acid for chronic kidney disease patients: randomized controlled trial 2025 · PTX + FA group · Adults aged 18–60 with stable stage 3–5 chronic kidney disease | 500 mcg | 26 weeks | 20 |
| [Hyperhomocysteinemia and treatment with antiepileptic drugs. Effects of different doses of folic acid] 2005 · 0.2 mg folic acid group · Adults with hyperhomocysteinemia receiving antiepileptic drugs | 200 mcg | 90 days | 18 |
| Vitamin B(6) supplementation improves pro-inflammatory responses in patients with rheumatoid arthritis 2010 · control · Patients with rheumatoid arthritis | 5 mg | 12 weeks | 15 |
| A pilot study of folic acid supplementation for improving homocysteine levels, cognitive and depressive status in eating disorders 2013 · supplemented group (SG) · Patients with eating disorders and low folate intake; mean age 24.2 years; sex not specified | 10 mg | 26 weeks | 12 |
| Folic acid mediated attenuation of loss of heterozygosity of DCC tumor suppressor gene in the colonic mucosa of patients with colorectal adenomas 2003 · folic acid group · Patients with colorectal adenomas; age and sex not specified | 5 mg | 1 year | 10 |
| Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome 2008 · Group B · Overweight patients with polycystic ovary syndrome; age and sex details not stated | 200 mcg | 12 weeks | 10 |
| Efficacy of methylcobalamin on lowering total homocysteine plasma concentrations in haemodialysis patients receiving high-dose folic acid supplementation 2002 · group I · Haemodialysis patients with chronic renal failure and hyperhomocysteinaemia | 15 mg | 3 weeks | 7 |
| Effect of folic acid and betaine on fasting and postmethionine-loading plasma homocysteine and methionine levels in chronic haemodialysis patients 1999 · Folic acid 5 mg daily without betaine · Adults with end-stage renal disease receiving maintenance haemodialysis | 5 mg | 12 weeks | — |
| Effect of folic acid and betaine on fasting and postmethionine-loading plasma homocysteine and methionine levels in chronic haemodialysis patients 1999 · Folic acid 5 mg daily (40-week phase) · Adults with end-stage renal disease receiving maintenance haemodialysis | 5 mg | 40 weeks | — |
| Low-dose folic acid supplementation does not influence plasma methionine concentrations in young non-pregnant women 1999 · 500 micrograms folic acid and placebo tablets on alternate days · Young non-pregnant women | 250 mcg | 4 weeks | — |
| Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter study 2000 · 15 mg/d folic acid group · Hemodialysis patients with hyperhomocysteinemia | 15 mg | 4 weeks | — |
| Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter study 2000 · 30 mg/d folic acid group · Hemodialysis patients with hyperhomocysteinemia | 30 mg | 4 weeks | — |
| Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter study 2000 · 60 mg/d folic acid group · Hemodialysis patients with hyperhomocysteinemia | 60 mg | 4 weeks | — |
| A controlled trial of the effect of folate supplements on homocysteine, lipids and hemorheology in end-stage renal disease 2000 · folic acid · Adults receiving hemodialysis or continuous ambulatory peritoneal dialysis with end-stage renal disease | 5 mg | 90 days | — |
| A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) 2000 · vitamins alone group · Patients with primary hypercholesterolaemia; age and sex not reported | 2 mg | 6 weeks | — |
| Effects of folate supplementation on two provisional molecular markers of colon cancer: a prospective, randomized trial 2001 · folate · people with adenomas after polypectomy; age and sex not specified | 5 mg | 1 year | — |
| Randomized trial of folic acid supplementation and serum homocysteine levels 2001 · 0.2 mg/d folic acid · Patients with ischemic heart disease; age and sex not specified | 200 mcg | 90 days | — |
| Concomitant supplemental vitamin A enhances the response to weekly supplemental iron and folic acid in anemic teenagers in urban Bangladesh 2001 · iron + folic acid · Teenage women in urban Bangladesh with hemoglobin concentrations of 80–120 g/L | 500 mcg | 12 weeks | — |
| Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy 2001 · fenofibrate plus folic acid · Patients with mixed hyperlipidemia | 5 mg | 9 weeks | — |
| The effect of folic acid supplementation on plasma homocysteine in an elderly population 2002 · 50 microg folic acid group · Adults aged 65–75 years | 50 mcg | 6 weeks | — |
| The effect of folic acid supplementation on plasma homocysteine in an elderly population 2002 · 100 microg folic acid group · Adults aged 65–75 years | 100 mcg | 6 weeks | — |
| The effect of folic acid supplementation on plasma homocysteine in an elderly population 2002 · 200 microg folic acid group · Adults aged 65–75 years | 200 mcg | 6 weeks | — |
| Randomized trial of methylcobalamin and folate effects on homocysteine in hemodialysis patients 2002 · Group B · Chronic hemodialysis patients without previous vitamin supplementation | 10 mg | 120 days | — |
| Low-dose folic acid lowers plasma homocysteine levels in women of child-bearing age 2002 · 100 microg/day folic acid group · Premenopausal women of child-bearing age | 100 mcg | 10 weeks | — |
| Low-dose folic acid lowers plasma homocysteine levels in women of child-bearing age 2002 · 200 microg/day folic acid group · Premenopausal women of child-bearing age | 200 mcg | 10 weeks | — |
| Dose-dependent effects of folic acid on plasma homocysteine in a randomized trial conducted among 723 individuals with coronary heart disease 2002 · 0.2 mg folic acid · People with a history of myocardial infarction or unstable angina | 200 mcg | — | — |
| Comparison of the effect of low-dose supplementation with L-5-methyltetrahydrofolate or folic acid on plasma homocysteine: a randomized placebo-controlled study 2003 · Folic acid group · Healthy volunteers; age and sex not specified | 100 mcg | 24 weeks | — |
| Folic acid and reduction of plasma homocysteine concentrations in older adults: a dose-response study 2003 · 50 micro g folic acid · Healthy men and women aged 50–75 years | 50 mcg | 12 weeks | — |
| Folic acid and reduction of plasma homocysteine concentrations in older adults: a dose-response study 2003 · 100 micro g folic acid · Healthy men and women aged 50–75 years | 100 mcg | 12 weeks | — |
| Folic acid and reduction of plasma homocysteine concentrations in older adults: a dose-response study 2003 · 200 micro g folic acid · Healthy men and women aged 50–75 years | 200 mcg | 12 weeks | — |
| Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease 2003 · Orally with 5 mg folic acid · Patients with stable Crohn's disease; age and sex not stated | 5 mg | 7 days | — |
| Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine 2003 · F+F group · Patients with combined hyperlipidemia; age and sex not specified | 5 mg | 9 weeks | — |
| Effects of folic acid supplementation on inflammatory and thrombogenic markers in chronic smokers. A randomised controlled trial 2003 · folic acid · Healthy chronic cigarette smokers; mean age 37.8 years; sex not specified | 5 mg | 4 weeks | — |
| Folic acid supplement decreases the homocysteine increasing effect of filtered coffee. A randomised placebo-controlled study 2003 · folic acid group · Healthy, nonsmoking men and women aged 29–65 years | 200 mcg | 4 weeks | — |
| The methylenetetrahydrofolate reductase C677T polymorphism is a major determinant of coffee-induced increase of plasma homocysteine: a randomized placebo controlled study 2004 · 200 microg folic acid group · Healthy, non-smoking men and women aged 29–65 years | 200 mcg | 4 weeks | — |
| Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke: a randomized substudy of the VITATOPS trial 2005 · vitamin therapy · Patients with recent transient ischemic attack or stroke; age and sex not reported | 2 mg | 26 weeks | — |
| Sustained homocysteine-lowering effect over time of folic acid-based multivitamin therapy in stroke patients despite increasing folate status in the population 2005 · active VITATOPS medication · Patients with stroke or transient ischemic attack | 2 mg | 26 weeks | — |
| L-folic acid supplementation in healthy postmenopausal women: effect on homocysteine and glycolipid metabolism 2005 · L-folic acid · Healthy, normoinsulinemic postmenopausal women | 7.5 mg | 8 weeks | — |
| Decrease of carotid intima-media thickness in patients at risk to cerebral ischemia after supplementation with folic acid, Vitamins B6 and B12 2005 · treatment group · Adults aged 60 ± 8 years with carotid intima-media thickness ≥1 mm and at risk of cerebral ischemia | 2.5 mg | 1 year | — |
| Randomized controlled trial of homocysteine-lowering vitamin treatment in elderly patients with vascular disease 2005 · folic acid plus vitamin B-12 · Adults aged 65 years or older with ischemic vascular disease | 2.5 mg | 1 year | — |
| Folate co-administration improves the effectiveness of fenofibrate to decrease the lipoprotein oxidation and endothelial dysfunction surrogates 2006 · Fenofibrate combined with folate · Subjects with hypercholesterolemia; age and sex not reported | 10 mg | — | — |
| No effect of B vitamins on ADMA levels in patients at increased cardiovascular risk 2006 · Study II: folic acid · Patients with type 2 diabetes and mild hyperhomocysteinaemia; ages and sex not stated | 5 mg | 26 weeks | — |
| Milk folate secretion is not impaired during iron deficiency in humans 2006 · multivitamin with iron · Breast-feeding mothers; age not reported | 400 mcg | — | — |
| Effect of short-term folate and vitamin B supplementation on blood homocysteine level and carotid artery wall thickness in chronic hemodialysis patients 2006 · Control group · Chronic hemodialysis patients with hyperhomocysteinemia; age and sex not specified | 5 mg | 26 weeks | — |
| Effect of folate supplementation on N-terminal pro-brain natriuretic peptide 2007 · 5.0 mg FA daily · Healthy adults, median age 57 years | 5 mg | 8 weeks | — |
| High- but not low-dose folic acid improves endothelial function in coronary artery disease 2006 · 5 mg folic acid group · Patients with coronary artery disease; age and sex not reported | 5 mg | 6 weeks | — |
| Folic acid does not improve endothelial function in obese children and adolescents 2007 · folic acid group · Obese children and adolescents; mean age 13.3 years; no diabetes | 5 mg | 8 weeks | — |
| Effects of folic acid and N-acetylcysteine on plasma homocysteine levels and endothelial function in patients with coronary artery disease 2007 · folic acid · Patients with hyperhomocysteinaemia and coronary artery disease; age and sex not reported | 5 mg | 8 weeks | — |
| Comparison study on the effect of prenatal administration of high dose and low dose folic acid 2009 · group one (high dose) · nulliparous pregnant women | 5 mg | — | — |
| Effect of long-term homocysteine reduction with B vitamins on arterial wall inflammation assessed by fluorodeoxyglucose positron emission tomography: a randomised double-blind, placebo-controlled trial 2009 · B-vitamin therapy · Adults with a history of ischemic stroke | 2 mg | 1461 days | — |
| Role of folic acid in atherosclerosis after kidney transplant: a double-blind, randomized, placebo-controlled clinical trial 2009 · folic acid group · Kidney transplant recipients; age and sex range not specified | 5 mg | 26 weeks | — |
| Efficacy of folate and vitamin B12 in lowering homocysteine concentrations in hemodialysis patients 2009 · group I (only folic acid) · Hemodialysis patients; age and sex not reported | 5 mg | 8 weeks | — |
| Efficacy of folate and vitamin B12 in lowering homocysteine concentrations in hemodialysis patients 2009 · group III (only folic acid) · Hemodialysis patients; age and sex not reported | 15 mg | 8 weeks | — |
| Effect of physiological doses of oral vitamin B12 on plasma homocysteine: a randomized, placebo-controlled, double-blind trial in India 2010 · B0 F200 (no vitamin B12, 200 μg folic acid) · Children and adults from rural families in India; participants included children (mean age 9 years), mothers and fathers | 200 mcg | 1 year | — |
| Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial 2010 · B-vitamin group · People with type 1 or type 2 diabetes and a clinical diagnosis of diabetic nephropathy | 2.5 mg | 3 years | — |
| A comparison of iron and folate with folate alone in hematologic recovery of children treated for acute malaria 2010 · folate alone group · Children aged 6–60 months with smear-positive malaria and anemia (hematocrit <33%) | 5 mg | 4 weeks | — |
| A dose-finding trial of the effect of long-term folic acid intervention: implications for food fortification policy 2011 · 0.2 mg/d folic acid · Patients with ischemic heart disease and healthy volunteers; ages and sex not specified | 200 mcg | 26 weeks | — |
| Effect of folic acid supplementation on homocysteine, serum total antioxidant capacity, and malondialdehyde in patients with type 2 diabetes mellitus 2011 · folic acid group · men with type 2 diabetes | 5 mg | 8 weeks | — |
| Effects of prenatal micronutrient and early food supplementation on maternal hemoglobin, birth weight, and infant mortality among children in Bangladesh: the MINIMat randomized trial 2012 · 30 mg iron and 400 μg folic acid; early food invitation · Pregnant women in poor communities in Bangladesh | 400 mcg | — | — |
| Effects of prenatal micronutrient and early food supplementation on maternal hemoglobin, birth weight, and infant mortality among children in Bangladesh: the MINIMat randomized trial 2012 · 30 mg iron and 400 μg folic acid; usual food invitation · Pregnant women in poor communities in Bangladesh | 400 mcg | — | — |
| Effects of prenatal micronutrient and early food supplementation on maternal hemoglobin, birth weight, and infant mortality among children in Bangladesh: the MINIMat randomized trial 2012 · MMS containing 15 micronutrients, including 30 mg iron and 400 μg folic acid; early food invitation · Pregnant women in poor communities in Bangladesh | 400 mcg | — | — |
| Effects of prenatal micronutrient and early food supplementation on maternal hemoglobin, birth weight, and infant mortality among children in Bangladesh: the MINIMat randomized trial 2012 · MMS containing 15 micronutrients, including 30 mg iron and 400 μg folic acid; usual food invitation · Pregnant women in poor communities in Bangladesh | 400 mcg | — | — |
| The C677T MTHFR genotypes influence the efficacy of B9 and B12 vitamins supplementation to lowering plasma total homocysteine in hemodialysis 2016 · Group A, t1: folic acid (B9) · Hemodialysis patients with C677T MTHFR genotypes | 10 mg | 60 days | — |
| The C677T MTHFR genotypes influence the efficacy of B9 and B12 vitamins supplementation to lowering plasma total homocysteine in hemodialysis 2016 · Group B, t2: folic acid (B9) · Hemodialysis patients with C677T MTHFR genotypes | 10 mg | 60 days | — |
| Comparative Study of the Effects of Tamoxifen Citrate and Folate on Semen Quality of the Infertile Male with Semen Abnormality 2015 · Folate · Infertile men with semen abnormalities | 5 mg | 90 days | — |
| Acceptability and Utilization of Three Nutritional Supplements during Pregnancy: Findings from a Longitudinal, Mixed-Methods Study in Niger 2018 · MMN group · Pregnant women enrolled before 30 weeks’ gestation in rural Niger | 400 mcg | 26 weeks | — |
| The Inclusion of Folic Acid in Weekly Iron-Folic Acid Supplements Confers no Additional Benefit on Anemia Reduction in Nonpregnant Women: A Randomized Controlled Trial in Malaysia 2021 · 60 mg Fe with 2.8 mg folic acid · Nonpregnant women aged 18–45 years in Malaysia | 400 mcg | 16 weeks | — |
| Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid 1995 · 10 mg folic acid group · Patients with acute myocardial infarction; age and sex not reported | 10 mg | 6 weeks | — |
| No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients 1998 · 5 mg folic acid (phase 1) · Haemodialysis patients with hyperhomocysteinaemia; age and sex not reported | 5 mg | 12 weeks | — |
| No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients 1998 · 5 mg folic acid (phase 2) · Haemodialysis patients with hyperhomocysteinaemia; age and sex not reported | 5 mg | 40 weeks | — |
| No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients 1998 · 15 mg folic acid (phase 3; all patients) · Haemodialysis patients with hyperhomocysteinaemia; age and sex not reported | 15 mg | 4 weeks | — |
| Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers 1998 · 5 mg folic acid · Healthy volunteers without hyperhomocysteinemia | 5 mg | — | — |
| Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: no change in endothelial function after long-term therapy 1998 · 5 mg folic acid alone daily · Peritoneal dialysis patients with hyperhomocysteinemia | 5 mg | 12 weeks | — |
| Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: no change in endothelial function after long-term therapy 1998 · 5 mg folic acid daily · Peritoneal dialysis patients with hyperhomocysteinemia | 5 mg | 40 weeks | — |
| Plasma homocyst(e)ine concentrations in pregnant and nonpregnant women with controlled folate intake 1998 · 450 microg/day folate intake · Women in the second trimester of pregnancy and young, healthy nonpregnant women | 330 mcg | 12 weeks | — |
| Effects of an Iodine-Containing Prenatal Multiple Micronutrient on Maternal and Infant Iodine Status and Thyroid Function: A Randomized Trial in The Gambia 2020 · FeFol · Pregnant women aged 18–45 years in rural West Kiang, The Gambia, with moderate iodine deficiency | 400 mcg | — | 219 |
| A Prenatal Multiple Micronutrient Supplement Produces Higher Maternal Vitamin B-12 Concentrations and Similar Folate, Ferritin, and Zinc Concentrations as the Standard 60-mg Iron Plus 400-μg Folic Acid Supplement in Rural Bangladeshi Women 2016 · Fe60F · Pregnant women in rural Bangladesh enrolled before 14 weeks of pregnancy | 400 mcg | 114 days | 216 |
| Impact of nutritional supplementation during pregnancy on antibody responses to diphtheria-tetanus-pertussis vaccination in infants: A randomised trial in The Gambia 2019 · MMN · Pregnant women aged 18–45 years, enrolled before 20 weeks’ gestation in rural Gambia | 400 mcg | 186 days | 179 |
| Impact of nutritional supplementation during pregnancy on antibody responses to diphtheria-tetanus-pertussis vaccination in infants: A randomised trial in The Gambia 2019 · FeFol · Pregnant women aged 18–45 years, enrolled before 20 weeks’ gestation in rural Gambia | 400 mcg | 186 days | 178 |
| A community-based randomized controlled trial providing weekly iron-folic acid supplementation increased serum- ferritin, -folate and hemoglobin concentration of adolescent girls in southern Ethiopia 2021 · WIFAS · Apparently healthy adolescent girls aged 10–19 years in southern Ethiopia | 57.1 mcg | 90 days | 113 |
| Weekly iron-folic acid supplements containing 2.8 mg folic acid are associated with a lower risk of neural tube defects than the current practice of 0.4 mg: a randomised controlled trial in Malaysia 2020 · 0.4 mg folic acid group · Women aged 18–45 years, predominantly 18–21, non-pregnant and not planning pregnancy | 57.1 mcg | 16 weeks | 110 |
| Small-Quantity Lipid-Based Nutrient Supplements Do Not Affect Plasma or Milk Retinol Concentrations Among Malawian Mothers, or Plasma Retinol Concentrations among Young Malawian or Ghanaian Children in Two Randomized Trials 2021 · IFA (Malawi mothers) · Women aged over 15 years, pregnant at enrollment (≤20 weeks), in Malawi | 400 mcg | — | 105 |
| Consumption of multiple micronutrients or small-quantity lipid-based nutrient supplements containing iodine at the recommended dose during pregnancy, compared with iron and folic acid, does not affect women's urinary iodine concentration in rural Malawi: a secondary outcome analysis of the iLiNS DYAD trial 2021 · iron–folic acid group (IFA) · Pregnant women enrolled at no more than 20 completed weeks of pregnancy in rural Malawi | 400 mcg | — | 104 |
| Serum Concentrations of Folate Forms Following Supplementation of Multimicronutrients with 400 µg or 800 µg Mix of (6S)-5-Methyltetrahydrofolate and Folic Acid (1:1) in Women of Childbearing Age 2024 · 800 µg group · Nonpregnant women aged 18–45 years in good physical and mental health | 400 mcg | 8 weeks | 101 |
| Serum Concentrations of Folate Forms Following Supplementation of Multimicronutrients with 400 µg or 800 µg Mix of (6S)-5-Methyltetrahydrofolate and Folic Acid (1:1) in Women of Childbearing Age 2024 · 400 µg group · Nonpregnant women aged 18–45 years in good physical and mental health | 200 mcg | 8 weeks | 100 |
| Myo-inositol nutritional supplement for prevention of gestational diabetes (EMmY): a randomised, placebo-controlled, double-blind pilot trial with nested qualitative study 2022 · intervention (myo-inositol) · Pregnant women aged at least 16 years with a singleton pregnancy at 12+0 to 15+6 weeks’ gestation and high risk of gestational diabetes | 400 mcg | — | 99 |
| Supplementation during pregnancy with small-quantity lipid-based nutrient supplements or multiple micronutrients, compared with iron and folic acid, increases women's urinary iodine concentration in semiurban Ghana: A randomized controlled trial 2018 · IFA group · Pregnant women aged 18 years or older, enrolled at 20 weeks of gestation or earlier, in semiurban Ghana | 400 mcg | — | 94 |
| Maternal multiple micronutrient supplementation in rural Pakistan increased some milk micronutrient concentrations, but not infant growth, at three-months postpartum: a randomized controlled trial substudy 2025 · Standard of care · Adolescent and young mothers aged 15–23 years in rural Pakistan; mothers in the substudy were breastfeeding infants aged about 3 months | 400 mcg | — | 89 |
| Weekly vitamin A and iron supplementation during pregnancy increases vitamin A concentration of breast milk but not iron status in Indonesian lactating women 2001 · weekly iron and folic acid group · Pregnant Indonesian women; age and specific health conditions not stated | 71.4 mcg | — | 88 |
| Weekly vitamin A and iron supplementation during pregnancy increases vitamin A concentration of breast milk but not iron status in Indonesian lactating women 2001 · weekly vitamin A, iron, and folic acid group · Pregnant Indonesian women; age and specific health conditions not stated | 71.4 mcg | — | 82 |
| mRNA Levels of Placental Iron and Zinc Transporter Genes Are Upregulated in Gambian Women with Low Iron and Zinc Status 2017 · FeFol group · Pregnant women aged 18–45 years with singleton pregnancies under 20 weeks in rural Gambia | 400 mcg | 184 days | 75 |
| Bread cofortified with folic acid and vitamin B-12 improves the folate and vitamin B-12 status of healthy older people: a randomized controlled trial 2008 · bread fortified with folic acid and vitamin B-12 · Men and women aged 50–75 years described as healthy older people | 138 mcg | 12 weeks | 72 |
| Effect of iron supplementation on serum zinc status of lactating women in Addis Ababa, Ethiopia 2005 · daily iron-supplemented group · Anaemic lactating women in urban slum communities of Addis Ababa | 400 mcg | 90 days | 71 |
| Effect of iron supplementation on serum zinc status of lactating women in Addis Ababa, Ethiopia 2005 · weekly iron-supplemented group · Anaemic lactating women in urban slum communities of Addis Ababa | 57.1 mcg | 90 days | 71 |
| Double-blind, placebo-controlled trial comparing effects of supplementation of two micronutrient sprinkles on fatty acid status in Cambodian infants 2007 · iron/folate · Cambodian infants aged 6 months at enrolment | 150 mcg | 1 year | 68 |
| Maternal serum unmetabolized folic acid concentration following multivitamin and mineral supplementation with or without folic acid after 12 weeks gestation: A randomized controlled trial 2024 · Control 800 µg FA/day · Pregnant women with singleton pregnancies, enrolled at 12–16 weeks’ gestation and intending to continue a folic-acid-containing supplement; maternal age averaged 31 years | 800 mcg | — | 52 |
| A pilot randomised controlled trial to reduce colorectal cancer risk markers associated with B-vitamin deficiency, insulin resistance and colonic inflammation 2005 · treatment arm · Adults aged 44–80 with previously resected colonic adenomatous polyps or intramucosal carcinoma | 3 mg | 4 weeks | 50 |
| Ascorbate is depleted by smoking and repleted by moderate supplementation: a study in male smokers and nonsmokers with matched dietary antioxidant intakes 2000 · nonsmokers receiving vitamin cocktail · Male nonsmokers selected for low fruit and vegetable intake | 400 mcg | 90 days | 38 |
| Ascorbate is depleted by smoking and repleted by moderate supplementation: a study in male smokers and nonsmokers with matched dietary antioxidant intakes 2000 · smokers receiving vitamin cocktail · Male smokers selected for low fruit and vegetable intake | 400 mcg | 90 days | 37 |
| Folic acid causes higher prevalence of detectable unmetabolized folic acid in serum than B-complex: a randomized trial 2016 · B-complex · Elderly people | 400 mcg | 23 days | 27 |
| Distribution of plasma folate forms in hemodialysis patients receiving high daily doses of L-folinic or folic acid 2002 · Folic acid group · Adults with chronic stable hemodialysis and hyperhomocysteinemia | 15 mg | 12 weeks | 24 |
| Folic acid enrichment of bread does not appear to affect zinc absorption in young women 2001 · A · Healthy women aged 22–33 years | 17 mcg | 1 day | 15 |
| Folic acid enrichment of bread does not appear to affect zinc absorption in young women 2001 · B · Healthy women aged 22–33 years | 144 mcg | 1 day | 15 |
| Folic acid enrichment of bread does not appear to affect zinc absorption in young women 2001 · D · Healthy women aged 22–33 years | 144 mcg | 1 day | 15 |
| Adding zinc to prenatal iron and folate supplements improves maternal and neonatal zinc status in a Peruvian population 1999 · Prenatal supplements with zinc · Pregnant women in a shantytown in Lima, Peru, beginning supplementation between gestation weeks 10 and 24 | 250 mcg | — | — |
| Adding zinc to prenatal iron and folate supplements improves maternal and neonatal zinc status in a Peruvian population 1999 · Prenatal supplements without zinc · Pregnant women in a shantytown in Lima, Peru, beginning supplementation between gestation weeks 10 and 24 | 250 mcg | — | — |
| Changes in iron status during pregnancy in peruvian women receiving prenatal iron and folic acid supplements with or without zinc 2000 · Iron and folic acid · Pregnant women in Peru, from 10–24 weeks gestation to 4 weeks postpartum | 250 mcg | — | — |
| Changes in iron status during pregnancy in peruvian women receiving prenatal iron and folic acid supplements with or without zinc 2000 · Iron, folic acid, and zinc · Pregnant women in Peru, from 10–24 weeks gestation to 4 weeks postpartum | 250 mcg | — | — |
| Effect of folic acid and vitamin C supplementation on folate status and homocysteine level: a randomised controlled trial in Italian smoker-blood donors 2002 · C: folic acid plus vitamin C · Italian repeat blood donors who smoked more than 15 cigarettes per day; age and sex not specified | 5 mg | 45 days | — |
| Holo-transcobalamin is an early marker of changes in cobalamin homeostasis. A randomized placebo-controlled study 2002 · Vitamin B(12), folic acid, and vitamin B(6) · Patients aged 38–80 years undergoing coronary angiography | 800 mcg | 12 weeks | — |
| Holo-transcobalamin is an early marker of changes in cobalamin homeostasis. A randomized placebo-controlled study 2002 · Vitamin B(12) and folic acid · Patients aged 38–80 years undergoing coronary angiography | 800 mcg | 12 weeks | — |
| Plasma vitamin B6 vitamers before and after oral vitamin B6 treatment: a randomized placebo-controlled study 2003 · Group A · Patients aged 38–80 years undergoing coronary angiography | 800 mcg | 12 weeks | — |
| Zinc plus beta-carotene supplementation of pregnant women is superior to beta-carotene supplementation alone in improving vitamin A status in both mothers and infants 2004 · beta-carotene · Pregnant women; age and specific condition not stated | 400 mcg | — | — |
| Bioavailability of food folates is 80% of that of folic acid 2007 · Group B · Healthy adults; age and sex not reported | 150 mcg | 4 weeks | — |
| Bioavailability of food folates is 80% of that of folic acid 2007 · Group C · Healthy adults; age and sex not reported | 249 mcg | 4 weeks | — |
| Bioavailability of food folates is 80% of that of folic acid 2007 · Group D · Healthy adults; age and sex not reported | 347 mcg | 4 weeks | — |
| Effects of fish-oil and folate supplementation of pregnant women on maternal and fetal plasma concentrations of docosahexaenoic acid and eicosapentaenoic acid: a European randomized multicenter trial 2007 · FO with MTHF · Pregnant women from gestation week 22 until delivery | 400 mcg | — | — |
| A randomised double-blind study comparing sodium feredetate with ferrous fumarate in anaemia in pregnancy 2007 · Group A · Pregnant women at 12–26 weeks’ gestation with iron-deficiency anaemia | 3 mg | 75 days | — |
| A randomised double-blind study comparing sodium feredetate with ferrous fumarate in anaemia in pregnancy 2007 · Group B · Pregnant women at 12–26 weeks’ gestation with iron-deficiency anaemia | 3 mg | 75 days | — |
| A randomised double-blind study comparing sodium feredetate with ferrous fumarate in anaemia in pregnancy 2007 · Group C · Pregnant women at 12–26 weeks’ gestation with iron-deficiency anaemia | 3 mg | 75 days | — |
| Influence of green and black tea on folic acid pharmacokinetics in healthy volunteers: potential risk of diminished folic acid bioavailability 2008 · 5 mg folic acid with green tea · Healthy volunteers; age and sex not specified | 5 mg | 1 day | — |
| Supplementation with a multivitamin containing 800 microg of folic acid shortens the time to reach the preventive red blood cell folate concentration in healthy women 2009 · verum group · Healthy females; age not reported | 800 mcg | 16 weeks | — |
| Concentrations of unmetabolized folic acid and primary folate forms in plasma after folic acid treatment in older adults 2011 · folic acid treatment group · Older adults, median age 82 years; sex and health condition not specified | 5 mg | 3 weeks | — |
| Vitamin B12 supplementation during pregnancy and postpartum improves B12 status of both mothers and infants but vaccine response in mothers only: a randomized clinical trial in Bangladesh 2016 · B12 supplementation · Bangladeshi pregnant women aged 18–35 years, 11–14 weeks pregnant, with hemoglobin <110 g/L | 400 mcg | — | — |
| Effects of a lipid-based nutrient supplement during pregnancy and lactation on maternal plasma fatty acid status and lipid profile: Results of two randomized controlled trials 2017 · iron and folic acid (IFA) · Pregnant women in Ghana and Malawi; Ghana participants were at least 18 years old, and Malawi participants were at least 15 years old | 400 mcg | — | — |
| Effect of Nutritional Interventions on Micronutrient Status in Pregnant Malawian Women with Moderate Malnutrition: A Randomized, Controlled Trial 2018 · CSB+IFA · Pregnant Malawian women aged 16–38 with moderate malnutrition | 400 mcg | 10 weeks | — |
| Multi-Micronutrient Fortified Rice Improved Serum Zinc and Folate Concentrations of Cambodian School Children. A Double-Blinded Cluster-Randomized Controlled Trial 2019 · NutriRice · Cambodian schoolchildren, approximately 4–12 years old, including children with zinc deficiency | 160 mcg | 26 weeks | — |
| Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease 1998 · Cereal providing 127 microg of folic acid daily · Men and women with coronary artery disease | 127 mcg | — | — |
| One year B-vitamins increases serum and whole blood folate forms and lowers plasma homocysteine in older Germans 2015 · B-vitamin supplementation · Older German adults, mean age 67 years | 500 mcg | 1 year | — |
| Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS 2014 · D-chiro-inositol group · Women with PCOS and menstrual irregularities | 400 mcg | 26 weeks | 25 |
| Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study 2013 · Group B · Overweight patients with polycystic ovary syndrome; age and sex not specified | 200 mg | 12 weeks | 10 |
| Effectiveness of routine antihelminthic treatment on anaemia in pregnancy in Rufiji District, Tanzania: a cluster randomised controlled trial 2011 · control arm · Pregnant women attending antenatal care in Rufiji District, Tanzania | 5 mg | — | 1,605 |
| Effectiveness of routine antihelminthic treatment on anaemia in pregnancy in Rufiji District, Tanzania: a cluster randomised controlled trial 2011 · study arm · Pregnant women attending antenatal care in Rufiji District, Tanzania | 5 mg | — | 1,475 |
| Effectiveness of weekly vitamin A (10,000 IU) and iron (60 mg) supplementation for adolescent boys and girls through schools in rural and urban East Java, Indonesia 2004 · Fe group · Adolescent boys and girls aged 12–15 years attending junior high schools in rural and urban East Java, Indonesia | 35.7 mcg | 14 weeks | 978 |
| Maternal B-vitamin and vitamin D status before, during, and after pregnancy and the influence of supplementation preconception and during pregnancy: Prespecified secondary analysis of the NiPPeR double-blind randomized controlled trial 2023 · intervention · Women planning pregnancy; generally healthy, recruited before conception | 400 mcg | — | 870 |
| Maternal B-vitamin and vitamin D status before, during, and after pregnancy and the influence of supplementation preconception and during pregnancy: Prespecified secondary analysis of the NiPPeR double-blind randomized controlled trial 2023 · control · Women planning pregnancy; generally healthy, recruited before conception | 400 mcg | — | 859 |
| Antenatal Multiple Micronutrient Supplementation Compared to Iron-Folic Acid Affects Micronutrient Status but Does Not Eliminate Deficiencies in a Randomized Controlled Trial Among Pregnant Women of Rural Bangladesh 2019 · MM · Pregnant women aged 12–45 years in rural Bangladesh | 600 mcg | 165 days | 749 |
| The impact of zinc and folic acid supplementation on sperm DNA methylation: results from the folic acid and zinc supplementation randomized clinical trial (FAZST) 2022 · FAZ group · Men aged 18 or older in couples seeking fertility treatment | 5 mg | 26 weeks | 713 |
| Effects of lipid-based nutrient supplements or multiple micronutrient supplements compared with iron and folic acid supplements during pregnancy on maternal haemoglobin and iron status 2018 · IFA group · Pregnant Malawian women aged over 15 years, enrolled at up to 20 gestational weeks | 400 mcg | — | 460 |
| Maternal cortisol and stress are associated with birth outcomes, but are not affected by lipid-based nutrient supplements during pregnancy: an analysis of data from a randomized controlled trial in rural Malawi 2015 · IFA · Pregnant women aged 15–49 years in rural Malawi, enrolled at up to 20 weeks of gestation | 400 mcg | — | 413 |
| Impact of small-quantity lipid-based nutrient supplement on hemoglobin, iron status and biomarkers of inflammation in pregnant Ghanaian women 2017 · IFA · Pregnant women in a semi-urban setting in Ghana | 400 mcg | — | 349 |
| Provision of Lipid-Based Nutrient Supplements to Mothers During Pregnancy and 6 Months Postpartum and to Their Infants from 6 to 18 Months Promotes Infant Gut Microbiota Diversity at 18 Months of Age but Not Microbiota Maturation in a Rural Malawian Setting: Secondary Outcomes of a Randomized Trial 2020 · IFA group · Pregnant women aged 15 years or older, enrolled at 20 or more weeks of gestation; mothers and infants in the IFA group, with no direct infant supplementation | 400 mcg | 548 days | 290 |
| The effectiveness of weekly iron supplementation in pregnant women of rural northern Malawi 2000 · daily iron/folate group · Pregnant women living in rural Malawi | 250 mcg | 10 weeks | 211 |
| The Effect of High Dose Folic Acid throughout Pregnancy on Homocysteine (Hcy) Concentration and Pre-Eclampsia: A Randomized Clinical Trial 2016 · Group 2 (High dose) · Healthy nulliparous pregnant women aged 20–30 years with singleton pregnancies | 5 mg | — | 210 |
| The effectiveness of weekly iron supplementation in pregnant women of rural northern Malawi 2000 · weekly iron/folate group · Pregnant women living in rural Malawi | 71.4 mcg | 10 weeks | 202 |
| Prenatal nutrition supplementation and growth biomarkers in preadolescent Bangladeshi children: A birth cohort study 2022 · Fe60F · Pregnant women in rural Bangladesh; age and sex beyond pregnancy not specified | 400 mcg | — | 184 |
| Daily Folic Acid and/or Vitamin B12 Supplementation Between 6 and 30 Months of Age and Cardiometabolic Risk Markers After 6-7 Years: A Follow-Up of a Randomized Controlled Trial 2023 · Vitamin B12 and folic acid · Children aged 6–30 months at enrollment | 150 mcg | 180 days | 184 |
| Impact of nutritional supplementation during pregnancy on antibody responses to diphtheria-tetanus-pertussis vaccination in infants: A randomised trial in The Gambia 2019 · PE + MMN · Pregnant women aged 18–45 years, enrolled before 20 weeks’ gestation in rural Gambia | 400 mcg | 186 days | 182 |
| Newborn micronutrient status biomarkers in a cluster-randomized trial of antenatal multiple micronutrient compared with iron folic acid supplementation in rural Bangladesh 2020 · MM · Pregnant women in rural Bangladesh; age range not specified; no disease condition specified | 600 mcg | — | 176 |
| Impact of nutritional supplementation during pregnancy on antibody responses to diphtheria-tetanus-pertussis vaccination in infants: A randomised trial in The Gambia 2019 · PE · Pregnant women aged 18–45 years, enrolled before 20 weeks’ gestation in rural Gambia | 400 mcg | 186 days | 170 |
| A prospective, partially randomized study of pregnancy outcomes and hematologic responses to oral and intramuscular iron treatment in moderately anemic pregnant women 2004 · Daily oral iron group · Pregnant women with moderate anemia | 500 mcg | — | 148 |
| Impact of anaemia prophylaxis in pregnancy on maternal haemoglobin, serum ferritin & birth weight 1991 · study group · Pregnant women at 16–24 weeks of gestation | 500 mcg | 100 days | 137 |
| Daily supplementation of a multiple micronutrient powder improves folate but not thiamine, riboflavin, or vitamin B(12) status among young Laotian children: a randomized controlled trial 2022 · micronutrient powder group (MNP) · Children aged 6–23 months in rural Lao PDR; no disease-based selection, with high prevalence of undernutrition and micronutrient deficiencies | 150 mcg | 36 weeks | 130 |
| Lowering plasma homocysteine concentrations of older men and women with folate, vitamin B-12, and vitamin B-6 does not affect the proportion of (n-3) long chain polyunsaturated fatty acids in plasma phosphatidylcholine 2008 · vitamin group · Men and women aged 65 years or older with plasma homocysteine concentrations of at least 13 micromol/L | 1 mg | 2 years | 127 |
| The effect of Lactiplantibacillus plantarum 299v together with a low dose of iron on iron status in healthy pregnant women: A randomized clinical trial 2021 · Lp group · Healthy, non-anemic pregnant women aged 18–42 years, with singleton pregnancies and iron-replete status at enrollment | 60 mcg | — | 120 |
| Influence of folic acid and vitamin B12 supplementation on arsenic methylation: A double-blinded, placebo-controlled trial in Bangladeshi children 2024 · FA + B12 supplementation group · Children aged 8–11 years in Bangladesh exposed to drinking-water arsenic above 50 μg/L | 400 mcg | 12 weeks | 118 |
| Relative efficacy of weekly and two differing doses of daily iron-folate supplementation in improving hemoglobin in mild and moderately anemic children between 3 and 5 years of age: a cluster randomized trial 2013 · Daily dose doubled (B) · Children aged 3–5 years with mild or moderate anemia (hemoglobin 7–10 g/dL) | 200 mcg | 100 days | 114 |
| Relative efficacy of weekly and two differing doses of daily iron-folate supplementation in improving hemoglobin in mild and moderately anemic children between 3 and 5 years of age: a cluster randomized trial 2013 · NNACP daily dose (A) · Children aged 3–5 years with mild or moderate anemia (hemoglobin 7–10 g/dL) | 100 mcg | 100 days | 112 |
| Relative efficacy of weekly and two differing doses of daily iron-folate supplementation in improving hemoglobin in mild and moderately anemic children between 3 and 5 years of age: a cluster randomized trial 2013 · Weekly dose (C) · Children aged 3–5 years with mild or moderate anemia (hemoglobin 7–10 g/dL) | 28.6 mcg | 100 days | 110 |
| Multiple micronutrient supplementation improves vitamin B₁₂ and folate concentrations of HIV infected children in Uganda: a randomized controlled trial 2011 · Multiple micronutrient supplementation (MMS) · HIV-infected children aged 1–5 years | 40 mcg | 26 weeks | 104 |
| Betaine and choline status modify the effects of folic acid and creatine supplementation on arsenic methylation in a randomized controlled trial of Bangladeshi adults 2021 · creatine+400FA · Adults aged 24–55 in Bangladesh exposed to arsenic through household drinking water | 400 mcg | 12 weeks | 104 |
| Effect of oral zinc supplementation on copper and haemoglobin levels in pregnant women 1994 · Gp B (zinc treated group) · Pregnant women in different trimesters of pregnancy | 10 mg | — | 104 |
| Folic Acid and Creatine as Therapeutic Approaches to Lower Blood Arsenic: A Randomized Controlled Trial 2015 · Creatine plus FA400, first phase · Adults aged 20–65 in Bangladesh selected for drinking from a well with arsenic above 50 μg/L; both folate-deficient and folate-sufficient participants | 400 mcg | 12 weeks | 103 |
| Low-Dose Creatine Supplementation Lowers Plasma Guanidinoacetate, but Not Plasma Homocysteine, in a Double-Blind, Randomized, Placebo-Controlled Trial 2015 · Cr+FA group · Bangladeshi adults | 400 mcg | 12 weeks | 103 |
| The Folic Acid and Creatine Trial: Treatment Effects of Supplementation on Arsenic Methylation Indices and Metabolite Concentrations in Blood in a Bangladeshi Population 2023 · creatine + 400FA · Adults aged 20–65 years in Bangladesh exposed to arsenic in drinking water; men and women, recruited independent of folate status | 400 mcg | 12 weeks | 103 |
| Antenatal iron supplements consumed daily produce oxidative stress in contrast to weekly supplementation in Mexican non-anemic women 2012 · daily supplementation · Pregnant non-anemic women; 30% were iron-deficient at week 20; ages and sex beyond pregnancy not specified | 400 mcg | 8 weeks | 100 |
| Effectiveness of Health Information Package Program on Knowledge and Compliance among Pregnant Women with Anemia: A Randomized Controlled Trial 2022 · intervention group · Pregnant women aged 18–45 years with anemia, at 14–16 weeks of gestation and with hemoglobin <11 g/dL and hematocrit <30%. | 500 mcg | 90 days | 98 |
| Effectiveness of Health Information Package Program on Knowledge and Compliance among Pregnant Women with Anemia: A Randomized Controlled Trial 2022 · control group · Pregnant women aged 18–45 years with anemia, at 14–16 weeks of gestation and with hemoglobin <11 g/dL and hematocrit <30%. | 500 mcg | 90 days | 98 |
| Paraoxonase 1, B Vitamins Supplementation, and Mild Cognitive Impairment 2021 · B-vitamin group · Men and women, mean age 77.6 years, with mild cognitive impairment | 800 mcg | 2 years | 95 |
| Red blood cell metallothionein as an indicator of zinc status during pregnancy 2008 · supplement without zinc · Pregnant women in coastal Peru, enrolled at 10–16 weeks gestation and considered low risk, carrying a singleton fetus | 250 mcg | — | 86 |
| Brain atrophy in cognitively impaired elderly: the importance of long-chain ω-3 fatty acids and B vitamin status in a randomized controlled trial 2015 · high-dose B vitamin supplementation · Adults aged 70 years or older with mild cognitive impairment | 800 mcg | 2 years | 85 |
| The effect of long-term homocysteine-lowering on carotid intima-media thickness and flow-mediated vasodilation in stroke patients: a randomized controlled trial and meta-analysis 2008 · Vitamins · People with a history of stroke or transient ischemic attack; age range and sex not restricted | 2 mg | 4 years | 83 |
| Vitamin B12 decreases, but does not normalize, homocysteine and methylmalonic acid in end-stage renal disease: a link with glycine metabolism and possible explanation of hyperhomocysteinemia in end-stage renal disease 2003 · Daily multivitamin therapy · Adults with end-stage renal disease receiving hemodialysis and with hyperhomocysteinemia | 1 mg | 4 weeks | 81 |
| Vitamin B12 decreases, but does not normalize, homocysteine and methylmalonic acid in end-stage renal disease: a link with glycine metabolism and possible explanation of hyperhomocysteinemia in end-stage renal disease 2003 · Daily multivitamin therapy with added vitamin B12 · Adults with end-stage renal disease receiving hemodialysis and with hyperhomocysteinemia | 1 mg | 4 weeks | 81 |
| Timing of folic acid/vitamin B12 supplementation and hematologic toxicity during first-line treatment of patients with nonsquamous non-small cell lung cancer using pemetrexed-based chemotherapy: The PEMVITASTART randomized trial 2019 · immediate arm (IA) · Adults with locally advanced or metastatic nonsquamous non-small cell lung cancer receiving pemetrexed-based chemotherapy | 1 mg | 18 weeks | 81 |
| Timing of folic acid/vitamin B12 supplementation and hematologic toxicity during first-line treatment of patients with nonsquamous non-small cell lung cancer using pemetrexed-based chemotherapy: The PEMVITASTART randomized trial 2019 · delayed arm (DA) · Adults with locally advanced or metastatic nonsquamous non-small cell lung cancer receiving pemetrexed-based chemotherapy | 1 mg | 18 weeks | 80 |
| Homocysteine-lowering treatment with folic acid plus vitamin B6 lowers urinary albumin excretion but not plasma markers of endothelial function or C-reactive protein: further analysis of secondary end-points of a randomized clinical trial 2003 · Folic acid plus vitamin B6 treatment · Healthy adults who were siblings of patients with premature atherosclerotic disease | 5 mg | 2 years | 78 |
| Effect of homocysteine-lowering treatment with folic acid plus vitamin B on cerebrovascular atherosclerosis and white matter abnormalities as determined by MRA and MRI: a placebo-controlled, randomized trial 2004 · vitamin-treated group · Healthy siblings of patients with premature atherosclerotic disease; mean age 46.0 years; sex not specified | 5 mg | 2 years | 78 |
| mRNA Levels of Placental Iron and Zinc Transporter Genes Are Upregulated in Gambian Women with Low Iron and Zinc Status 2017 · PE group · Pregnant women aged 18–45 years with singleton pregnancies under 20 weeks in rural Gambia | 400 mcg | 184 days | 76 |
| mRNA Levels of Placental Iron and Zinc Transporter Genes Are Upregulated in Gambian Women with Low Iron and Zinc Status 2017 · MMN group · Pregnant women aged 18–45 years with singleton pregnancies under 20 weeks in rural Gambia | 400 mcg | 184 days | 75 |
| mRNA Levels of Placental Iron and Zinc Transporter Genes Are Upregulated in Gambian Women with Low Iron and Zinc Status 2017 · PE+MMN group · Pregnant women aged 18–45 years with singleton pregnancies under 20 weeks in rural Gambia | 400 mcg | 184 days | 75 |
| Red blood cell metallothionein as an indicator of zinc status during pregnancy 2008 · supplement with zinc · Pregnant women in coastal Peru, enrolled at 10–16 weeks gestation and considered low risk, carrying a singleton fetus | 250 mcg | — | 72 |
| Daily versus weekly iron supplementation and prevention of iron deficiency anaemia in lactating women 2003 · daily supplementation group · Lactating anaemic mothers in urban slum communities; age range and sex beyond lactating mothers not stated | 400 mcg | — | 71 |
| Double-blind, placebo-controlled trial comparing effects of supplementation with two different combinations of micronutrients delivered as sprinkles on growth, anemia, and iron deficiency in cambodian infants 2006 · MMN · Infants aged 6 months living in Kompong Chhnang Province, Cambodia | 150 mcg | 1 year | 68 |
| Double-blind, placebo-controlled trial comparing effects of supplementation with two different combinations of micronutrients delivered as sprinkles on growth, anemia, and iron deficiency in cambodian infants 2006 · FFA · Infants aged 6 months living in Kompong Chhnang Province, Cambodia | 150 mcg | 1 year | 68 |
| Double-blind, placebo-controlled trial comparing effects of supplementation of two micronutrient sprinkles on fatty acid status in Cambodian infants 2007 · mineral/micronutrient (MMN) · Cambodian infants aged 6 months at enrolment | 150 mcg | 1 year | 68 |
| Hyperhomocysteinemia in Japanese patients with convalescent stage ischemic stroke: effect of combined therapy with folic acid and mecobalamine 2002 · combined vitamin B(12) and folic acid group · Japanese patients with ischemic stroke in the convalescent stage | 5 mg | 8 weeks | 64 |
| Supplementation with antioxidant micronutrients in pregnant women with obesity: a randomized controlled trial 2024 · Intervention group · Pregnant women with obesity (BMI ≥30 kg/m²) | 800 mcg | — | 64 |
| Effects of folic acid and vitamin B complex on serum C-reactive protein and albumin levels in stable hemodialysis patients 2007 · Folic acid and vitamin B complex · Adults receiving maintenance hemodialysis; age and sex range not reported | 5 mg | 90 days | 61 |
| Weekly iron folate supplementation in adolescent girls--an effective nutritional measure for the management of iron deficiency anaemia 2013 · Daily IFA Supplementation Group · Adolescent girls aged 10–19 years with anaemia (haemoglobin <12 g/dL) | 1.5 mg | 90 days | 60 |
| Myoinositol plus α-lactalbumin supplementation, insulin resistance and birth outcomes in women with gestational diabetes mellitus: a randomized, controlled study 2021 · Treated group · Women aged 18–44 with gestational diabetes mellitus and a singleton pregnancy | 400 mcg | 60 days | 60 |
| Effect of oral zinc supplementation on copper and haemoglobin levels in pregnant women 1994 · Gp A (untreated control group) · Pregnant women in different trimesters of pregnancy | 10 mg | — | 58 |
| Weekly iron as a safe alternative to daily supplementation for nonanemic pregnant women 2006 · Daily supplementation (DS) · Pregnant women with singleton pregnancies, at gestational week 20, with hemoglobin >115 g/L; nonanemic | 200 mcg | 16 weeks | 56 |
| Effect of myo-inositol supplementation on ICSI outcomes among poor ovarian responder patients: A randomized controlled trial 2020 · Group A · Poor responder patients undergoing ICSI; age and sex details not reported | 400 mcg | — | 56 |
| Intermittent iron supplementation regimens are able to maintain safe maternal hemoglobin concentrations during pregnancy in Venezuela 2004 · weekly (WS) · Pregnant women at 10–30 weeks of gestation | 71.4 mcg | 14 weeks | 52 |
| Homocysteine thiolactone contributes to the prognostic value of fibrin clot structure/function in coronary artery disease 2022 · Folic acid + vitamins B12, B6 · Adults with suspected coronary artery disease undergoing angiography for stable angina; mean age 61.2 years, 71.5% male | 800 mcg | 1387 days | 52 |
| Homocysteine thiolactone contributes to the prognostic value of fibrin clot structure/function in coronary artery disease 2022 · Folic acid + vitamin B12 · Adults with suspected coronary artery disease undergoing angiography for stable angina; mean age 61.2 years, 71.5% male | 800 mcg | 1387 days | 52 |
| A combination of iron and retinol supplementation benefits iron status, IL-2 level and lymphocyte proliferation in anemic pregnant women 2010 · Group IF · Anemic pregnant women with hemoglobin 80 to less than 110 g/L | 400 mcg | 60 days | 46 |
| A combination of iron and retinol supplementation benefits iron status, IL-2 level and lymphocyte proliferation in anemic pregnant women 2010 · Group IR · Anemic pregnant women with hemoglobin 80 to less than 110 g/L | 400 mcg | 60 days | 46 |
| Efficacy of different strategies to treat anemia in children: a randomized clinical trial 2010 · Iron plus folic acid supplement (IFS) · Children aged 6–42 months with anemia in rural communities in Mexico | 37.5 mcg | 120 days | 42 |
| Impact of daily versus weekly hematinic supplementation on anemia in pregnant women 2002 · Group I (daily therapy) · Pregnant women; age range and anemia status not specified | 500 g | 14 weeks | 40 |
| Impact of daily versus weekly hematinic supplementation on anemia in pregnant women 2002 · Group II (weekly therapy) · Pregnant women; age range and anemia status not specified | 71.4 g | 14 weeks | 40 |
| [Impact of adding folic acid, vitamin B(12) and probucol to standard antihypertensive medication on plasma homocysteine and asymmetric dimethylarginine levels of essential hypertension patients] 2012 · group 2 · Patients with essential hypertension; age and sex not reported | 5 mg | 12 weeks | 40 |
| [Impact of adding folic acid, vitamin B(12) and probucol to standard antihypertensive medication on plasma homocysteine and asymmetric dimethylarginine levels of essential hypertension patients] 2012 · group 3 · Patients with essential hypertension; age and sex not reported | 5 mg | 12 weeks | 40 |
| Betaine supplementation decreases post-methionine hyperhomocysteinemia in chronic renal failure 2002 · Folic acid and pyridoxine without glycine betaine · Patients with chronic renal failure who were folate and pyridoxine replete | 5 mg | 90 days | 36 |
| Betaine supplementation decreases post-methionine hyperhomocysteinemia in chronic renal failure 2002 · Folic acid, pyridoxine, and glycine betaine · Patients with chronic renal failure who were folate and pyridoxine replete | 5 mg | 90 days | 36 |
| Randomized trial of FX high flux vs standard high flux dialysis for homocysteine clearance 2005 · All patients receiving vitamin therapy · Haemodialysis patients with end-stage renal disease; age and sex not reported | 5 mg | 24 weeks | 35 |
| An open-label, randomized, parallel-group comparative study of the efficacy of sorghum bicolor extract in preoperative anemia 2017 · test group · Patients with preoperative anemia booked for myomectomy; age and sex details not stated | 5 mg | 3 weeks | 34 |
| [Efficacy and safety of two vitamin supplement regimens on homocysteine levels in hemodialysis patients. Prospective, randomized clinical trial] 2005 · Supraphysiological daily-dose regimen · Adults with stable maintenance hemodialysis (mean age 68 years; 48% male) | 15 mg | 1 year | 33 |
| Effect of B vitamins-fortified foods on primary school children in Beijing 2006 · B vitamin compound supplementation group · Normal primary school children aged 9–11 years | 130 mcg | — | 33 |
| An open-label, randomized, parallel-group comparative study of the efficacy of sorghum bicolor extract in preoperative anemia 2017 · control group · Patients with preoperative anemia booked for myomectomy; age and sex details not stated | 5 mg | 3 weeks | 32 |
| A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours 2006 · Pemetrexed dose-escalation cohorts receiving folate and vitamin B12 supplementation · Japanese adults aged 20–75 with incurable solid tumours | 500 mcg | — | 31 |
| Folate, vitamin B12, homocysteine status and DNA damage in young Australian adults 1998 · supplemented group · Young Australian adults aged 18–32 years; males and females; not folate deficient, with 4.4% vitamin B12 deficient | 700 mcg | 26 weeks | 31 |
| [Effects of intervention therapy of methylcobalamin and folic acid on plasma homocysteine concentration and homocysteine thiolactonases/paraoxonase activity in patients with type 2 diabetes mellitus] 2007 · Group IV · Patients with type 2 diabetes mellitus | 5 mg | 12 weeks | 30 |
| Effects of plasma homocysteine levels on serum HTase/PON activity in patients with type 2 diabetes 2008 · Group III · Patients with type 2 diabetes; age and sex not specified | 5 mg | 2 weeks | 30 |
| A Randomized Pilot Trial to Evaluate the Bioavailability of Natural versus Synthetic Vitamin B Complexes in Healthy Humans and Their Effects on Homocysteine, Oxidative Stress, and Antioxidant Levels 2019 · Natural vitamin B complex (group N) · Healthy adults; age range and sex not specified | 690 mcg | 6 weeks | 30 |
| A Randomized Pilot Trial to Evaluate the Bioavailability of Natural versus Synthetic Vitamin B Complexes in Healthy Humans and Their Effects on Homocysteine, Oxidative Stress, and Antioxidant Levels 2019 · Synthetic vitamin B complex (group S) · Healthy adults; age range and sex not specified | 690 mcg | 6 weeks | 30 |
| Plasma homocysteine and markers for oxidative stress and inflammation in patients with coronary artery disease--a prospective randomized study of vitamin supplementation 2005 · open therapy with vitamins · Adults with ischemic heart disease and plasma homocysteine at least 15.0 micromol/L | 5 mg | 90 days | 29 |
| Preliminary results of the effect of treatment of hyperhomocysteinemia and its relationship with inflammation, coagulation status, and endothelial function after renal transplantation 2005 · Hyperhomocysteinemia patients treated with folic acid and vitamin B12 · Renal transplant recipients with hyperhomocysteinemia | 10 mg | 90 days | 29 |
| The impact of folate status and folic acid supplementation on the micronucleus frequency in human erythrocytes 2006 · folic acid, vitamin B12 and vitamin B6 supplementation group · Both-sex participants without folate deficiency; age not reported | 800 mcg | 7 days | 29 |
| Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients 2003 · group A · Adults with hyperhomocysteinemia who were stable renal-transplant recipients | 5 mg | 26 weeks | 28 |
| [Efficacy and safety of two vitamin supplement regimens on homocysteine levels in hemodialysis patients. Prospective, randomized clinical trial] 2005 · Daily renal multivitamin regimen · Adults with stable maintenance hemodialysis (mean age 68 years; 48% male) | 5 mg | 1 year | 27 |
| Comparative study of response to treatment with supraphysiologic doses of B-vitamins in hyperhomocysteinemic hemodialysis patients 2004 · Group A · Hemodialysis patients with hyperhomocysteinemia; age and sex not reported | 15 mg | — | 26 |
| Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients 2000 · FA group · Adults with chronic, stable hyperhomocysteinemia receiving hemodialysis | 15 mg | 12 weeks | 25 |
| Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients 2001 · Folic acid group · Adults with chronic, stable hyperhomocysteinemia receiving maintenance hemodialysis | 15 mg | 12 weeks | 25 |
| Inositol for the prevention of neural tube defects: a pilot randomised controlled trial 2016 · inositol+FA group · Women aged 18–40 planning pregnancy, with a history of a previous neural tube defect-affected pregnancy | 5 mg | — | 25 |
| Rapid communication: L-folinic acid versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients 2001 · Folic acid group · Adults with chronic, stable hyperhomocysteinemia receiving hemodialysis | 15 mg | 12 weeks | 24 |
| Comparative study of response to treatment with supraphysiologic doses of B-vitamins in hyperhomocysteinemic hemodialysis patients 2004 · Group B · Hemodialysis patients with hyperhomocysteinemia; age and sex not reported | 15 mg | — | 24 |
| Antioxidant supplementation with or without B-group vitamins after acute ischemic stroke: a randomized controlled trial 2006 · B-group vitamins · Acute ischemic stroke patients treated within 12 hours of symptom onset | 5 mg | 2 weeks | 24 |
| Antioxidant supplementation with or without B-group vitamins after acute ischemic stroke: a randomized controlled trial 2006 · Antioxidant vitamins plus B-group vitamins · Acute ischemic stroke patients treated within 12 hours of symptom onset | 5 mg | 2 weeks | 24 |
| The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes 2011 · study group · Women with gestational diabetes treated with diet | 400 mcg | 8 weeks | 24 |
| Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients 1999 · group 1 · Chronic, stable renal transplant recipients; age and sex not stated | 2.4 mg | 12 weeks | 20 |
| Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients 1999 · group 2 · Chronic, stable renal transplant recipients; age and sex not stated | 400 mcg | 12 weeks | 20 |
| Randomized controlled trial of the effect of short-term coadministration of methylcobalamin and folate on serum ADMA concentration in patients receiving long-term hemodialysis 2010 · methylcobalamin group · Patients undergoing long-term hemodialysis | 15 mg | 3 weeks | 20 |
| Vitamin B(6) supplementation improves pro-inflammatory responses in patients with rheumatoid arthritis 2010 · vitamin B(6) · Patients with rheumatoid arthritis | 5 mg | 12 weeks | 20 |
| Effect of inositol stereoisomers at different dosages in gestational diabetes: an open-label, parallel, randomized controlled trial 2018 · MI treatment · Pregnant women with gestational diabetes mellitus | 400 mcg | 8 weeks | 20 |
| Effect of inositol stereoisomers at different dosages in gestational diabetes: an open-label, parallel, randomized controlled trial 2018 · MI plus DCI treatment · Pregnant women with gestational diabetes mellitus | 400 mcg | 8 weeks | 20 |
| Effect of Myo-Inositol Treatment on Serum Asprosin Levels of Pregnant Women: A Prospective Randomized Controlled Pilot Study 2025 · Group 1 · Pregnant women aged 18–40 without the stated exclusion conditions | 400 mcg | 21 weeks | 20 |
| Hyperhomocysteinemia and endothelial function in young subjects: effects of vitamin supplementation 2002 · vitamin supplementation · Male volunteers aged 40 years or younger; nine matched pairs received vitamins, including hyperhomocysteinemic and normohomocysteinemic subjects | 600 mcg | 8 weeks | 18 |
| [Treatment of hyperhomocysteinemia and endothelial dysfunction in renal-transplant recipients with vitamin B] 2005 · vitamin treatment (group A) · Stable hyperhomocysteinemic renal-transplant recipients | 5 mg | 26 weeks | 18 |
| Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial 2020 · DHA treatment arm · Cognitively unimpaired men and women aged 55 years and older with a first-degree family history of dementia | 800 mcg | 26 weeks | 18 |
| The effects of gum arabic oral treatment on the metabolic profile of chronic renal failure patients under regular haemodialysis in Central Sudan 2008 · group B · Patients with chronic renal failure receiving regular haemodialysis; age and sex not reported | 5 mg | 90 days | 14 |
| Nutritional status-dependent DNA methylation modifications on adipose tissue in systemic lupus erythematosus women following folic acid and vitamin B12 supplementation: a randomized double-blind placebo-controlled trial 2026 · excess-body-weight intervention group · Women aged 18–45 with inactive systemic lupus erythematosus and excess body weight (BMI ≥25 kg/m²) | 400 mcg | 12 weeks | 14 |
| Nutritional status-dependent DNA methylation modifications on adipose tissue in systemic lupus erythematosus women following folic acid and vitamin B12 supplementation: a randomized double-blind placebo-controlled trial 2026 · normal-weight intervention group · Women aged 18–45 with inactive systemic lupus erythematosus and normal weight (BMI 18.5–24.9 kg/m²) | 400 mcg | 12 weeks | 11 |
| Effect of multivitamins on plasma homocysteine and folate levels in patients on hemodialysis 1999 · Nephro-Vite Rx · Adults with chronic kidney disease receiving hemodialysis who were not taking vitamin or folate supplements | 1 mg | 3 weeks | 11 |
| Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients 2001 · Renal transplant recipients · Renal transplant recipients with hyperhomocysteinemia | 2.4 mg | 12 weeks | 10 |
| Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome 2008 · Group A · Overweight patients with polycystic ovary syndrome; age and sex details not stated | 200 mcg | 12 weeks | 10 |
| Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study 2013 · Group A · Overweight patients with polycystic ovary syndrome; age and sex not specified | 200 mg | 12 weeks | 10 |
| Folic acid and vitamin B12 are more effective than vitamin B6 in lowering fasting plasma homocysteine concentration in patients with coronary artery disease 2004 · folic acid combined with vitamin B(12) · Patients with coronary artery disease and at least 70% stenosis of one major coronary artery | 5 mg | 12 weeks | 9 |
| Efficacy of methylcobalamin on lowering total homocysteine plasma concentrations in haemodialysis patients receiving high-dose folic acid supplementation 2002 · group II · Haemodialysis patients with chronic renal failure and hyperhomocysteinaemia | 15 mg | 3 weeks | 7 |
| Efficacy of methylcobalamin on lowering total homocysteine plasma concentrations in haemodialysis patients receiving high-dose folic acid supplementation 2002 · group III · Haemodialysis patients with chronic renal failure and hyperhomocysteinaemia | 15 mg | 3 weeks | 7 |
| Treatment of hyperhomocysteinemia in renal transplant recipients. A randomized, placebo-controlled trial 1997 · folic acid plus vitamin B12 · Clinically stable renal transplant recipients | 5 mg | — | 7 |
| Treatment of hyperhomocysteinemia in renal transplant recipients. A randomized, placebo-controlled trial 1997 · vitamin B6, folic acid, and vitamin B12 · Clinically stable renal transplant recipients | 5 mg | — | 7 |
| Effect of folic acid and betaine on fasting and postmethionine-loading plasma homocysteine and methionine levels in chronic haemodialysis patients 1999 · Folic acid 5 mg daily with betaine · Adults with end-stage renal disease receiving maintenance haemodialysis | 5 mg | 12 weeks | — |
| Folate administration reduces circulating homocysteine levels in NIDDM patients on long-term metformin treatment 1998 · folate group · Adults treated with metformin for at least 1 year; 26 had NIDDM and 2 had hyperlipidaemia. Baseline homocysteine was within the reference range. | 250 mcg | 12 weeks | — |
| Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients 2000 · iron group · Critically ill anemic adults admitted to a multidisciplinary intensive care unit | 1 mg | 2 weeks | — |
| Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients 2000 · EPO group · Critically ill anemic adults admitted to a multidisciplinary intensive care unit | 1 mg | 2 weeks | — |
| Anthelminthic treatment and haemoglobin concentrations during pregnancy 2000 · iron-folate supplements · Pregnant women in Sierra Leone | 5 mg | — | — |
| Changes in markers of anemia and iron metabolism and how they are influenced by antianemics in postpartum period 2001 · second group · Women after spontaneous delivery; age and postpartum condition details not reported | 350 mcg | 60 days | — |
| Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients 2001 · Hemodialysis patients receiving folic acid · Hemodialysis patients with hyperhomocysteinemia and baseline total homocysteine comparable to the renal transplant recipients | 15 mg | 12 weeks | — |
| Oral vitamin B(12) and high-dose folic acid in hemodialysis patients with hyper-homocyst(e)inemia 2001 · 0 mg folic acid group · Adults with hyper-homocyst(e)inemia receiving hemodialysis for end-stage renal disease | 1 mg | 4 weeks | — |
| Low-dose vitamin B-6 effectively lowers fasting plasma homocysteine in healthy elderly persons who are folate and riboflavin replete 2001 · Vitamin B-6 supplementation group · Healthy adults aged 63–80 years; folate- and riboflavin-replete, with no vitamin B-12 deficiency | 400 mcg | 12 weeks | — |
| Albendazole therapy and reduced decline in haemoglobin concentration during pregnancy (Sierra Leone) 2001 · iron-folate supplements · Pregnant women in Sierra Leone | 5 mg | — | — |
| The effect of weekly iron supplementation on anaemia and on iron deficiency among female tea pluckers in Bangladesh 2001 · weekly iron supplementation · Adult female tea pluckers in Bangladesh | 28.6 mg | 24 weeks | — |
| Concomitant supplemental vitamin A enhances the response to weekly supplemental iron and folic acid in anemic teenagers in urban Bangladesh 2001 · iron + folic acid + vitamin A · Teenage women in urban Bangladesh with hemoglobin concentrations of 80–120 g/L | 500 mcg | 12 weeks | — |
| Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate 2001 · fenofibrate plus vitamins · men with hyperlipidemia | 650 mcg | 6 weeks | — |
| Total homocysteine lowering treatment among coronary artery disease patients in the era of folic acid-fortified cereal grain flour 2002 · Folic acid, riboflavin, and vitamin B12 without vitamin B6 · Adults with stable coronary artery disease; mean age 60.1 years; 29.8% women | 2.5 mg | 12 weeks | — |
| Hyperhomocysteinaemia therapy in haemodialysis patients: folinic versus folic acid in combination with vitamin B6 and B12 2002 · Group 3 · Chronic haemodialysis patients; age and sex not specified | 6.43 mg | 26 weeks | — |
| A randomised trial in Mali of the effectiveness of weekly iron supplements given by teachers on the haemoglobin concentrations of schoolchildren 2002 · weekly iron tablets · Schoolchildren aged 6–19 years in rural community schools in Kolondieba district, Mali | 35.7 mcg | 10 weeks | — |
| Randomized trial of methylcobalamin and folate effects on homocysteine in hemodialysis patients 2002 · Group A · Chronic hemodialysis patients without previous vitamin supplementation | 10 mg | 120 days | — |
| Effect of homocysteine reduction by B-vitamin supplementation on markers of clotting activation 2002 · high-dose B-vitamin supplements · Healthy volunteers with homocysteine >16 μmol/L or ≤16 μmol/L | 5 mg | 8 weeks | — |
| Coronary endothelial function in hyperhomocysteinemia: improvement after treatment with folic acid and cobalamin in patients with coronary artery disease 2002 · folic acid/cobalamin treated group · Patients with coronary artery disease and hyperhomocysteinemia, plasma homocysteine ≥16 micromol/L; age and sex not reported | 5 mg | 26 weeks | — |
| Effect of riboflavin supplementation on plasma homocysteine in elderly people with low riboflavin status 2002 · Folic acid and riboflavin group (Part 2, second phase) · Healthy elderly people with sub-optimal riboflavin status | 400 mcg | 12 weeks | — |
| Reduction of plasma homocysteine and serum methylmalonate concentrations in apparently healthy elderly subjects after treatment with folic acid, vitamin B12 and vitamin B6: a randomised trial 2003 · B-vitamin treatment · Community-dwelling apparently healthy adults aged 70–93 years; median age 76 years | 800 mcg | 120 days | — |
| Supplementation with micronutrients in addition to iron and folic acid does not further improve the hematologic status of pregnant women in rural Nepal 2003 · folic acid plus iron · Pregnant women in rural Nepal | 400 mcg | — | — |
| Mineral water fortified with folic acid, vitamins B6, B12, D and calcium improves folate status and decreases plasma homocysteine concentration in men and women 2004 · Fortified mineral water · Free-living men and women without folate deficiency or elevated homocysteine | 563 mcg | 8 weeks | — |
| Breakfast cereal fortified with folic acid, vitamin B-6, and vitamin B-12 increases vitamin concentrations and reduces homocysteine concentrations: a randomized trial 2004 · Fortified cereal group · Volunteers aged 50–85 years without the listed medical conditions who did not regularly use multiple or B-vitamin supplements or highly fortified breakfast cereal | 440 mcg | 12 weeks | — |
| Randomized controlled trial of prenatal zinc supplementation and fetal bone growth 2004 · supplements containing 60 mg Fe and 250 microg folic acid, without 25 mg Zn · Pregnant women in Peru, enrolled at 10–16 weeks of gestation | 250 mcg | — | — |
| Randomized controlled trial of prenatal zinc supplementation and fetal bone growth 2004 · supplements containing 60 mg Fe and 250 microg folic acid, with 25 mg Zn · Pregnant women in Peru, enrolled at 10–16 weeks of gestation | 250 mcg | — | — |
| Changes in basal and postmethionine load concentrations of total homocysteine and cystathionine after B vitamin intervention 2004 · group B · Patients with suspected coronary artery disease; age and sex not stated | 5.8 mg | 90 days | — |
| Insulin resistance and endothelial function are improved after folate and vitamin B12 therapy in patients with metabolic syndrome: relationship between homocysteine levels and hyperinsulinemia 2004 · group 2 · Patients with metabolic syndrome; age range and sex not reported | 5 mg | 30 days | — |
| Zinc plus beta-carotene supplementation of pregnant women is superior to beta-carotene supplementation alone in improving vitamin A status in both mothers and infants 2004 · beta-carotene plus zinc · Pregnant women; age and specific condition not stated | 400 mcg | — | — |
| The effect of homocysteine reduction by B-vitamin supplementation on markers of endothelial dysfunction 2004 · B-vitamins · Healthy volunteers, including hyperhomocysteinemic and normohomocysteinemic participants | 5 mg | 8 weeks | — |
| Efficacy of B vitamins in lowering homocysteine in older men: maximal effects for those with B12 deficiency and hyperhomocysteinemia 2006 · Vitamin group · Community-dwelling men aged 75 years or older | 2 mg | 2 years | — |
| Effects of short-term folic acid and/or riboflavin supplementation on serum folate and plasma total homocysteine concentrations in young Japanese male subjects 2006 · FAR group · Healthy Japanese men aged 20–29 years | 800 mcg | 2 weeks | — |
| No effect of B vitamins on ADMA levels in patients at increased cardiovascular risk 2006 · Study I: B vitamins · Siblings of patients with clinical atherosclerotic disease and postmethionine hyperhomocysteinaemia; ages and sex not stated | 5 mg | 1 year | — |
| Short-term daily or weekly administration of micronutrient Sprinkles has high compliance and does not cause iron overload in Chinese schoolchildren: a cluster-randomised trial 2006 · daily group · Children aged 3–6 years in a kindergarten in northern China | 150 mcg | 13 weeks | — |
| Effect of short-term folate and vitamin B supplementation on blood homocysteine level and carotid artery wall thickness in chronic hemodialysis patients 2006 · Treatment group · Chronic hemodialysis patients with hyperhomocysteinemia; age and sex not specified | 15 mg | 26 weeks | — |
| Effect of fortified spread on homocysteine concentration in apparently healthy volunteers 2007 · spread 1 · Apparently healthy adult volunteers; 50% male; age range not reported | 200 mcg | 6 weeks | — |
| Effect of fortified spread on homocysteine concentration in apparently healthy volunteers 2007 · spread 2 · Apparently healthy adult volunteers; 50% male; age range not reported | 400 mcg | 6 weeks | — |
| Homocysteine-lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease 2007 · A: folic acid/vitamin B12/vitamin B6 · Adults aged 38–80 with suspected coronary artery disease | 800 mcg | 26 weeks | — |
| Homocysteine-lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease 2007 · B: folic acid/vitamin B12 · Adults aged 38–80 with suspected coronary artery disease | 800 mcg | 26 weeks | — |
| Folic acid and vitamin B-12 supplementation does not favorably influence uracil incorporation and promoter methylation in rectal mucosa DNA of subjects with previous colorectal adenomas 2007 · folic acid plus vitamin B-12 · People with a history of colorectal adenoma and MTHFR CC or TT genotype | 5 mg | 26 weeks | — |
| Treatment of hyperhomocysteinemia and endothelial dysfunction in renal transplant recipients with B vitamins in the Chinese population 2008 · folate treatment · Chinese renal transplant recipients with hyperhomocysteinemia; age and sex not reported | 5 mg | 26 weeks | — |
| Effect of homocysteine-lowering therapy on arterial elasticity and metabolic parameters in metformin-treated diabetic patients 2008 · group 1 · Adults with diabetes treated with high-dose metformin | 1 mg | 120 days | — |
| Serum biomarkers for atrophic gastritis and antibodies against Helicobacter pylori in the elderly: Implications for vitamin B12, folic acid and iron status and response to oral vitamin therapy 2008 · oral vitamin treatment · Community-dwelling adults, mean age 76 years | 800 mcg | 120 days | — |
| Weekly may be as efficacious as daily folic acid supplementation in improving folate status and lowering serum homocysteine concentrations in Guatemalan women 2008 · weekly 5000 microg folic acid group · Healthy reproductive-aged women in Guatemala | 714 mcg | 12 weeks | — |
| Weekly may be as efficacious as daily folic acid supplementation in improving folate status and lowering serum homocysteine concentrations in Guatemalan women 2008 · weekly 2800 microg folic acid group · Healthy reproductive-aged women in Guatemala | 400 mcg | 12 weeks | — |
| Weekly may be as efficacious as daily folic acid supplementation in improving folate status and lowering serum homocysteine concentrations in Guatemalan women 2008 · daily 400 microg folic acid group · Healthy reproductive-aged women in Guatemala | 400 mcg | 12 weeks | — |
| Weekly may be as efficacious as daily folic acid supplementation in improving folate status and lowering serum homocysteine concentrations in Guatemalan women 2008 · daily 200 microg folic acid group · Healthy reproductive-aged women in Guatemala | 200 mcg | 12 weeks | — |
| The effects of vitamin supplementation and MTHFR (C677T) genotype on homocysteine-lowering and migraine disability 2009 · vitamin supplementation · patients diagnosed with migraine with aura; age and sex not reported | 2 mg | 26 weeks | — |
| Leaf concentrate as an alternative to iron and folic acid supplements for anaemic adolescent girls: a randomised controlled trial in India 2010 · Fe and folic acid (IFA) · Anaemic adolescent girls aged 14–18 years | 500 mcg | 90 days | — |
| Leaf concentrate as an alternative to iron and folic acid supplements for anaemic adolescent girls: a randomised controlled trial in India 2010 · Leaf concentrate (LC) · Anaemic adolescent girls aged 14–18 years | 13 mcg | 90 days | — |
| Efficacy of folate and vitamin B12 in lowering homocysteine concentrations in hemodialysis patients 2009 · group II (folic acid and vitamin B12) · Hemodialysis patients; age and sex not reported | 5 mg | 8 weeks | — |
| Efficacy of folate and vitamin B12 in lowering homocysteine concentrations in hemodialysis patients 2009 · group IV (folic acid and vitamin B12) · Hemodialysis patients; age and sex not reported | 15 mg | 8 weeks | — |
| Homocysteine-lowering vitamins do not lower plasma S-adenosylhomocysteine in older people with elevated homocysteine concentrations 2010 · vitamins group · Healthy adults aged 65 years or older with elevated homocysteine (>13 micromol/l) | 1 mg | 2 years | — |
| Effect of physiological doses of oral vitamin B12 on plasma homocysteine: a randomized, placebo-controlled, double-blind trial in India 2010 · B2 F200 (2 μg vitamin B12 and 200 μg folic acid) · Children and adults from rural families in India; participants included children (mean age 9 years), mothers and fathers, with common vitamin B12 deficiency and elevated homocysteine | 200 mcg | 1 year | — |
| Effect of physiological doses of oral vitamin B12 on plasma homocysteine: a randomized, placebo-controlled, double-blind trial in India 2010 · B10 F200 (10 μg vitamin B12 and 200 μg folic acid) · Children and adults from rural families in India; participants included children (mean age 9 years), mothers and fathers, with common vitamin B12 deficiency and elevated homocysteine | 200 mcg | 1 year | — |
| Community-level micronutrient fortification of school lunch meals improved vitamin A, folate, and iron status of schoolchildren in Himalayan villages of India 2010 · multiple micronutrients (treatment group) · Schoolchildren aged 6–10 years in Himalayan villages of India | 225 mcg | 240 days | — |
| Supplementation of iron alone and combined with vitamins improves haematological status, erythrocyte membrane fluidity and oxidative stress in anaemic pregnant women 2010 · group IF · Pregnant women with anaemia | 400 mcg | 60 days | — |
| A comparison of iron and folate with folate alone in hematologic recovery of children treated for acute malaria 2010 · iron plus folate group · Children aged 6–60 months with smear-positive malaria and anemia (hematocrit <33%) | 5 mg | 4 weeks | — |
| Patterns of compliance with prenatal iron supplementation among Peruvian women 2014 · Iron and folate without zinc · Pregnant women enrolled at 10–24 weeks of gestation and followed through 4 weeks postpartum | 250 mcg | — | — |
| Patterns of compliance with prenatal iron supplementation among Peruvian women 2014 · Iron, folate, and zinc · Pregnant women enrolled at 10–24 weeks of gestation and followed through 4 weeks postpartum | 250 mcg | — | — |
| Effects of prenatal micronutrient and early food supplementation on maternal hemoglobin, birth weight, and infant mortality among children in Bangladesh: the MINIMat randomized trial 2012 · 60 mg iron and 400 μg folic acid; early food invitation · Pregnant women in poor communities in Bangladesh | 400 mcg | — | — |
| Effects of prenatal micronutrient and early food supplementation on maternal hemoglobin, birth weight, and infant mortality among children in Bangladesh: the MINIMat randomized trial 2012 · 60 mg iron and 400 μg folic acid; usual food invitation · Pregnant women in poor communities in Bangladesh | 400 mcg | — | — |
| Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment 2013 · B-vitamin treatment · Elderly adults with mild cognitive impairment and increased dementia risk | 800 mcg | 2 years | — |
| The association between progression of atherosclerosis and the methylated amino acids asymmetric dimethylarginine and trimethyllysine 2013 · Folic acid plus vitamin B12 plus vitamin B6 · Adults with suspected or established coronary artery disease who underwent coronary angiography; median age 60 years | 800 mcg | 316 days | — |
| The association between progression of atherosclerosis and the methylated amino acids asymmetric dimethylarginine and trimethyllysine 2013 · Folic acid plus vitamin B12 · Adults with suspected or established coronary artery disease who underwent coronary angiography; median age 60 years | 800 mcg | 316 days | — |
| Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome 2016 · Group A · Women of reproductive age with polycystic ovarian syndrome undergoing IVF | 400 mcg | — | — |
| Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome 2016 · Group B · Women of reproductive age with polycystic ovarian syndrome undergoing IVF | 400 mcg | — | — |
| The C677T MTHFR genotypes influence the efficacy of B9 and B12 vitamins supplementation to lowering plasma total homocysteine in hemodialysis 2016 · Group A, t3: folic acid plus vitamin B12 · Hemodialysis patients with C677T MTHFR genotypes | 10 mg | 60 days | — |
| The C677T MTHFR genotypes influence the efficacy of B9 and B12 vitamins supplementation to lowering plasma total homocysteine in hemodialysis 2016 · Group B, t3: vitamin B12 plus folic acid · Hemodialysis patients with C677T MTHFR genotypes | 10 mg | 60 days | — |
| Supplementation with Folic Acid, but Not Creatine, Increases Plasma Betaine, Decreases Plasma Dimethylglycine, and Prevents a Decrease in Plasma Choline in Arsenic-Exposed Bangladeshi Adults 2016 · Creatine plus FA400 · Arsenic-exposed adults aged 24–55 in Bangladesh | 400 mcg | 12 weeks | — |
| Lipid-Based Nutrient Supplements During Pregnancy and Lactation Did Not Affect Human Milk Oligosaccharides and Bioactive Proteins in a Randomized Trial 2017 · IFA group · Pregnant women over 15 years old, enrolled at no more than 20 weeks’ gestation, in Malawi; continued postpartum for the breast-milk assessment | 400 mcg | — | — |
| Acceptability and Utilization of Three Nutritional Supplements during Pregnancy: Findings from a Longitudinal, Mixed-Methods Study in Niger 2018 · IFA group · Pregnant women enrolled before 30 weeks’ gestation in rural Niger | 400 mcg | 26 weeks | — |
| Urinary excretion of homocysteine thiolactone and the risk of acute myocardial infarction in coronary artery disease patients: the WENBIT trial 2019 · folic acid + vitamin B12 + vitamin B6 · Adults with suspected coronary artery disease who underwent coronary angiography; mean age about 61 years, 69.8% male | 800 mcg | 165 weeks | — |
| Urinary excretion of homocysteine thiolactone and the risk of acute myocardial infarction in coronary artery disease patients: the WENBIT trial 2019 · folic acid + vitamin B12 · Adults with suspected coronary artery disease who underwent coronary angiography; mean age about 61 years, 69.8% male | 800 mcg | 165 weeks | — |
| Folic acid supplementation enhances arsenic methylation: results from a folic acid and creatine supplementation randomized controlled trial in Bangladesh 2019 · 400 μg folic acid plus 3 g creatine group · Bangladeshi participants exposed to arsenic through drinking water; the majority were folate sufficient | 400 mcg | 24 weeks | — |
| Influence of Dietary Supplementation for Hyperhomocysteinemia Treatments 2020 · oxifolic · Adults aged 48 ± 14 years, men and women, with moderate hyperhomocysteinemia | 300 mcg | 90 days | — |
| Impact of daily-supervised administration of a package of iron and folic acid and vitamin B(12) on hemoglobin levels among adolescent girls (12-19 years): a cluster randomized control trial 2021 · Experimental group-IFA with vitamin B12 · Adolescent girls aged 12–19 years with mild or moderate anemia | 500 mcg | 90 days | — |
| Impact of daily-supervised administration of a package of iron and folic acid and vitamin B(12) on hemoglobin levels among adolescent girls (12-19 years): a cluster randomized control trial 2021 · Control group-IFA · Adolescent girls aged 12–19 years with mild or moderate anemia | 500 mcg | 90 days | — |
| The Inclusion of Folic Acid in Weekly Iron-Folic Acid Supplements Confers no Additional Benefit on Anemia Reduction in Nonpregnant Women: A Randomized Controlled Trial in Malaysia 2021 · 60 mg Fe with 0.4 mg folic acid · Nonpregnant women aged 18–45 years in Malaysia | 57.1 mcg | 16 weeks | — |
| Low-dose daily folic acid (400 μg) supplementation does not affect regulation of folate transporters found present throughout the terminal ileum and colon of humans: a randomized clinical trial 2024 · 400 μg folic acid group · Adults | 400 mcg | 16 weeks | — |
| The ameliorative effect of myo-inositol on apoptosis-related genes expression in cumulus cells of women with polycystic ovary syndrome undergoing ICSI and its relationship with the quality of oocyte and embryo 2025 · MYO group · Infertile women with PCOS undergoing ICSI; age range and sex beyond women not reported | 2 mg | 6 weeks | — |
| Vitamin requirements for the treatment of hyperhomocysteinemia in humans 1994 · combination of folic acid, vitamin B-12 and vitamin B-6 · men with hyperhomocysteinemia | 650 mcg | 6 weeks | — |
| Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia 1993 · daily vitamin supplement · Apparently healthy men with moderate hyperhomocysteinemia | 1 mg | 6 weeks | — |
| Weekly micronutrient supplementation to build iron stores in female Indonesian adolescents 1997 · daily supplementation group · female Indonesian high-school adolescents | 250 mcg | 90 days | — |
| Weekly micronutrient supplementation to build iron stores in female Indonesian adolescents 1997 · weekly supplementation group (60 mg Fe) · female Indonesian high-school adolescents | 71.4 mg | 90 days | — |
| Weekly micronutrient supplementation to build iron stores in female Indonesian adolescents 1997 · weekly supplementation group (120 mg Fe) · female Indonesian high-school adolescents | 71.4 mg | 90 days | — |
| No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients 1998 · 5 mg folic acid plus 4 g betaine (phase 1) · Haemodialysis patients with hyperhomocysteinaemia; age and sex not reported | 5 mg | 12 weeks | — |
| Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers 1998 · high-dose multivitamin supplements · Patients with a history of recurrent venous thrombosis and hyperhomocysteinemic healthy volunteers | 5 mg | — | — |
| Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: no change in endothelial function after long-term therapy 1998 · 5 mg folic acid and 4 g betaine daily · Peritoneal dialysis patients with hyperhomocysteinemia | 5 mg | 12 weeks | — |
| Effects of folic acid and combinations of folic acid and vitamin B-12 on plasma homocysteine concentrations in healthy, young women 1998 · 400 microg folic acid + 6 microg vitamin B-12 · Female volunteers of childbearing age | 400 mcg | 4 weeks | — |
| Effects of folic acid and combinations of folic acid and vitamin B-12 on plasma homocysteine concentrations in healthy, young women 1998 · 400 microg folic acid + 400 microg vitamin B-12 · Female volunteers of childbearing age | 400 mcg | 4 weeks | — |
| Randomized, double-blind, placebo-controlled trial of selenium supplements among HIV-infected pregnant women in Tanzania: effects on maternal and child outcomes 2008 · selenium group · Pregnant women aged about 27.5 years on average, at 12–27 weeks of gestation, living with HIV in Dar es Salaam, Tanzania | 1.05 mg | — | 456 |
| Effects of prenatal micronutrient and early food supplementation on metabolic status of the offspring at 4.5 years of age. The MINIMat randomized trial in rural Bangladesh 2016 · MMS · Pregnant women in rural Bangladesh; offspring assessed at 4.5 years | 400 mcg | — | 439 |
| Maternal cortisol and stress are associated with birth outcomes, but are not affected by lipid-based nutrient supplements during pregnancy: an analysis of data from a randomized controlled trial in rural Malawi 2015 · LNS · Pregnant women aged 15–49 years in rural Malawi, enrolled at up to 20 weeks of gestation | 400 mcg | — | 418 |
| Maternal cortisol and stress are associated with birth outcomes, but are not affected by lipid-based nutrient supplements during pregnancy: an analysis of data from a randomized controlled trial in rural Malawi 2015 · MMN · Pregnant women aged 15–49 years in rural Malawi, enrolled at up to 20 weeks of gestation | 400 mcg | — | 415 |
| Micronutrient Sprinkles reduce anemia among 9- to 24-mo-old children when delivered through an integrated health and nutrition program in rural Haiti 2007 · Sprinkles-WSB (S-WSB) · Children aged 9–24 months in rural Haiti receiving take-home fortified wheat-soy blend rations | 160 mcg | 60 days | 254 |
| A novel nutritional supplement to reduce plasma homocysteine in nonpregnant women: A randomised controlled trial in The Gambia 2019 · UNIMMAP tablet · Nonpregnant, non-lactating healthy women aged 18–45 years in West Kiang, The Gambia; women of reproductive age with common micronutrient deficiencies in the population | 400 mcg | 12 weeks | 105 |
| A novel nutritional supplement to reduce plasma homocysteine in nonpregnant women: A randomised controlled trial in The Gambia 2019 · drink powder · Nonpregnant, non-lactating healthy women aged 18–45 years in West Kiang, The Gambia; women of reproductive age with common micronutrient deficiencies in the population | 800 mcg | 12 weeks | 93 |
| Nutraceutical approaches to homocysteine lowering in hypertensive subjects at low cardiovascular risk: a multicenter, randomized clinical trial 2016 · Normocis 400® group · Adults with stage 1 essential hypertension and hyper-homocysteinemia (HCys ≥15 μmol/L), without a history of cardiovascular or cerebrovascular disease; mean age 62.8 years, 63.5% male | 400 mcg | 60 days | 52 |
| Effects of poly-bioactive compounds on lipid profile and body weight in a moderately hypercholesterolemic population with low cardiovascular disease risk: a multicenter randomized trial 2014 · Intervention (Armolipid Plus/AP) · Men and women older than 18 years with mild-moderate hypercholesterolemia and elevated LDL-c, candidates for lifestyle intervention without hypolipemic drug treatment | 200 mcg | 12 weeks | 51 |
| Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD 2009 · Treatment group · Adults with stage 2 to 4 chronic kidney disease and creatinine clearance of 15 to 70 mL/min/1.73 m² | 5 mg | 2 years | 47 |
| Effects of low-dose B vitamins plus betaine supplementation on lowering homocysteine concentrations among Chinese adults with hyperhomocysteinemia: a randomized, double-blind, controlled preliminary clinical trial 2023 · supplement group · Chinese adults aged 18–65 with hyperhomocysteinemia (blood homocysteine 15–100 μmol/L) | 400 mcg | 12 weeks | 44 |
| Effects of milk enriched with omega-3 fatty acid, oleic acid and folic acid in patients with metabolic syndrome 2006 · test group · Patients with metabolic syndrome; age and sex not specified | 150 mcg | 90 days | 36 |
| The impact of a standardized micronutrient supplementation on PCOS-typical parameters: a randomized controlled trial 2019 · Multinutrient supplementation group · Women aged 19–35 with polycystic ovary syndrome (PCOS) | 800 mcg | 90 days | 30 |
| Plasma trimethylamine-N-oxide following supplementation with vitamin D or D plus B vitamins 2017 · vitamin D + B arm · Participants; age, sex, and health condition not specified | 500 mcg | 1 year | 25 |
| A Mixed Flavonoid-Fish Oil Supplement Induces Immune-Enhancing and Anti-Inflammatory Transcriptomic Changes in Adult Obese and Overweight Women-A Randomized Controlled Trial 2016 · Q-Mix · Women aged 40–70 years who were overweight or obese (BMI ≥25 kg/m²), without the listed major diseases | 400 mcg | 10 weeks | 24 |
| Effects of a New Combination of Medical Food on Endothelial Function and Lipid Profile in Dyslipidemic Subjects: A Pilot Randomized Trial 2019 · Nutraceutical B · Adults aged 18–75 with elevated serum cholesterol not requiring statins or statin-intolerant; people with cardiovascular disease and uncontrolled diabetes were excluded. | 200 mcg | 6 weeks | 23 |
| Nutraceutical Effects on Glucose and Lipid Metabolism in Patients with Impaired Fasting Glucose: A Pilot, Double-Blind, Placebo-Controlled, Randomized Clinical Trial on a Combined Product 2017 · Active nutraceutical · Adults with impaired fasting glucose, ages 54.6 ± 11.3 years on average; men and women | 300 mcg | 8 weeks | 20 |
| Effects of baked products enriched with n-3 fatty acids, folates, β-glucans, and tocopherol in patients with mild mixed hyperlipidemia 2012 · active diet · Adults with mild plasma lipid abnormalities (mild mixed hyperlipidemia) | 1.6 mg | 30 days | 16 |
| High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients 1996 · Supraphysiologic-dose B-vitamin supplementation · Hyperhomocysteinemic dialysis patients | 15 mg | 8 weeks | 15 |
| Folic acid 5 or 15 mg/d similarly reduces plasma homocysteine in patients with moderate-advanced chronic renal failure 2006 · FA-15 · Adults aged 45–71 years with moderate-severe chronic renal failure | 15 mg | 180 days | 9 |
| Folic acid 5 or 15 mg/d similarly reduces plasma homocysteine in patients with moderate-advanced chronic renal failure 2006 · FA-5 · Adults aged 45–71 years with moderate-severe chronic renal failure | 5 mg | 180 days | 8 |
| Antioxidants, but not B-group vitamins increase the resistance of low-density lipoprotein to oxidation: a randomized, factorial design, placebo-controlled trial 1999 · B vitamins with antioxidant vitamins · Men aged 30–49 with plasma homocysteine concentration ≥8.34 μmol/L | 1 mg | 8 weeks | — |
| Oral vitamin B(12) and high-dose folic acid in hemodialysis patients with hyper-homocyst(e)inemia 2001 · 5 mg folic acid group · Adults with hyper-homocyst(e)inemia receiving hemodialysis for end-stage renal disease | 6 mg | 4 weeks | — |
| Oral vitamin B(12) and high-dose folic acid in hemodialysis patients with hyper-homocyst(e)inemia 2001 · 20 mg folic acid group · Adults with hyper-homocyst(e)inemia receiving hemodialysis for end-stage renal disease | 21 mg | 4 weeks | — |
| Prophylactic iron supplementation in pregnant women in Norway 2001 · 15 mg iron daily · Non-anaemic pregnant women, allocated at about 10 weeks of pregnancy | 100 mcg | — | — |
| Total homocysteine lowering treatment among coronary artery disease patients in the era of folic acid-fortified cereal grain flour 2002 · Folic acid, riboflavin, and vitamin B12 with vitamin B6 · Adults with stable coronary artery disease; mean age 60.1 years; 29.8% women | 2.5 mg | 12 weeks | — |
| Supplementation with micronutrients in addition to iron and folic acid does not further improve the hematologic status of pregnant women in rural Nepal 2003 · folic acid plus iron and zinc · Pregnant women in rural Nepal | 400 mcg | — | — |
| Supplementation with micronutrients in addition to iron and folic acid does not further improve the hematologic status of pregnant women in rural Nepal 2003 · folic acid plus iron, zinc and multiple micronutrients · Pregnant women in rural Nepal | 400 mcg | — | — |
| Folate therapy and in-stent restenosis after coronary stenting 2004 · folate group · Patients who had undergone successful coronary stenting | 1.2 mg | 26 weeks | — |
| Changes in basal and postmethionine load concentrations of total homocysteine and cystathionine after B vitamin intervention 2004 · group A · Patients with suspected coronary artery disease; age and sex not stated | 5.8 mg | 90 days | — |
| Homocysteine in chronic kidney disease: Effect of low protein diet and repletion with B vitamins 2005 · All subjects · Adults with chronic kidney disease in MDRD Study A (GFR 25–55 mL/min/1.73 m²) or Study B (GFR 13–24 mL/min/1.73 m²) | 1 mg | 1 year | — |
| No effect of homocysteine-lowering therapy on vascular inflammation and haemostasis in peripheral arterial occlusive disease 2006 · B-vitamin group · Patients with symptomatic peripheral arterial occlusive disease and elevated homocysteine levels | 5 mg | 6 weeks | — |
| One year B and D vitamins supplementation improves metabolic bone markers 2013 · group A · Healthy adults older than 54 years | 500 mcg | 1 year | — |
| Co-administration of methyl donors along with guanidinoacetic acid reduces the incidence of hyperhomocysteinaemia compared with guanidinoacetic acid administration alone 2013 · GAA with methyl donors group · Healthy male and female volunteers | 600 mcg | 8 weeks | — |
| Effects of mixed dietary supplements on total plasma homocysteine concentrations (tHcy): a randomized, double-blind, placebo-controlled trial 2012 · supplement group · hospitalized, acutely ill older patients recovering from acute illness; sex and age range not stated | 200 mcg | 6 weeks | — |
| One-carbon metabolites and telomere length in a prospective and randomized study of B- and/or D-vitamin supplementation 2017 · group A · Adults older than 54 years; no specific condition stated | 500 mcg | 1 year | — |
| Multimicronutrient and omega-3 fatty acid supplementation reduces low-grade inflammation in older participants: An exploratory study 2025 · multimicronutrient and n-3 PUFA supplementation · Healthy, physically active older adults; mean age 75.6 ± 3.9 years; sex not specified | 400 mcg | 12 weeks | — |
| Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS 2014 · Myo-inositol group · Women with PCOS and menstrual irregularities | 400 mcg | 26 weeks | 25 |
| The effectiveness of inositol and metformin on infertile polycystic ovary syndrome women with resistant to letrozole 2019 · Group III · Infertile women with polycystic ovary syndrome who did not ovulate after letrozole treatment | 400 mcg | 90 days | — |
| Vitamin B12 Supplementation in Addition to Folic Acid and Iron Improves Hematological and Biochemical Markers in Pregnancy: A Randomized Controlled Trial 2020 · intervention group · Healthy, nonanemic pregnant women; age and sex details beyond pregnancy not reported | 5 mg | 100 days | — |
| Vitamin B12 Supplementation in Addition to Folic Acid and Iron Improves Hematological and Biochemical Markers in Pregnancy: A Randomized Controlled Trial 2020 · control group · Healthy, nonanemic pregnant women; age and sex details beyond pregnancy not reported | 5 mg | 100 days | — |
| Effect of antenatal multiple micronutrient supplementation on anthropometry and blood pressure in mid-childhood in Nepal: follow-up of a double-blind randomised controlled trial 2014 · control group (iron and folic acid supplement) · Pregnant women attending antenatal care in Nepal; no specific age range or deficiency criterion stated | 400 mcg | — | 600 |
| Effects of prenatal micronutrient and early food supplementation on metabolic status of the offspring at 4.5 years of age. The MINIMat randomized trial in rural Bangladesh 2016 · Fe30F · Pregnant women in rural Bangladesh; offspring assessed at 4.5 years | 400 mcg | — | 458 |
| Effects of prenatal micronutrient and early food supplementation on metabolic status of the offspring at 4.5 years of age. The MINIMat randomized trial in rural Bangladesh 2016 · Fe60F · Pregnant women in rural Bangladesh; offspring assessed at 4.5 years | 400 mcg | — | 454 |
| Effect of prenatal micronutrient-fortified balanced energy-protein supplementation on maternal and newborn body composition: A sub-study from the MISAME-III randomized controlled efficacy trial in rural Burkina Faso 2023 · Control · Pregnant women aged 15–40 years, enrolled before 21 completed weeks of gestation; maternal and newborn body composition were assessed postpartum | 400 mcg | — | 440 |
| Sex-Specific Associations between One-Carbon Metabolism Indices and Posttranslational Histone Modifications in Arsenic-Exposed Bangladeshi Adults 2017 · 800 µg FA/day · Adults aged 20–65 exposed to household well-water arsenic ≥50 µg/L | 800 mcg | 12 weeks | 154 |
| Sex-Specific Associations between One-Carbon Metabolism Indices and Posttranslational Histone Modifications in Arsenic-Exposed Bangladeshi Adults 2017 · 3 g creatine + 400 µg FA/day · Adults aged 20–65 exposed to household well-water arsenic ≥50 µg/L | 400 mcg | 12 weeks | 104 |
| Small-Quantity Lipid-Based Nutrient Supplements Do Not Affect Plasma or Milk Retinol Concentrations Among Malawian Mothers, or Plasma Retinol Concentrations among Young Malawian or Ghanaian Children in Two Randomized Trials 2021 · IFA (Ghana mothers) · Women aged 18 years or older, pregnant at enrollment (≤20 weeks), in Ghana | 400 mcg | — | 97 |
| The effects of gum arabic oral treatment on the metabolic profile of chronic renal failure patients under regular haemodialysis in Central Sudan 2008 · group C (control group) · Patients with chronic renal failure receiving regular haemodialysis; age and sex not reported | 5 mg | 90 days | 10 |
| Betaine as a determinant of postmethionine load total plasma homocysteine before and after B-vitamin supplementation 2004 · folic acid, vitamin B12, and vitamin B6 group · Patients undergoing coronary angiography | 800 mcg | 1 year | — |
| Betaine as a determinant of postmethionine load total plasma homocysteine before and after B-vitamin supplementation 2004 · folic acid and vitamin B12 group · Patients undergoing coronary angiography | 800 mcg | 1 year | — |
| Baseline plasma total homocysteine and adenoma recurrence: results from a double blind randomized clinical trial of aspirin and folate supplementation 2010 · folic acid supplementation group · Adults aged 21–80 with a history of colorectal adenomas | 1 mg | 3 years | — |
| Preconception Micronutrient Supplementation with Iron and Folic Acid Compared with Folic Acid Alone Affects Linear Growth and Fine Motor Development at 2 Years of Age: A Randomized Controlled Trial in Vietnam 2017 · FA group · Women in Vietnam receiving preconception supplementation; age and health status not stated | 400 mcg | — | — |
| The myo-inositol effect on the oocyte quality and fertilization rate among women with polycystic ovary syndrome undergoing assisted reproductive technology cycles: a randomized clinical trial 2019 · control group · infertile women with PCOS undergoing assisted reproductive technology cycles; age not reported | 400 mg | 30 days | — |
| Defining the plasma folate concentration associated with the red blood cell folate concentration threshold for optimal neural tube defects prevention: a population-based, randomized trial of folic acid supplementation 2019 · 25 μg 4 times a day · Women of reproductive age in northern China; nonpregnant; no diagnosed condition specified for those eligible for supplementation | 100 mcg | 26 weeks | — |
| Defining the plasma folate concentration associated with the red blood cell folate concentration threshold for optimal neural tube defects prevention: a population-based, randomized trial of folic acid supplementation 2019 · 100 μg 1 time a day · Women of reproductive age in northern China; nonpregnant; no diagnosed condition specified for those eligible for supplementation | 100 mcg | 26 weeks | — |
| Defining the plasma folate concentration associated with the red blood cell folate concentration threshold for optimal neural tube defects prevention: a population-based, randomized trial of folic acid supplementation 2019 · 100 μg 4 times a day · Women of reproductive age in northern China; nonpregnant; no diagnosed condition specified for those eligible for supplementation | 400 mcg | 26 weeks | — |
| Defining the plasma folate concentration associated with the red blood cell folate concentration threshold for optimal neural tube defects prevention: a population-based, randomized trial of folic acid supplementation 2019 · 400 μg 1 time a day · Women of reproductive age in northern China; nonpregnant; no diagnosed condition specified for those eligible for supplementation | 400 mcg | 26 weeks | — |
| Defining the plasma folate concentration associated with the red blood cell folate concentration threshold for optimal neural tube defects prevention: a population-based, randomized trial of folic acid supplementation 2019 · 4000 μg 1 time a day · Women of reproductive age in northern China; nonpregnant; no diagnosed condition specified for those eligible for supplementation | 4 mg | 26 weeks | — |
| Defining the plasma folate concentration associated with the red blood cell folate concentration threshold for optimal neural tube defects prevention: a population-based, randomized trial of folic acid supplementation 2019 · 4000 μg 1 time per week · Women of reproductive age in northern China; nonpregnant; no diagnosed condition specified for those eligible for supplementation | 571 mcg | 26 weeks | — |
| Fortified balanced energy-protein supplementation during pregnancy and lactation and infant growth in rural Burkina Faso: A 2 × 2 factorial individually randomized controlled trial 2023 · Prenatal and postnatal IFA only supplementation · Pregnant women aged 15–40 years in rural Burkina Faso who continued into lactation | 400 mcg | — | — |